

Armstrong PW, Adams PX, Al-Khalidi HR, Hamm C, Holmes D, O'Neill W, Todaro TG, Vahanian A, Van de Werf F, Granger CB, APEX-AMI Steering Committee. Assessment of Pexelizumab in Acute Myocardial Infarction (APEX AMI): a multicenter, randomized, double-blind, parallel-group, placebo-controlled study of pexelizumab in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention. 2005;149:402-7 (Trial design)

Armstrong PW (see Kaul et al). 2005;149:637-44

Ärnlöv J, Lind L, Andrén B, Risérus U, Berglund L, Lithell H. A Doppler-derived index of combined left ventricular systolic and diastolic function is an independent predictor of cardiovascular mortality in elderly men. 2005;149:902-7

Arrigo F (see de Gregorio et al). 2005;149:1091-8

Arteaga E, Ianni BM, Fernandes F, Mady C. Benign outcome in a long-term follow-up of patients with hypertrophic cardiomyopathy in Brazil. 2005;149:1099-105

Asinger RW (see Bart et al). 2005;149:888-93

Aslan SM (see Dogan et al). 2005;149:1037-42

Aspelin P, Aubry P, Fransson S-G, Strasser R, Willenbrock R, Lundkvist J. Cost-effectiveness of iodixanol in patients at high risk of contrast-induced nephropathy. 2005;149:298-303

Atalay H (see Gulcan et al). 2005;149:917-20

Aubry P (see Aspelin et al). 2005;149:298-303

Avezum A, Makdisse M, Spencer F, Gore JM, Fox KAA, Montalescot G, Eagle KA, White K, Mehta RH, Knobel E, Collet JP, GRACE Investigators. Impact of age on management and outcome of acute coronary syndrome: observations from the Global Registry of Acute Coronary Events (GRACE). 2005;149:67-73

Avezum A, Makdisse M. Thrombolytic therapy for eligible elderly patients with acute myocardial infarction. 2005;149:e27 (Letter reply)

B

Backes RJ (see Frantz et al). 2005;149:541-7

Badaracco R (see Macin et al). 2005;149:451-7

Badimon JJ (see Viles-Gonzalez et al). 2005;149:S19-31

Baeza R (see Shah et al). 2005;149:240-53 (Meetings)

Baeza RG (see Patel et al). 2005;149:1009-19 (Meetings)

Bagger JP (see Kapur et al). 2005;149:13-9 (Trial design)

Baggish AL (see Krauser et al). 2005;149:744-50

Bahrmann P (see Werner et al). 2005;149:129-37

Bailey KR (see Frantz et al). 2005;149:541-7

Bairey Merz CN (see Lewis et al). 2005;149:527-33

Bakhai A (see Reed et al). 2005;149:434-43 (Meetings)

Balady GJ (see Savage et al). 2005;149:627-31

Ballantyne CM, Abate N, Yuan Z, King TR, Palmisano J. Dose-comparison study of the combination of ezetimibe and simvastatin (Vytorin) versus atorvastatin in patients with hypercholesterolemia: the Vytorin Versus Atorvastatin (VYVA) Study. 2005;149:464-73. Correction 2005;149:882

Ballman KV (see Gurevitz et al). 2005;149:316-21

Bañuelos C (see Alfonso et al). 2005;149:335.e1-335.e8

Banzer JA (see Savage et al). 2005;149:627-31

Barbieri B (see Nienaber et al). 2005;149:592-9 (Trial design)

Bardy GH (see Al-Khatib et al). 2005;149:1020-34 (Meetings)

Barlera S (see Maggioni et al). 2005;149:548-57

Barletta G (see Conti et al). 2005;149:894-901

Barrell P (see Flaker et al). 2005;149:657-63

Barrera-Ramirez CF, Pineda-Pompa LR, Ilarraga H. Aortic stenosis and angiotensin-converting enzyme inhibitors—rupture of an ancient paradigm? 2005;149:e5 (Letter)

Barron HV (see Rathore et al). 2005;149:1074-81

Bart BA, Erlien DA, Herzog CA, Asinger RW. Marked differences between patients referred for stress echocardiography and myocardial perfusion imaging studies. 2005;149:888-93

Bartunek J (see Van Laethem et al). 2005;149:175-80

Bass T (see Silber et al). 2005;149:689-94

Bates DW (see Sequist et al). 2005;149:74-81

Battler A (see Iakobishvili et al). 2005;149:98-103

Baughman KL (see Ardehali et al). 2005;149:7-12 (Curriculum cardiol.)

Bax J (see Yu et al). 2005;149:600-5 (Trial design)

Bax JJ (see Kaandorp et al). 2005;149:200-8 (Curriculum cardiol.)

Bax JJ, Schuijff JD. Which role for multislice computed tomography in clinical cardiology? 2005;149:960-1 (Editorial)

Beanlands R (see Ling et al). 2005;149:1137.e9-1137.e16

Beaton L (see Reid et al). 2005;149:862-8

Beatt KJ (see Kapur et al). 2005;149:13-9 (Trial design)

Beck CA, Eisenberg MJ, Pilote L. Invasive versus noninvasive management of ST-elevation acute myocardial infarction: a review of clinical trials and observational studies. 2005;149:194-9 (Curriculum cardiol.)

Beck JD (see Offenbacher and Beck). 2005;149:950-4 (Editorial)

Becker RC. Novel constructs for thrombin inhibition. 2005;149:S61-72

Becker RC. Thrombin: science and application in clinical practice. 2005;149:S1

Becker RC. Understanding the dynamics of thrombin in cardiovascular disease: pathobiology and biochemistry for the clinician. 2005;149:S2-8

Becker RC (see Armani and Becker). 2005;149:971-6, 977-83 (Progress cardiol.)

Beckman K (see Flaker et al). 2005;149:657-63

Behar S (see Iakobishvili et al). 2005;149:98-103

Belew K (see Flaker et al). 2005;149:657-63

Beifiglio M (see Franciosi et al). 2005;149:104-11

Bentley J (see Smith et al). 2005;149:444-50

Bereznicki LR (see Jackson et al). 2005;149:e3 (Letter)

Berger PB, Best PJM, Topol EJ, White J, DiBattiste PM, Chan AW, Kristensen SD, Herrmann HC, Moliterno DJ. The relation of renal function to ischemic and bleeding outcomes with 2 different glycoprotein IIb/IIIa inhibitors: the Do Tirofiban and ReoPro Give Similar Efficacy Outcome (TARGET) trial. 2005;149:869-75

Berglund L (see Ärnlöv et al). 2005;149:902-7

Berkowitz RL (see Adams et al). 2005;149:209-16 (Trial design)

Berliner S, Rogowski O, Aharonov S, Mardi T, Tolshinsky T, Rozenblat M, Justo D, Deutsch V, Serov J, Shapira I, Zeltzer D. Erythrocyte adhesiveness/aggregation: a novel biomarker for the detection of low-grade internal inflammation in individuals with atherosclerotic risk factors and proven vascular disease. 2005;149:260-7

Berlowitz DR (see Borzecki et al). 2005;149:785-94 (Meetings)

Bertomeu V (see Bodí et al). 2005;149:268-74

Bertoni AG, Bonds DE, Thom T, Chen GJ, Goff DC Jr. Acute coronary syndrome national statistics: challenges in definitions. 2005;149:1055-61

Best PJM (see Berger et al). 2005;149:869-75

Bhatt DL (see Fathi and Bhatt). 2005;149:947-9 (Editorial)

Bhatt DL (see Gurin and Bhatt). 2005;149:S43-53

Bhatt DL (see Karha and Bhatt). 2005;149:384-7 (Editorial)

Bhatt DL (see Rajagopal and Bhatt). 2005;149:955-6 (Editorial)

Bhatt DL (see Rajagopal et al). 2005;149:534-40

Biasucci LM (see Biondi-Zocca et al). 2005;149:504-11

Bigger JT (see Al-Khatib et al). 2005;149:1020-34 (Meetings)

Bilo HJG (see van der Horst et al). 2005;149:585-91 (Trial design)

Binkley PF, Nunziata E, Liu-Stratton Y, Cooke G. A polymorphism of the endothelial nitric oxide synthase promoter is associated with an increase in autonomic imbalance in patients with congestive heart failure. 2005;149:342-8

Biondi-Zocca GGL, Abbate A, Agostoni P, Testa L, Burzotta F, Lotrione M, Trani C, Biasucci LM. Long-term benefits of an early invasive management in acute coronary syndromes depend on intracoronary stenting and aggressive antiplatelet treatment: a metaregression. 2005;149:504-11

Birdsall CW (see Sachdev et al). 2005;149:730-6

Bittner V (see Powell et al). 2005;149:851-5

Black IW (see Jasper et al). 2005;149:309-15

Blair SN (see Eisenman et al). 2005;149:46-53

Blanchet M, Sheppard R, Racine N, Ducharme A, Curnier D, Tardif JC, Sirois P, Lamoureux MC-C, De Champlain J, White M. Effects of angiotensin-converting enzyme inhibitor plus irbesartan on maximal and submaximal exercise capacity and neurohumoral activation in patients with congestive heart failure. 2005;149:938.e1-938.e7

Blazing M. Statin therapy—time to turn the focus from efficacy to implementation? 2005;149:381-3 (Editorial)

Blumenthal JA (see Powell et al). 2005;149:851-5

Blumenthal RS (see Budoff et al). 2005;149:695-700

Boam AB (see Muni et al). 2005;149:415-33 (Meetings)

Bodi V, Sanchis J, Llacer Á, Falcà L, Núñez J, Pellicer M, Bertomeu V, Ruiz V, Chorro FJ. Multimarker risk strategy for predicting 1-month and 1-year major events in non-ST-elevation acute coronary syndromes. 2005;149:268-74

Boersma E (see Ix et al). 2005;149:512-9

Böhme E (see Haberl et al). 2005;149:1112-9

Bonan R (see Silber et al). 2005;149:689-94

Bonds DE (see Bertoni et al). 2005;149:1055-61

Boone J (see Kerr et al). 2005;149:489-96

Borzecki AM, Oliveria SA, Berlowitz DR. Barriers to hypertension control. 2005;149:785-94 (Meetings)

Bosch J (see Dagenais et al). 2005;149:54-60

Bosker HA (see Hagens et al). 2005;149:1106-11

Bosworth HB, Olsen MK, Oddone EZ. Improving blood pressure control by tailored feedback to patients and clinicians. 2005;149:795-803 (Meetings)

Bott-Silverman CE (see O'Neill et al). 2005;149:363-9

Boyko V (see Jakobishvili et al). 2005;149:98-103

Braden G (see Carrozza et al). 2005;149:1136.e1-1136.e7

Bragadecesh T (see de Gregorio et al). 2005;149:1091-98

Bratschko RO (see Seinost et al). 2005;149:1050-4

Braun P (see Carrozza et al). 2005;149:1136.e1-1136.e7

Braunwald E (see Antman et al). 2005;149:217-26 (Trial design)

Braunwald E (see Giugliano et al). 2005;149:994-1002 (Trial design)

Braunwald E (see Mega et al). 2005;149:846-50

Braunwald E (see Smith et al). 2005;149:444-50

Braunwald E (see Cantor et al). 2005;149:27-83

Breall J (see Carrozza et al). 2005;149:1136.e1-1136.e7

Brenneman CI (see Sachdev et al). 2005;149:730-6

Brenner RM (see Mix et al). 2005;149:408-13 (Trial design)

Briggs AH (see Reed et al). 2005;149:434-43 (Meetings)

Briski A (see Vrtovec et al). 2005;149:632-6

Brizuela M (see Macin et al). 2005;149:451-7

Brodmann M (see Seinost et al). 2005;149:1050-4

Brosteanu O (see Sick et al). 2005;149:681-8. Correction 2005;149:1136

Brunken RC (see Rajagopal et al). 2005;149:534-40

Bucci A (see Pierdomenico et al). 2005;149:934-8

Buck J (see Haberl et al). 2005;149:1112-9

Budhwani N, Patel S, Dwyer EM Jr. Electrocardiographic diagnosis of left ventricular hypertrophy: the effect of left ventricular wall thickness, size, and mass on the specific criteria for left ventricular hypertrophy. 2005;149:709-14

Budoff MJ, Yu D, Nasir K, Mehrotra R, Chen L, Takasu J, Agrawal N, Liu ST, Blumenthal RS. Diabetes and progression of coronary calcium under the influence of statin therapy. 2005;149:695-700

Burg MM (see Powell et al). 2005;149:851-5

Burke S (see Ferramosca et al). 2005;149:820-5

Burkhoff D, Lefer DJ. Cardioprotection before revascularization in ischemic myocardial injury and the potential role of hemoglobin-based oxygen carriers. 2005;149:573-9 (Progress cardiol.)

Burnett JC (see Frantz et al). 2005;149:541-7

Burzotta F (see Biondi-Zocca et al). 2005;149:504-11

Busch I (see Sick et al). 2005;149:681-8. Correction 2005;149:1136

Buxton AE (see Al-Khatib et al). 2005;149:1020-34 (Meetings)

C

Califf RM, Mark DB. Plagiarism notice. 2005;149:743

Califf RM, Petersen JL, Hasselblad V, Mahaffey KW, Ferguson JJ. A perspective on trials comparing enoxaparin and unfractionated heparin in the treatment of non-ST-elevation acute coronary syndromes. 2005;149:S91-9

Califf RM (see Al-Khatib et al). 2005;149:1020-34 (Meetings)

Califf RM (see Eisenstein et al). 2005;149:482-8

Califf RM (see Giugliano et al). 2005;149:994-1002 (Trial design)

Califf RM (see Meine et al). 2005;149:670-4

Califf RM (see Miranda et al). 2005;149:20-32, 33-45 (Meetings)

Califf RM (see Muni et al). 2005;149:415-33 (Meetings)

Califf RM (see Reed et al). 2005;149:434-43 (Meetings)

Calvin JE (see Powell et al). 2005;149:851-5

Cameron R (see Krauser et al). 2005;149:744-50

Cannon CP (see Cantor et al). 2005;149:275-83

Cannon CP (see Gomberg-Maitland et al). 2005;149:613-8
Cannon CP (see Sabatine et al). 2005;149:227-33 (Trial design)
Cannon CP (see Smith et al). 2005;149:444-50
Cantor WJ, Goodman SG, Cannon CP, Murphy SA, Charlesworth A, Braunwald E, Langer A. Early cardiac catheterization is associated with lower mortality only among high-risk patients with ST- and non-ST-elevation acute coronary syndromes: observations from the OPUS-TIMI 16 trial. 2005;149:275-83
Carrozza JP, Caussin C, Braden G, Braun P, Hansell F, Fatzinger R, Walters G, Kussmaul W, Breall J, TriActiv Pilot Study Investigators. Embolic protection during saphenous vein graft intervention using a second-generation balloon protection device: results from the combined US and European pilot study of the TriActiv Balloon Protected Flush Extraction System. 2005;149:1136.e1-1136.e7
Carson PE (see Maggioni et al). 2005;149:548-57
Case C (see Smart et al). 2005;149:152-8
Casscells W, Vasseghi MF, Siadaty MS, Madjid M, Sidiqui H, Lal B, Payvar S. Hypothermia is a bedside predictor of imminent death in patients with congestive heart failure. 2005;149:927-33
Catellier D (see Powell et al). 2005;149:851-5
Caussin C (see Carrozza et al). 2005;149:1136.e1-1136.e7
Centor RM (see Ahmed et al). 2005;149:737-43
Cerè E (see Maggioni et al). 2005;149:548-57
Chae CU (see Krauser et al). 2005;149:744-50
Chaitman B (see Lewis et al). 2005;149:527-33
Chambless LE (see Wattanakit et al). 2005;149:606-12
Chan AKY (see Zhang et al). 2005;149:497-503
Chan AW (see Berger et al). 2005;149:869-75
Chandrasekaran K (see Gurevitz et al). 2005;149:316-21
Charlesworth A (see Cantor et al). 2005;149:275-83
Chasan-Taber S (see Ferramosca et al). 2005;149:820-5
Chaudhry MR (see Eisenberg et al). 2005;149:813-9
Chen A (see Krauser et al). 2005;149:744-50
Chen AY (see Kandzari et al). 2005;149:474-81
Chen AY (see Meine et al). 2005;149:1043-49
Chen GJ (see Bertoni et al). 2005;149:1055-61
Chen L (see Budoff et al). 2005;149:695-700
Cheng TO. Transseptal left heart catheterization as an alternative to retrograde left ventricular catheterization for patients with aortic stenosis. 2005;149:e15 (Letter)
Chertow GM (see Ferramosca et al). 2005;149:820-5
Chetcuti S (see Mukherjee et al). 2005;149:1003-8 (Trial design)
Chew P (see Antman et al). 2005;149:217-26 (Trial design)
Chiou K-R, Wu M-T, Hsiao S-H, Mar G-Y, Pan H-B, Yang C-F, Liu C-P. Safety and accuracy of multidetector row computed tomography for early assessment of residual stenosis of the infarct-related artery and the number of diseased vessels after acute myocardial infarction. 2005;149:701-8
Chirinos JA (see Medina-Lezama et al). 2005;149:e13 (Letter)
Chirinos-Pacheco J (see Medina-Lezama et al). 2005;149:e13 (Letter)
Chockalingam A. Aortic stenosis and angiotensin-converting enzyme inhibitors—rupture of an ancient paradigm? 2005;149:e7 (Letter reply)
Chorro FJ (see Bodi et al). 2005;149:268-74
Christian TF (see Kwok et al). 2005;149:145-51
Chun S (see Richardson et al). 2005;149:458-63
Chung E (see Yu et al). 2005;149:600-5 (Trial design)
Chung ML (see Zambroski et al). 2005;149:558-64
Ciabatti N (see Petronio et al). 2005;149:520-6
Cialzeta JR (see Macin et al). 2005;149:451-7
Cleland JGF (see Torp-Pedersen et al). 2005;149:370-6
Coglitore S (see de Gregorio et al). 2005;149:1091-8
Cohen DJ (see Reed et al). 2005;149:434-43 (Meetings)
Cohn JN (see Maggioni et al). 2005;149:548-57
Collet J-P (see Avezum et al). 2005;149:67-73
Colletta M (see Rubboli et al). 2005;149:e1 (Letter)
Collins-Nakai R (see King et al). 2005;149:761-7 (Trial design)
COMET Investigators (see Torp-Pedersen et al). 2005;149:370-6
Connolly S (see Al-Khatib et al). 2005;149:1020-34 (Meetings)
Connolly SJ (see Kerr et al). 2005;149:489-96
Conti A, Sammiceli L, Gallini C, Costanzo EN, Antonucci D, Barletta G. Assessment of patients with low-risk chest pain in the emergency department: head-to-head comparison of exercise stress echocardiography and exercise myocardial SPECT. 2005;149:894-901
Cook EF (see Sequist et al). 2005;149:74-81
Cooke G (see Binkley et al). 2005;149:342-8
Cooper ME (see Mix et al). 2005;149:408-13 (Trial design)
Corley SD (see DiMarco et al). 2005;149:650-6
Costanzo EN (see Conti et al). 2005;149:894-901
Costanzo MR (see Adams et al). 2005;149:209-16 (Trial design)
Courcol RJ (see Klug et al). 2005;149:322-8
Cowper PA (see Kaul et al). 2005;149:637-44
Coyle D (see Reid et al). 2005;149:862-8
Crawford SL (see Matthews et al). 2005;149:1066-73
Crijns HJGM (see Hagens et al). 2005;149:1106-11
CRUSADE Investigators (see Meine et al). 2005;149:1043-9
Cuccurullo F (see Pierdomenico et al). 2005;149:934-8
Curnier D (see Blanchet et al). 2005;149:938.e1-938.e7
Currie G (see King et al). 2005;149:761-7 (Trial design)
Curtis AB, Seals AA, Safford RE, Slater W, Tullo NG, Vidaillet H, Wilber DJ, Slee A, AFFIRM Investigators. Clinical factors associated with abandonment of a rate-control or a rhythm-control strategy for the management of atrial fibrillation in the AFFIRM study. 2005;149:304-8
Czernik A (see Haberl et al). 2005;149:1112-9

D

Dafoe WA (see Reid et al). 2005;149:862-8
Dagenais GR, Yi Q, Mann JFE, Bosch J, Pogue J, Yusuf S, Heart Outcomes Prevention Evaluation (HOPE) Study Investigators. Prognostic impact of body weight and abdominal obesity in women and men with cardiovascular disease. 2005;149:54-60
Daley J (see Zhang et al). 2005;149:856-61
Dambrink J-HE (see van der Horst et al). 2005;149:1135.e1-1135.e9
Davis KE (see Denardo et al). 2005;149:138-44
Dawn B, Paliwal VS, Raza ST, Mastali K, Longaker RA, Stoddard MF. Left ventricular outflow tract obstruction provoked during

dobutamine stress echocardiography predicts future chest pain, syncope, and near syncope. 2005;149:908-16

de Belder MA (see Kapur et al). 2005;149:13-9 (Trial design)

De Berardis G (see Franciosi et al). 2005;149:104-11

de Boer M-J (see van der Horst et al). 2005;149:585-91 (Trial design), 1135.e1-1135.e9

De Carlo M (see Petronio et al). 2005;149:520-6

De Caterina R, Lorenzoni R. Clopidogrel-aspirin combination for atrial fibrillation: CLAAF is not CLEAR. 2005;149:e4 (Letter reply)

De Champlain J (see Blanchet et al). 2005;149:938.e1-938.e7

de Feyter P (see Arampatzis et al). 2005;149:329-35

de Gregorio C, Micari A, Grimaldi P, Bragadeesh T, Arrigo F, Coglitore S. Behavior of both epicardial and intramural coronary artery flow velocities in various models of myocardial hypertrophy: role for left ventricular outflow tract obstruction. 2005;149:1091-8

de Groot E (see Kastelein et al). 2005;149:234-9 (Trial design)

de Lemos JA (see Drazner and de Lemos). 2005;149:187-9 (Editorial)

de Lemos JA (see Sims et al). 2005;149:1062-5

De Luca G (see van der Horst et al). 2005;149:1135.e1-1135.e9

De Luca L, De Persio G, Minati M, Iacoboni C, Fedele F. Effects of abciximab and preprocedural glycemic control in diabetic patients undergoing elective coronary stenting. 2005;149: 1135.e11-1135.e18

De Persio G (see De Luca et al). 2005;149:1135.e11-1135.e18

de Roos A (see Kaandorp et al). 2005;149:200-8 (Curriculum cardiol.)

de Zeeuw D (see Mix et al). 2005;149:408-13 (Trial design)

Decker WW (see Elesber et al). 2005;149:826-31

Deedwania PC, Giles TD, Klibaner M, Ghali JK, Herlitz J, Hildebrandt P, Kjekshus J, Spinar J, Vitovec J, Stanbrook H, Wikstrand J, MERIT-HF Study Group. Efficacy, safety and tolerability of metoprolol CR/XL in patients with diabetes and chronic heart failure: experiences from MERIT-HF. 2005;149:159-67

DeFronzo RA (see Miranda et al). 2005;149:20-32, 33-45 (Meetings)

DeGregorio M (see Mukherjee et al). 2005;149:1003-8 (Trial design)

deKemp RA (see Ling et al). 2005;149:1137.e9-1137.e16

Delles C (see John et al). 2005;149:473.e1-473.e10

Demircan S (see Gulcan et al). 2005;149:917-20

Denardo SJ, Davis KE, Tcheng JE. Elective percutaneous coronary intervention using broad-spectrum antiplatelet therapy (epifibatide, clopidogrel, and aspirin) alone, without scheduled unfractionated heparin or other antithrombin therapy. 2005;149:138-44

Derby CA (see Matthews et al). 2005;149:1066-73

Deutsch V (see Berliner et al). 2005;149:260-7

Di Lenarda A (see Torp-Pedersen et al). 2005;149:370-6

Di Nardo B (see Franciosi et al). 2005;149:104-11

Di Pasquale G (see Rubboli et al). 2005;149:e1 (Letter)

Di Tullio MR (see Kohsaka and Di Tullio). 2005;149:e31 (Letter reply)

Di Tullio MR (see Kohsaka et al). 2005;149:181-6

DiBattiste PM (see Berger et al). 2005;149:869-75

DiBattiste PM (see Mega et al). 2005;149:846-50

DiMarco JP, Flaker G, Waldo AL, Corley SD, Greene HL, Safford RE, Rosenfeld LE, Mitrani G, Nemeth M, AFFIRM Investigators. Factors affecting bleeding risk during anticoagulant therapy in patients with atrial fibrillation: observations from the Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) Study. 2005;149:650-6

Dogan A, Ozgul M, Ozaydin M, Aslan SM, Gedikli O, Altinbas A. Effect of clopidogrel plus aspirin on tissue perfusion and coronary flow in patients with ST-segment elevation myocardial infarction: a new reperfusion strategy. 2005;149:1037-42

Donahue MP, Allen AS. Genetic association studies in cardiology. 2005;149:964-70 (Progress cardiol.)

Dorian P (see Kerr et al). 2005;149:489-96

Doval H (see Macin et al). 2005;149:451-7

Downey J (see Jones et al). 2005;149:e1

Doyle M (see Lewis et al). 2005;149:527-33

Drazner MH, de Lemos JA. Unexpected BNP levels in patients with advanced heart failure: a tale of caution and promise. 2005; 149:187-9 (Editorial)

Drummond MF (see Reed et al). 2005;149:434-43 (Meetings)

Dubourg O (see Mansencal and Dubourg). 2005;149:e29 (Letter)

Ducharme A (see Blanchet et al). 2005;149:938.e1-938.e7

Duchesne L (see Ling et al). 2005;149:1137.e9-1137.e16

Dwyer EM Jr (see Budhwani et al). 2005;149:709-14

Dzavik V, Sleeper LA, Picard MH, Sanborn TA, Lowe AM, Gin K, Saucedo J, Webb JG, Menon V, Slater JN, Hochman JS, SHOCK Investigators. Outcome of patients aged 75 years in the SHould we emergently revascularize Occluded Coronaries in cardiogenic shock (SHOCK) trial: do elderly patients with acute myocardial infarction complicated by cardiogenic shock respond differently to emergent revascularization? 2005;149:1128-34

E

Eagle KA (see Avezum et al). 2005;149:67-73

Eagle KA (see Mukherjee et al). 2005;149:1003-8 (Trial design)

EARLY ACS Steering Committee (see Giugliano et al). 2005;149:994-1002 (Trial design)

Ebrahim I (see Eisenberg et al). 2005;149:813-9

Edmundowicz D (see Lewis et al). 2005;149:527-33

Eisenberg MJ, Teng FF, Chaudhry MR, Ortiz J, Sobkowski W, Ebrahim I, Saligrama RS, Serio K, Lader E, Pilote L, NQWMI Investigators. Impact of invasive management versus noninvasive management on functional status and quality of life following non-Q-wave myocardial infarction: a randomized clinical trial. 2005;149:813-9

Eisenberg MJ (see Beck et al). 2005;149:194-9 (Curriculum cardiol.)

Eisenberg MJ (see Ludvig et al). 2005;149:565-72 (Curriculum cardiol.)

Eisenmann JC, Wickel EE, Welk GJ, Blair SN. Relationship between adolescent fitness and fatness and cardiovascular disease risk factors in adulthood: the Aerobics Center Longitudinal Study (ACLS). 2005;149:46-53

Eisenstein EL, Lemons PW II, Tardiff BE, Schulman KA, Jolly MK, Califf RM. Reducing the costs of phase III cardiovascular clinical trials. 2005;149:482-8

Eisenstein EL (see Kaul et al). 2005;149:637-44

Elesber AA, Decker WW, Smars PA, Hodge DO, Shen W-K. Impact of the application of the American College of Emergency Physicians recommendations for the admission of patients with syncope on a retrospectively studied population presenting to the emergency department. 2005;149:826-31

Ellenbogen KA (see Al-Khatib et al). 2005;149:1020-34 (Meetings)

Emerman CL (see Adams et al). 2005;149:209-16 (Trial design)

Emig U (see Werner et al). 2005;149:129-37

Engdahl J (see Herlitz et al). 2005;149:61-6

Engel G (see Richardson et al). 2005;149:458-63

ENRICHD Investigators (see Powell et al). 2005;149:851-5

Erdman RAM (see Pedersen et al). 2005;149:664-9

Erlien DA (see Bart et al). 2005;149:888-93

Escaned J (see Alfonso et al). 2005;149:335.e1-335.e8

Every NR (see Rathore et al). 2005;149:1074-81

ExTRACT-TIMI 25 Investigators (see Antman et al). 2005;149:217-26 (Trial design)

Ezekowitz M (see Palagummi et al). 2005;149:S32-5

F

Fácala L (see Bodi et al). 2005;149:268-74

Faglia E, Manuela M, Antonella Q, Michela G, Vincenzo C, Maurizio C, Roberto M, Alberto M. Risk reduction of cardiac events by screening of unknown asymptomatic coronary artery disease in subjects with type 2 diabetes mellitus at high cardiovascular risk: an open-label randomized pilot study. 2005;149:283.e1-283.e6

Fananapazir L (see Sachdev et al). 2005;149:730-6

Fang JC (see Shah et al). 2005;149:715-21

Fang ZY, Schull-Meade R, Leano R, Mottram PM, Prins JB, Marwick TH. Screening for heart disease in diabetic subjects. 2005;149:349-54

Farías EF (see Macin et al). 2005;149:451-7

Faris P (see King et al). 2005;149:761-7 (Trial design)

Fathi RB, Bhatt DL. Enhancing reperfusion therapy for myocardial infarction with dual antiplatelet therapy: breaking the glass ceiling. 2005;149:947-9 (Editorial)

Fatzinger R (see Carrozza et al). 2005;149:1136.e1-1136.e7

Fedele F (see De Luca et al). 2005;149:1135.e11-1135.e18

Fedewa M (see Yu et al). 2005;149:600-5 (Trial design)

Feldman AM (see Al-Khatib et al). 2005;149:1020-34 (Meetings)

Ferguson JJ (see Califf et al). 2005;149:591-9

Ferguson JJ (see Mahaffey and Ferguson). 2005;149:S81-90

Fernandes F (see Arteaga et al). 2005;149:1099-105

Fernandes O (see Nagge et al). 2005;149:e21 (Letter)

Ferramosca E, Burke S, Chasan-Taber S, Ratti C, Chertow GM, Raggi P. Potential antiatherogenic and anti-inflammatory properties of sevelamer in maintenance hemodialysis patients. 2005;149:820-5

Figulla HR (see Werner et al). 2005;149:129-37

Flaker G (see DiMarco et al). 2005;149:650-6

Flaker GC, Belew K, Beckman K, Vidaillet H, Kron J, Safford R, Mickel M, Barrell P, AFFIRM Investigators. Asymptomatic atrial fibrillation: demographic features and prognostic information from the Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) study. 2005;149:657-63

Flavell CM (see Shah et al). 2005;149:715-21

Fleites H (see Alfonso et al). 2005;149:335.e1-335.e8

Floras JS (see Harvey et al). 2005;149:291-7

Floras JS (see Nolan et al). 2005;149:1137.e1-1137.e7

Folsom AR (see Wattanakit et al). 2005;149:606-12

Fonarow GC. Practical considerations of <gb>-blockade in the management of the post-myocardial infarction patient. 2005;149:984-93 (Curriculum cardiol.)

Fonarow GC (see Adams et al). 2005;149:209-16 (Trial design)

Fonarow GC (see Smooke et al). 2005;149:168-74

Foody JM (see Rathore et al). 2005;149:121-8

Ford ES (see Ajani et al). 2005;149:254-9

Fox KAA (see Antman et al). 2005;149:217-26 (Trial design)

Fox KAA (see Avezum et al). 2005;149:67-73

Fox RD (see Holmes et al). 2005;149:883-7

Foy JR (see Muni et al). 2005;149:415-33 (Meetings)

Franciosi M, Pellegrini F, De Berardis G, Belfiglio M, Di Nardo B, Greenfield S, Kaplan SH, Rossi MCE, Sacco M, Tognoni G, Valentini M, Nicolucci A. Quality of Care and Outcomes in Type 2 Diabetes (QuED) Study Group. Impact of physicians' beliefs and practices on cholesterol levels in patients with type 2 diabetes: a longitudinal assessment. 2005;149:104-11

Franciosi V (see Macin et al). 2005;149:451-7

Francis GS (see Parameswaran et al). 2005;149:921-6

Franklin SS (see Griffith et al). 2005;149:769-75 (Meetings)

Fransson S-G (see Aspelin et al). 2005;149:298-303

Frantz RP, Olson LJ, Grill D, Moualla SK, Nelson SM, Nobrega TP, Hanna RD, Backes RJ, Mookadam F, Heublein D, Bailey KR, Burnett JC. Carvedilol therapy is associated with a sustained decline in brain natriuretic peptide levels in patients with congestive heart failure. 2005;149:541-7

Frederick PD (see Rathore et al). 2005;149:1074-81

Freedland KE (see Powell et al). 2005;149:851-5

Friedman PA (see Gurevitz et al). 2005;149:316-21

Froelicher VF (see Richardson et al). 2005;149:458-63

Fung W-H (see Zhang et al). 2005;149:497-503

Fuster V (see Viles-Gonzalez et al). 2005;149:S19-31

G

Gallini C (see Conti et al). 2005;149:894-901

Galvao M (see Adams et al). 2005;149:209-16 (Trial design)

Gami AS, Holly TA, Rosenthal JE. To the Editor. 2005;149:e11 (Letter reply)

Gana TJ (see Glasser et al). 2005;149:290.e1-290.e9

Gans ROB (see van der Horst et al). 2005;149:585-91 (Trial design)

García P (see Alfonso et al). 2005;149:335.e1-335.e8

Garratt KN (see Singh et al). 2005;149:753-60 (Curriculum cardiol.)

Gasser R (see Seinost et al). 2005;149:1050-4

Ge J (see Kim et al). 2005;149:336-41

Gedikli O (see Dogan et al). 2005;149:1037-42

Gehl HB (see Steen et al). 2005;149:564.e1-564.e7

Gersh BJ (see Gurevitz et al). 2005;149:316-21

Ghali JK (see Deedwania et al). 2005;149:159-67

Ghio S (see Yu et al). 2005;149:600-5 (Trial design)

Giannitis E (see Steen et al). 2005;149:564.e1-564.e7

Gibbons RJ (see Kwok et al). 2005;149:145-51

Gibler WB (see Kandzari et al). 2005;149:474-81

Gibler WB (see Meine et al). 2005;149:1043-9

Gibson CM (see Giugliano et al). 2005;149:994-1002 (Trial design)

Gibson CM (see Mega et al). 2005;149:846-50

Gibson CM (see Sabatine et al). 2005;149:227-33 (Trial design)

Gilbert J (see Giugliano et al). 2005;149:994-1002 (Trial design)

Giles TD (see Deedwania et al). 2005;149:159-67

Gin K (see Dzavik et al). 2005;149:1128-34

GIPS Investigators (see van der Horst et al). 2005;149:585-91 (Trial design)

Giugliano RP, Newby LK, Harrington RA, Gibson M, Van de Werf F, Armstrong P, Montalescot G, Gilbert J, Strony JT, Califf RM, Braunwald E, Early ACS Steering Committee. The Early Glycoprotein IIb/IIIa Inhibition in Non-ST-Segment Elevation Acute Coronary Syndrome (Early ACS) trial: a randomized placebo-controlled trial evaluating the clinical benefits of early front-loaded eptifibatide in the treatment of patients with non-ST-segment elevation acute coronary syndrome—study design and rationale. 2005;149:994-1002 (Trial design)

Givertz MM (see Shah et al). 2005;149:715-21

Glasser SP, Gana TJ, Pascual LG, Albert KS. Efficacy and safety of a once-daily graded-release diltiazem formulation dosed at bedtime compared to placebo and to morning dosing in chronic stable angina pectoris. 2005;149:290.e1-290.e9

Glazer R (see Maggioni et al). 2005;149:548-57

Glazier JJ. Attenuation of reperfusion microvascular ischemia by aqueous oxygen: experimental and clinical observations. 2005;149:580-4 (Progress cardiol.)

Glick HA (see Reed et al). 2005;149:434-43 (Meetings)

Gnanasakthy A (see Reed et al). 2005;149:434-43 (Meetings)

Goedhart D (see Arampatzis et al). 2005;149:329-35

Goedicke J (see Kapur et al). 2005;149:13-9 (Trial design)

Goethals M (see Van Laethem et al). 2005;149:175-80

Goff DC Jr (see Bertoni et al). 2005;149:1055-61

Gomberg-Maitland M, Murphy SA, Moliterno DJ, Cannon CP. Are we appropriately triaging patients with unstable angina? 2005;149:613-8

Goodman S. Enoxaparin and glycoprotein IIb/IIIa inhibition in non-ST-elevation acute coronary syndrome: insights from the INTERACT trial. 2005;149:S73-80

Goodman SG (see Cantor et al). 2005;149:275-83

Gore JM (see Avezum et al). 2005;149:67-73

Görge G (see Meyer et al). 2005;149:926.e1-926.e7

Gosselink ATM (see van der Horst et al). 2005;149:1135.e1-1135.e9

Goyal A (see Patel et al). 2005;149:1009-19 (Meetings)

Goyal A (see Shah et al). 2005;149:240-53 (Meetings)

GRACE Investigators (see Avezum et al). 2005;149:67-73

Granger CB (see Armstrong et al). 2005;149:402-7 (Trial design)

Granger CB (see Kaul et al). 2005;149:637-44

Granger CB (see Meine et al). 2005;149:670-4

Green M (see Kerr et al). 2005;149:489-96

Green R (see Holmes et al). 2005;149:883-7

Greene HL (see DiMarco et al). 2005;149:650-6

Greenfield S (see Franciosi et al). 2005;149:104-11

Griffith TF, Klassen PS, Franklin SS. Systolic hypertension: an overview. 2005;149:769-75 (Meetings)

Grill D (see Frantz et al). 2005;149:541-7

Grimaldi P (see de Gregorio et al). 2005;149:1091-8

Grimm RA (see Jasper et al). 2005;149:309-15

Grossman PM (see Mukherjee et al). 2005;149:1003-8 (Trial design)

Gulcan O, Sezgin AT, Demircan S, Atalay H, Turkoz R. Effect of coronary artery bypass grafting and aneurysmectomy on QT dispersion in moderate or severe left ventricular dysfunction. 2005;149:917-20

Gupta R (see Parameswaran et al). 2005;149:921-6

Gurevitz OT, Ammash NM, Malouf JF, Chandrasekaran K, Rosales AG, Ballman KV, Hammill SC, White RD, Gersh BJ, Friedman PA. Comparative efficacy of monophasic and biphasic waveforms for transthoracic cardioversion of atrial fibrillation and atrial flutter. 2005;149:316-21

Gurm HS, Bhatt DL. Thrombin, an ideal target for pharmacological inhibition: a review of direct thrombin inhibitors. 2005;149: S43-53

Gurm HS (see Rajagopal et al). 2005;149:534-40

Guyton JR (see Miranda et al). 2005;149:20-32, 33-45 (Meetings)

H

Haberl R, Tittus J, Böhme E, Czernik A, Richartz BM, Buck J, Steinbigler P. Multislice spiral computed tomographic angiography of coronary arteries in patients with suspected coronary artery disease: an effective filter before catheter angiography? 2005;149:1112-9

Hageus VE, Crijns HJGM, Van Veldhuisen DJ, Van Den Berg MP, Rienstra M, Ranchot AV, Bosker HA, Kamp O, Tijssen JGP, Vecger NJGM, Van Gelder IC, RAtc Control versus Electrical cardioversion for persistent atrial fibrillation study group. Rate control versus rhythm control for patients with persistent atrial fibrillation with mild to moderate heart failure: results from the RAtc Control versus Electrical cardioversion (RACE) study. 2005;149:1106-11

Halabi A (see Shah et al). 2005;149:240-53 (Meetings)

Halabi AR, Harrington RA. Should we routinely supplement coronary patients with folate therapy to prevent in-stent restenosis? 2005;149:1035-6 (Evidence-based consult)

Halabi AR (see Patel et al). 2005;149:1009-19 (Meetings)

Hall RJ (see Kapur et al). 2005;149:13-9 (Trial design)

Haluska B (see Smart et al). 2005;149:152-8

Hamm C (see Armstrong et al). 2005;149:402-7 (Trial design)

Hammill SC (see Gurevitz et al). 2005;149:316-21

Hanna RD (see Frantz et al). 2005;149:541-7

Hanrath P (see Torp-Pedersen et al). 2005;149:370-6

Hansell F (see Carrozza et al). 2005;149:1136.e1-1136.e7

Hansson L-O (see Saleh et al). 2005;149:876-82
Harrington RA (see Giugliano et al). 2005;149:994-1002 (Trial design)
Harrington RA (see Halabi and Harrington). 2005;149:1035-6 (Evidence-based consult)
Harrington RA (see Kandzari et al). 2005;149:474-81
Harrington RA (see Petersen and Harrington). 2005;149:190-3 (Editorial)
Harvey PJ, Picton PE, Su WS, Morris BL, Notarius CF, Floras JS. Exercise as an alternative to oral estrogen for amelioration of endothelial dysfunction in postmenopausal women. 2005;149:291-7
Hasdai D (see Iakobishvili et al). 2005;149:98-103
Hasdai D. Should we aggressively treat elderly patients with cardiogenic shock? 2005;149:962-3 (Editorial)
Hasselblad V (see Califff et al). 2005;149:S91-9
Hasselblad V (see Shah et al). 2005;149:715-21
Hasselblad V (see Whellan et al). 2005;149:722-9
Havranek EP (see Rathore et al). 2005;149:121-8
Hayashi T, Kiyoshima T, Matsuura M, Ueno M, Kobayashi N, Yabushita H, Kurooka A, Taniguchi M, Miyatake M, Kimura A, Ishikawa K. Plaque erosion in the culprit lesion is prone to develop a smaller myocardial infarction size compared with plaque rupture. 2005;149:284-90
Heart Outcomes Prevention Evaluation (HOPE) Study Investigators (see Dagenais et al). 2005;149:54-60
Henke P (see Mukherjee et al). 2005;149:1003-8 (Trial design)
Hennekens CH (see Pocock et al). 2005;149:939-43
Heo S (see Zambroski et al). 2005;149:558-64
Herlitz J, Engdahl J, Svensson L, Ängquist K-A, Young M, Holmberg S. Factors associated with an increased chance of survival among patients suffering from an out-of-hospital cardiac arrest in a national perspective in Sweden. 2005;149:61-6
Herlitz J (see Deedwania et al). 2005;149:159-67
Hernández R (see Alfonso et al). 2005;149:335.e1-335.e8
Herrin J (see Rathore et al). 2005;149:121-8
Herrmann HC (see Berger et al). 2005;149:869-75
Herzog CA (see Bart et al). 2005;149:888-93
Herzum M (see Alter et al). 2005;149:1082-90
Heublein D (see Frantz et al). 2005;149:541-7
Heuser RR (see Silber et al). 2005;149:689-94
Higaki J (see Ogimoto et al). 2005;149:e19 (Letter)
Higginson I (see Ling et al). 2005;149:1137.e9-1137.e16
Hildebrandt K (see Meyer et al). 2005;149:926.e1-926.e7
Hildebrandt P (see Deedwania et al). 2005;149:159-67
Hirayama H (see Yoshida et al). 2005;149:e2
Hirsch AT (see Mukherjee et al). 2005;149:1003-8 (Trial design)
Hlatky MA (see Reed et al). 2005;149:434-43 (Meetings)
Hochman JS (see Dzavik et al). 2005;149:1128-34
Hodge DO (see Elesber et al). 2005;149:826-31
Hodge DO (see Kwok et al). 2005;149:145-51
Hodgson PK (see Holmes et al). 2005;149:883-7
Holly TA (see Gami et al). 2005;149:e11 (Letter reply)
Holmberg S (see Herlitz et al). 2005;149:61-6
Holmes D (see Armstrong et al). 2005;149:402-7 (Trial design)
Holmes DR Jr, Fox RD, Tommaso C, Hodgson PK, Green R, Rocha-Singh K, Rosenfield K. Renal and iliac artery stenting by interventional cardiologists and vascular surgeons: the Foundation to Advance Medical Education (FAME) initiative. 2005;149:883-7
Holmes DR Jr (see Singh et al). 2005;149:753-60 (Curriculum cardiol.)
Homma S (see Kohsaka et al). 2005;149:181-6
Hong M-K (see Kim et al). 2005;149:336-41
Hoornje JCA (see van der Horst et al). 2005;149:1135.e1-1135.e9
Horton DP (see Adams et al). 2005;149:209-16 (Trial design)
Horwich TB (see Smooke et al). 2005;149:168-74
Hsiao S-H (see Chiou et al). 2005;149:701-8
Huh J (see Nagge et al). 2005;149:e21 (Letter)
Humphries KH (see Kerr et al). 2005;149:489-96

Iacoboni C (see De Luca et al). 2005;149:1135.e11-1135.e18
Iakobishvili Z, Behar S, Boyko V, Battler A, Hasdai D. Does current treatment of cardiogenic shock complicating the acute coronary syndromes comply with guidelines? 2005;149:98-103
Ianni BM (see Arteaga et al). 2005;149:1099-105
Ikonomidis I, Lekakis J, Vamvakou G, Andreotti F, Nihoyannopoulos P. Cigarette smoking is associated with increased circulating proinflammatory and procoagulant markers in patients with chronic coronary artery disease: effects of aspirin treatment. 2005;149:832-9
Ilarraza H (see Barrera-Ramírez et al). 2005;149:e5 (Letter)
INSTEAD study collaborators (see Nienaber et al). 2005;149:592-9 (Trial design)
Ioannidis G (see Koulouris et al). 2005;149:840-5
Irqsuzi M (see Alter et al). 2005;149:1082-90
Ishikawa K (see Hayashi et al). 2005;149:284-90
Ivanovich P (see Miz et al). 2005;149:408-13 (Trial design)
Ix JH, Mercado N, Shlipak MG, Lemos PA, Boersma E, Lindeboom W, O'Neill WW, Wijns W, Serruys PW. Association of chronic kidney disease with clinical outcomes after coronary revascularization: the arterial revascularization therapies study (ARTS). 2005;149:512-9

Jackson SL, Peterson GM, Bereznicki LR. Clopidogrel-aspirin combination for atrial fibrillation: CLAAF is not CLEAR. 2005;149:e3 (Letter)
Jacobi J (see John et al). 2005;149:473.e1-473.e10
James SK, Oldgren J, Lindbäck J, Johnston N, Siegbahn A, Wallentin L. An acute inflammatory reaction induced by myocardial damage is superimposed on a chronic inflammation in unstable coronary artery disease. 2005;149:619-26
Jamrozik K (see Kapur et al). 2005;149:13-9 (Trial design)
Janardhanan R, Moon JCC, Pennell DJ, Senior R. Myocardial contrast echocardiography accurately reflects transmurality of myocardial necrosis and predicts contractile reserve after acute myocardial infarction. 2005;149:355-62
Januzzi JL Jr (see Krauser et al). 2005;149:744-50
Jasper SE, Lieber EA, Murray RD, Apperson-Hansen C, Black IW, Grimm RA, Pape LA, Klein AL, ACUTE Investigators. Impact of

cardioversion strategy on functional capacity in patients with atrial fibrillation: the Assessment of Cardioversion Using Transesophageal Echocardiography (ACUTE) Study. 2005;149:309-15

Jensen J (see Saleh et al). 2005;149:876-82

Jiang F (see Antman et al). 2005;149:217-26 (Trial design)

John S, Schneider MP, Delles C, Jacobi J, Schmieder RE. Lipid-independent effects of statins on endothelial function and bioavailability of nitric oxide in hypercholesterolemic patients. 2005;149:473.e1-473.e10

Johnston N (see James et al). 2005;149:619-26

Jolly MK (see Eisenstein et al). 2005;149:482-8

Jones PH, McKenney JM, Karalis DG, Downey J, NASDAC Investigators. Comparison of the efficacy and safety of atorvastatin initiated at different starting doses in patients with dyslipidemia. 2005;149:e1

Jordaens L (see Pedersen et al). 2005;149:664-9

Justo D (see Berliner et al). 2005;149:260-7

K

Kaandorp TAM, Lamb HJ, Bax JJ, van der Wall EE, de Roos A. Magnetic resonance imaging of coronary arteries, the ischemic cascade, and myocardial infarction. 2005;149:200-8 (Curriculum cardiol.)

Kacet S (see Klug et al). 2005;149:322-8

Kadish A (see Al-Khatib et al). 2005;149:1020-34 (Meetings)

Kadish A (see Passman and Kadish). 2005;149:957-9 (Editorial)

Kamath MV (see Nolan et al). 2005;149:1137.e1-1137.e7

Kamp O (see Hagens et al). 2005;149:1106-11

Kandzari DE, Roe MT, Chen AY, Lytle BL, Pollack CV Jr, Harrington RA, Ohman EM, Gibler WB, Peterson ED. Influence of clinical trial enrollment on the quality of care and outcomes for patients with non-ST-segment elevation acute coronary syndromes. 2005;149:474-81

Kaplan SH (see Franciosi et al). 2005;149:104-11

Kapur A, Malii IS, Bagger JP, Anderson JR, Kooner JS, Thomas M, Punjabi P, Mayet J, Millane T, Goedelke J, Jamrozik K, de Belder MA, Hall RJ, Beatt KJ. The Coronary Artery Revascularisation in Diabetes (CARDIA) trial: background, aims, and design. 2005;149:13-9 (Trial design)

Karabinos I (see Koulouris et al). 2005;149:840-5

Karalis DG (see Jones et al). 2005;149:e1

Karha J, Bhatt DL. Plaque regression—a new target for antiatherosclerotic therapy. 2005;149:384-7 (Editorial)

Kasper EK (see Ardehali et al). 2005;149:7-12 (Curriculum cardiol.)

Kassab S (see Mukherjee et al). 2005;149:1003-8 (Trial design)

Kastelein JJP, Sager PT, de Groot E, Veltri E. Comparison of ezetimibe plus simvastatin versus simvastatin monotherapy on atherosclerosis progression in familial hypercholesterolemia: design and rationale of the Ezetimibe and Simvastatin in Hypercholesterolemia Enhances Atherosclerosis Regression (ENHANCE) trial. 2005;149:234-9 (Trial design)

Katostaras T (see Koulouris et al). 2005;149:840-5

Katus HA (see Steen et al). 2005;149:564.e1-564.e7

Kaul P, Armstrong PW, Cowper PA, Eisenstein EL, Granger CB, Van de Werf F, Mark DB. Economic analysis of the Assessment of the Safety and Efficacy of a New Thrombolytic Regimen (ASSENT-3) study: costs of reperfusion strategies in acute myocardial infarction. 2005;149:637-44

Kerr CR, Humphries KH, Talajic M, Klein GJ, Connolly SJ, Green M, Boone J, Sheldon R, Dorian P, Newman D. Progression to chronic atrial fibrillation after the initial diagnosis of paroxysmal atrial fibrillation: results from the Canadian Registry of Atrial Fibrillation. 2005;149:489-96

Al-Khalidi HR (see Armstrong et al). 2005;149:402-7 (Trial design)

Al-Khatib SM, Sanders GD, Mark DB, Lee KL, Bardy GH, Bigger JT, Buxton AE, Connolly S, Kadish A, Moss A, Feldman AM, Ellenbogen KA, Singh S, Califf RM. Implantable cardioverter defibrillators and cardiac resynchronization therapy in patients with left ventricular dysfunction: randomized trial evidence through 2004. 2005;149:1020-34 (Meetings)

Al-Khatib SM (see Meine et al). 2005;149:670-4

Kilaru R (see Meine et al). 2005;149:670-4

Kim Y-H, Lee CW, Hong M-K, Park S-W, Tahk S-J, Yang J-Y, Saito S, Santosso T, Quan L, Ge J, Weissman NJ, Lansky AJ, Mintz GS, Park SJ. Randomized comparison of carbon ion-implanted stent versus bare metal stent in coronary artery disease: the Asian Pacific Multicenter Arthos Stent Study (PASS) trial. 2005;149:336-41

Kimura A (see Hayashi et al). 2005;149:284-90

Kindermann I (see Meyer et al). 2005;149:926.e1-926.e7

Kindermann W (see Meyer et al). 2005;149:926.e1-926.e7

King KM, Tsuyuki R, Faris P, Currie G, Maitland A, Collins-Nakai R. The Women's Recovery from Sternotomy (WREST) Study: design of a randomized trial of a novel undergarment for early use after sternotomy. 2005;149:761-7 (Trial design)

King TR (see Ballantyne et al). 2005;149:464-73. Correction 2005;149:882

Kisch S (see Nicenaber et al). 2005;149:592-9 (Trial design)

Kiyoshima T (see Hayashi et al). 2005;149:284-90

Kjekshus J (see Deedwania et al). 2005;149:159-67

Klassen PS (see Griffith et al). 2005;149:769-75 (Meetings)

Klein AL (see Jasper et al). 2005;149:309-15

Klein GJ (see Kerr et al). 2005;149:489-96

Klibaner M (see Deedwania et al). 2005;149:159-67

Klug D, Wallet F, Kacet S, Courcol RJ. Detailed bacteriologic tests to identify the origin of transvenous pacing system infections indicate a high prevalence of multiple organisms. 2005;149:322-8

Knobel E (see Avezum et al). 2005;149:67-73

Kobayashi N (see Hayashi et al). 2005;149:284-90

Kocijanec A (see Vrtovec et al). 2005;149:632-6

Kohsaka S, Di Tullio MR. Assessment of left ventricular mass using echocardiography: use of fundamental imaging. 2005;149:e31 (Letter reply)

Kohsaka S, Sciacca RR, Sugioka K, Sacco RL, Homma S, Di Tullio MR. Additional impact of electrocardiographic over echocardiographic diagnosis of left ventricular hypertrophy for predicting the risk of ischemic stroke. 2005;149:181-6

Komajda M (see Torp-Pedersen et al). 2005;149:370-6

Kooner JS (see Kapur et al). 2005;149:13-9 (Trial design)

Koulouris S, Lekatsas I, Karabinos I, Ioannidis G, Katostaras T, Kranidis A, Triantafillou K, Thalassinos N, Anthopoulos L. Microalbuminuria: a strong predictor of 3-year adverse prognosis in nondiabetic patients with acute myocardial infarction. 2005;149:840-5

Kranidis A (see Koulouris et al). 2005;149:840-5

Krauser DG, Lloyd-Jones DM, Chae CU, Cameron R, Anwaruddin S, Baggish AL, Chen A, Tung R, Januzzi JL Jr. Effect of body mass index on natriuretic peptide levels in patients with acute congestive heart failure: a ProBNP Investigation of Dyspnea in the Emergency Department (PRIDE) substudy. 2005;149:744-50

Kristensen SD (see Berger et al). 2005;149:869-75

Kron J (see Flaker et al). 2005;149:657-63

Krumholz HM (see Rathore et al). 2005;149:121-8, 1074-81

Kruse MW, Lee JJ. To the Editor. 2005;149:e23 (Letter reply)

Kuethe F (see Werner et al). 2005;149:129-37

Kulke C (see Steen et al). 2005;149:564.e1-564.e7

Kuntz RE (see Muni et al). 2005;149:415-33 (Meetings)

Kuntz RE (see Silber et al). 2005;149:689-94

Kurooka A (see Hayashi et al). 2005;149:284-90

Kussmaul W (see Carrozza et al). 2005;149:1136.e1-1136.e7

Kwok JMF, Christian TF, Miller TD, Hodge DO, Gibbons RJ. Incremental prognostic value of exercise single-photon emission computed tomographic (SPECT) thallium 201 imaging in patients with ST-T abnormalities on their resting electrocardiograms. 2005;149:145-51

L

Laarman GJ (see Rahel et al). 2005;149:414.e1-414.e3 (Trial design)

Lader E (see Eisenberg et al). 2005;149:813-9

Lai B (see Casscells et al). 2005;149:927-33

Lam G (see Shah et al). 2005;149:240-53 (Meetings)

Lam WWM (see Zhang et al). 2005;149:497-503

Lamb HJ (see Kaandorp et al). 2005;149:200-8 (Curriculum cardiol.)

Lamoureux M-C (see Blanchet et al). 2005;149:938.e1-938.e7

Lampert S (see Sequist et al). 2005;149:74-81

Langer A (see Cantor et al). 2005;149:275-83

Lansky AJ (see Kim et al). 2005;149:336-41

Lansky AJ (see Silber et al). 2005;149:689-94

Lapenna D (see Pierdomenico et al). 2005;149:934-8

Lasala J (see Silber et al). 2005;149:689-94

Latini R (see Maggioni et al). 2005;149:548-57

Lauer MS (see Rajagopal et al). 2005;149:534-40

Leano R (see Fang et al). 2005;149:349-54

Leano R (see Smart et al). 2005;149:152-8

Leclercq C (see Yu et al). 2005;149:600-5 (Trial design)

Lee CW (see Kim et al). 2005;149:336-41

Lee JJ (see Kruse and Lee). 2005;149:e23 (Letter reply)

Lee KL (see Al-Khatib et al). 2005;149:1020-34 (Meetings)

Lee TH (see Sequist et al). 2005;149:74-81

Lefer DJ (see Burkhoff and Lefer). 2005;149:573-9 (Progress cardiol.)

Lehrke S (see Steen et al). 2005;149:564.e1-564.e7

LeJemtel TH (see Adams et al). 2005;149:209-16 (Trial design)

Lekakis J (see Ikonomidis et al). 2005;149:832-9

Lekatsas I (see Koulouris et al). 2005;149:840-5

Lemons PW II (see Eisenstein et al). 2005;149:482-8

Lemos PA (see Arampatzis et al). 2005;149:329-35

Lemos PA (see Ix et al). 2005;149:512-9

Lennon RJ (see Singh et al). 2005;149:753-60 (Curriculum cardiol.)

León AR (see Yu et al). 2005;149:600-5 (Trial design)

Levey AS (see Mix et al). 2005;149:408-13 (Trial design)

Lewis EF (see Shah et al). 2005;149:715-21

Lewis JF, McGorray S, Lin L, Pepine CJ, Chaitman B, Doyle M, Edmundowicz D, Sharaf BL, Bairey Merz CN. Exercise treadmill testing using a modified exercise protocol in women with suspected myocardial ischemia: findings from the National Heart, Lung and Blood Institute-sponsored Women's Ischemia Syndrome Evaluation (WISE). 2005;149:527-33

Lieber EA (see Jasper et al). 2005;149:309-15

Lima JA (see Steen et al). 2005;149:564.e1-564.e7

Limbruno U (see Petronio et al). 2005;149:520-6

Lin L (see Lewis et al). 2005;149:527-33

Lind L (see Ärnlöv et al). 2005;149:902-7

Lindbäck J (see James et al). 2005;149:619-26

Lindbäck J (see Stenstrand et al). 2005;149:82-90

Lindeboom W (see Ix et al). 2005;149:512-9

Lindenfeld J. Prevalence of anemia and effects on mortality in patients with heart failure. 2005;149:391-401 (Curriculum cardiol.)

Ling MC, Ruddy TD, deKemp RA, Ukkonen H, Duchesne L, Higginson L, Williams KAP, McPherson R, Beanlands R. Early effects of statin therapy on endothelial function and microvascular reactivity in patients with coronary artery disease. 2005;149:1137.e9-1137.e16

LIPS Investigators (see Arampatzis et al). 2005;149:329-35

Lithell H (see Ärnlöv et al). 2005;149:902-7

Liu C-P (see Chiou et al). 2005;149:701-8

Liu ST (see Budoff et al). 2005;149:695-700

Liu-Stratton Y (see Binkley et al). 2005;149:342-8

Llacer À (see Bodí et al). 2005;149:268-74

Lloyd-Jones DM (see Krauser et al). 2005;149:744-50

Longaker RA (see Dawn et al). 2005;149:908-16

Lorenzoni R (see De Caterina and Lorenzoni). 2005;149:e4 (Letter reply)

Lotriente M (see Biondi-Zoccali et al). 2005;149:504-11

Lowe AM (see Dzavik et al). 2005;149:1128-34

Luciano AE (see Mukherjee et al). 2005;149:1003-8 (Trial design)

Ludwig J, Miner B, Eisenberg MJ. Smoking cessation in patients with coronary artery disease. 2005;149:565-72 (Curriculum cardiol.)

Lundkvist J (see Aspelin et al). 2005;149:298-303

Lutiger B (see Torp-Pedersen et al). 2005;149:370-6

Luttrell J (see Zhang et al). 2005;149:856-61

Lytle BL (see Kandzari et al). 2005;149:474-81

M

Macaya C (see Alfonso et al). 2005;149:335.e1-335.e8

Macin SM, Perna ER, Farías EF, Franciosi V, Cialzeta JR, Brizuela M, Medina F, Tajer C, Doval H, Badaracco R. Atorvastatin has an

important acute anti-inflammatory effect in patients with acute coronary syndrome: results of a randomized, double-blind, placebo-controlled study. 2005;149:451-7

Madjid M (see Casscells et al). 2005;149:927-33

Mady C (see Arteaga et al). 2005;149:1099-105

Maewal P (see Sims et al). 2005;149:1062-5

Maggioni AP, Latini R, Carson PE, Singh SN, Barlera S, Glazer R, Masson S, Cerè E, Tognoni G, Cohn JN. Valsartan reduces the incidence of atrial fibrillation in patients with heart failure: results from the Valsartan Heart Failure Trial (Val-HeFT). 2005;149:548-57

Mahaffey KW, Ferguson JJ. Exploring the role of enoxaparin in the management of high-risk patients with non-ST-elevation acute coronary syndromes: the SYNERGY trial. 2005;149:S81-90

Mahaffey KW (see Califff et al). 2005;149:S91-9

Maisch B (see Alter et al). 2005;149:1082-90

Maitland A (see King et al). 2005;149:761-7 (Trial design)

Makdisse M (see Avezum and Makdisse). 2005;149:e27 (Letter reply)

Makdisse M (see Avezum et al). 2005;149:67-73

Malik IS (see Kapur et al). 2005;149:13-9 (Trial design)

Malouf JF (see Gurevitz et al). 2005;149:316-21

Mancini M (see Pierdomenico et al). 2005;149:934-8

Manente BM (see Pierdomenico et al). 2005;149:934-8

Mann JFE (see Dagenais et al). 2005;149:54-60

Mann KG. The challenge of regulating anticoagulant drugs: focus on warfarin. 2005;149:S36-42

Mansencal N, Dubourg O. Assessment of left ventricular mass using echocardiography: use of fundamental imaging. 2005;149:e29 (Letter)

Manuela M (see Faglia et al). 2005;149:283.e1-283.e6

Mar G-Y (see Chiou et al). 2005;149:701-8

Mardi T (see Berliner et al). 2005;149:260-7

Mariani M (see Petronio et al). 2005;149:520-6

Mark DB (see Al-Khatib et al). 2005;149:1020-34 (Meetings)

Mark DB (see Califff and Mark). 2005;149:743

Mark DB (see Kaul et al). 2005;149:637-44

Mark DB (see Reed et al). 2005;149:434-43 (Meetings)

Marwick TH (see Fang et al). 2005;149:349-54

Marwick TH (see Smart et al). 2005;149:152-8

Masoudi FA (see Rathore et al). 2005;149:121-8

Masson S (see Maggioni et al). 2005;149:548-57

Mastali K (see Dawn et al). 2005;149:908-16

Matsuura M (see Hayashi et al). 2005;149:284-90

Matthews KA, Sowers MF, Derby CA, Stein E, Miracle-McMahill H, Crawford SL, Pasternak RC. Ethnic differences in cardiovascular risk factor burden among middle-aged women: Study of Women's Health Across the Nation (SWAN). 2005;149:1066-73

Maurizio C (see Faglia et al). 2005;149:283.e1-283.e6

Mayct J (see Kapur et al). 2005;149:13-9 (Trial design)

Mayhew A (see Reid et al). 2005;149:862-8

McCabe CH (see Antman et al). 2005;149:217-26 (Trial design)

McCabe CH (see Sabatine et al). 2005;149:227-33 (Trial design)

McCabe CH (see Smith et al). 2005;149:444-50

McGill JB (see Mix et al). 2005;149:408-13 (Trial design)

McGorray S (see Lewis et al). 2005;149:527-33

McGuire DK (see Sims et al). 2005;149:1062-5

McKenney JM (see Jones et al). 2005;149:e1

McLean KA (see Yusuf et al). 2005;149:e25-6 (Letter)

McMurray JJV (see Mix et al). 2005;149:408-13 (Trial design)

McPherson R (see Ling et al). 2005;149:1137.e9-1137.e16

McRae AT III (see O'Neill et al). 2005;149:363-9

Medina F (see Macin et al). 2005;149:451-7

Medina-Lezama J, Chirinos-Pacheco J, Chirinos JA. Cardiovascular disease in Latin America. 2005;149:e13 (Letter)

Mega JL, Morrow DA, Sabatine MS, Zhao X-Q, Snapinn SM, DiBattiste PM, Gibson CM, Antman EM, Braunwald E, Théroux P. Correlation between the TIMI risk score and high-risk angiographic findings in non-ST-elevation acute coronary syndromes: observations from the Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) trial. 2005;149:846-50

Mehrotra R (see Budoff et al). 2005;149:695-700

Mehta RH (see Avezum et al). 2005;149:67-73

Meine TJ, Al-Khatib SM, Alexander JH, Granger CB, White HD, Kilaru R, Williams K, Ohman EM, Topol E, Califff RM. Incidence, predictors, and outcomes of high-degree atrioventricular block complicating acute myocardial infarction treated with thrombolytic therapy. 2005;149:670-4

Meine TJ, Roe MT, Chen AY, Patel MR, Washam JB, Ohman EM, Peacock WF, Pollack CV Jr, Gibler WB, Peterson ED, CRUSADE Investigators. Association of intravenous morphine use and outcomes in acute coronary syndromes: results from the CRUSADE Quality Improvement Initiative. 2005;149:1043-9

Melloni C (see Patel et al). 2005;149:1009-19 (Meetings)

Menon V (see Dzavik et al). 2005;149:1128-34

Mercado N (see Ix et al). 2005;149:512-9

MERIT-HF Study Group (see Deedwania et al). 2005;149:159-67

Merlino J (see Yu et al). 2005;149:600-5 (Trial design)

Mernoff DB (see Rifkin and Mernoff). 2005;149:1120-7

Merten C (see Steen et al). 2005;149:564.e1-564.e7

Metra M (see Torp-Pedersen et al). 2005;149:370-6

Meyer T, Görge G, Schwaab B, Hildebrandt K, Walldorf J, Schäfer C, Kindermann I, Scharhag J, Kindermann W. An alternative approach for exercise prescription and efficacy testing in patients with chronic heart failure: a randomized controlled training study. 2005;149:926.e1-926.e7

Mezzetti A (see Pierdomenico et al). 2005;149:934-8

Micari A (see de Gregorio et al). 2005;149:1091-8

Michela G (see Faglia et al). 2005;149:283.e1-283.e6

Micheli A (see Petronio et al). 2005;149:520-6

Mickel M (see Flaker et al). 2005;149:657-63

Miki T (see Ogimoto et al). 2005;149:e19 (Letter)

Millane T (see Kapur et al). 2005;149:13-9 (Trial design)

Miller TD (see Kwok et al). 2005;149:145-51

Minati M (see De Luca et al). 2005;149:1135.e11-1135.e18

Miner B (see Ludwig et al). 2005;149:565-72 (Curriculum cardioli.)

Mintz GS (see Kim et al). 2005;149:336-41

Miracle-McMahill H (see Matthews et al). 2005;149:1066-73

Miranda PJ, DeFrondo RA, Califff RM, Guyton JR. Metabolic syndrome: definition, pathophysiology, and mechanisms. 2005;149:33-45 (Meetings)

Miranda PJ, DeFronzo RA, Califf RM, Guyton JR. Metabolic syndrome: evaluation of pathological and therapeutic outcomes. 2005;149:20-32 (Meetings)

Mishra RA (see Yusuf et al). 2005;149:e25-6 (Letter)

Mitchell GF, Pfeffer MA. Evaluation and management of patients with uncontrolled systolic hypertension: is another new paradigm really needed? 2005;149:776-84 (Meetings)

Mitchell RG (see Shah et al). 2005;149:240-53 (Meetings)

Mitrani G (see DiMarco et al). 2005;149:650-6

Mix T-CH, Brenner RM, Cooper ME, de Zeeuw D, Ivanovich P, Levey AS, McGill JB, McMurray JJV, Parfrey PS, Parving H-H, Pereira BJG, Remuzzi G, Singh AK, Solomon SD, Stehman-Breen C, Toto RD, Pfeffer MA. Rationale—Trial to Reduce Cardiovascular Events with Aranesp Therapy (TREAT): evolving the management of cardiovascular risk in patients with chronic kidney disease. 2005;149:408-13 (Trial design)

Miyatake M (see Hayashi et al). 2005;149:284-90

Mohiddin SA (see Sachdev et al). 2005;149:730-6

Mokdad AH (see Ajani et al). 2005;149:254-9

Moliterno DJ (see Berger et al). 2005;149:869-75

Moliterno DJ (see Gomberg-Maitland et al). 2005;149:613-8

Montalescot G (see Avezum et al). 2005;149:67-73

Montalescot G (see Giugliano et al). 2005;149:994-1002 (Trial design)

Mookadam F (see Frantz et al). 2005;149:541-7

Moon JCC (see Janardhanan et al). 2005;149:355-62

Moosdorf R (see Alter et al). 2005;149:1082-90

Moreno R (see Alfonso et al). 2005;149:335.e1-335.e8

Morrin L (see Reid et al). 2005;149:862-8

Morris BL (see Harvey et al). 2005;149:291-7

Morrow DA (see Antman et al). 2005;149:217-26 (Trial design)

Morrow DA (see Mega et al). 2005;149:846-50

Moscucci M (see Mukherjee et al). 2005;149:1003-8 (Trial design)

Moser DK (see Zambroski et al). 2005;149:558-64

Moss A (see Al-Khatib et al). 2005;149:1020-34 (Meetings)

Mottram PM (see Fang et al). 2005;149:349-54

Mottram PM (see Smart et al). 2005;149:152-8

Moualla SK (see Frantz et al). 2005;149:541-7

Mudge G Jr (see Shah et al). 2005;149:715-21

Mukherjee D, Munir K, Hirsch AT, Chetcuti S, Grossman PM, Rajagopalan S, Nallamothu BK, Moscucci M, Henke P, Kassab E, Sohal C, Riba A, Person D, Luciano AE, DeGregorio M, Patel K, Rutkowski KC, Eagle KA. Development of a multicenter peripheral arterial interventional database: the PVD-QI². 2005;149:1003-8 (Trial design)

Muni NI, Califf RM, Foy JR, Boam AB, Zuckerman BD, Kuntz RE. Coronary drug-eluting stent development: issues in trial design. 2005;149:415-33 (Meetings)

Munir K (see Mukherjee et al). 2005;149:1003-8 (Trial design)

Murohara T (see Yoshida et al). 2005;149:e2

Murphy SA (see Cantor et al). 2005;149:275-83

Murphy SA (see Gomberg-Maitland et al). 2005;149:613-8

Murphy SA (see Smith et al). 2005;149:444-50

Murray RD (see Jasper et al). 2005;149:309-15

N

Nagge J, Fernandes O, Huh J. To the Editor. 2005;149:e21 (Letter)

Nallamothu BK (see Mukherjee et al). 2005;149:1003-8 (Trial design)

Nanasato M (see Yoshida et al). 2005;149:e2

NASDAC Investigators (see Jones et al). 2005;149:e1

Nasir K (see Budoff et al). 2005;149:695-700

Nellens P (see Van Laethem et al). 2005;149:175-80

Nelson SM (see Frantz et al). 2005;149:541-7

Nemeth M (see DiMarco et al). 2005;149:650-6

Neuhaus K-L (see Zeymer et al). 2005;149:91-7

Newby LK (see Giugliano et al). 2005;149:994-1002 (Trial design)

Newman D. Atrial fibrillation and quality of life: clarity or evidence-based confusion? 2005;149:4-6 (Editorial)

Newman D (see Kerr et al). 2005;149:489-96

Ng K (see O'Neill et al). 2005;149:363-9

Nicolucci A (see Franciosi et al). 2005;149:104-11

Niebauer J (see Sick et al). 2005;149:681-8. Correction 2005;149:1136

Nienaber CA, Zannetti S, Barbieri B, Kische S, Schareck W, Rehders TC, INSTEAD study collaborators. INvestigation of STent grafts in patients with type B Aortic Dissection: design of the INSTEAD trial—a prospective, multicenter, European randomized trial. 2005;149:592-9 (Trial design)

Nieto FJ (see Wattanakit et al). 2005;149:606-12

Nihoyannopoulos P (see Ikonomidis et al). 2005;149:832-9

Nihoyannopoulos P (see Yu et al). 2005;149:600-5 (Trial design)

Nisanci Y (see Pamukcu et al). 2005;149:675-80

Nobrega TP (see Frantz et al). 2005;149:541-7

Noël B. Regarding the mechanism of statin-induced myopathy. 2005;149:e3 (Letter)

Nohria A (see Shah et al). 2005;149:715-21

Nolan RP, Kamath MV, Floras JS, Stanley J, Pang C, Picton P, Young QR. Heart rate variability biofeedback as a behavioral neurocardiac intervention to enhance vagal heart rate control. 2005;149:1137.e1-1137.e7

Nordin M (see Saleh et al). 2005;149:876-82

Notarbartolo D (see Yu et al). 2005;149:600-5 (Trial design)

Notarius CF (see Harvey et al). 2005;149:291-7

NQWMI Investigators (see Eisenberg et al). 2005;149:813-9

Núñez J (see Bodí et al). 2005;149:268-74

Nunziatta E (see Binkley et al). 2005;149:342-8

O

○

O'Brien BJ (see Reed et al). 2005;149:434-43 (Meetings)

O'Connor CM (see Whellan et al). 2005;149:722-9

O'Connor GT (see Zhang et al). 2005;149:856-61

Oddone EZ (see Bosworth et al). 2005;149:795-803 (Meetings)

Offenbacher S, Beck JD. A perspective on the potential cardioprotective benefits of periodontal therapy. 2005;149:950-4 (Editorial)

Oflaz H (see Pamukcu et al). 2005;149:675-80

Ogimoto A, Shigematsu Y, Higaki J, Miki T. Angiotensin-converting enzyme inhibitors as a new therapy for atrial fibrillation? Controversy. 2005;149:e19 (Letter)

Ohman EM (see Kandzari et al). 2005;149:474-81

Ohman EM (see Meine et al). 2005;149:670-4, 1043-9

Oldgren J (see James et al). 2005;149:619-26

Oldridge NB (see Reid et al). 2005;149:862-8

Oliveira G (see Shah et al). 2005;149:240-53 (Meetings)

Oliveira GBF (see Patel et al). 2005;149:1009-19 (Meetings)

Oliveria SA (see Borzecki et al). 2005;149:785-94 (Meetings)

Olsen MK (see Bosworth et al). 2005;149:795-803 (Meetings)

Olson LJ (see Frantz et al). 2005;149:541-7

O'Neill JO, Bott-Silverman CE, McRae AT III, Troughton RW, Ng K, Starling RC, Young JB. B-type natriuretic peptide levels are not a surrogate marker for invasive hemodynamics during management of patients with severe heart failure. 2005;149:363-9

O'Neill W (see Armstrong et al). 2005;149:402-7 (Trial design)

O'Neill W (see Silber et al). 2005;149:689-94

O'Neill WW (see Ix et al). 2005;149:512-9

Ordin DL (see Rathore et al). 2005;149:121-8

Ortiz J (see Eisenberg et al). 2005;149:813-9

Ottenvanger JP (see van der Horst et al). 2005;149:585-91 (Trial design), 1135.e1-1135.e9

Ozaydin M (see Dogan et al). 2005;149:1037-42

Ozgul M (see Dogan et al). 2005;149:1037-42

P

Page RL (see Patton and Page). 2005;149:388-90 (Editorial)

Palagummi P, Saltzman H, Ezekowitz M. Direct thrombin inhibitors: stroke prevention in atrial fibrillation and potential anti-inflammatory properties. 2005;149:S32-5

Paliwal VS (see Dawn et al). 2005;149:908-16

Palmissano J (see Ballantyne et al). 2005;149:464-73. Correction 2005;149:882

Pamukcu B, Oflaz H, Nisanci Y. The role of platelet glycoprotein IIIa polymorphism in the high prevalence of in vitro aspirin resistance in patients with intracoronary stent restenosis. 2005;149:675-80

Pan H-B (see Chiou et al). 2005;149:701-8

Pang C (see Nolan et al). 2005;149:1137.e1-1137.e7

Papadakis S (see Reid et al). 2005;149:862-8

Pape LA (see Jasper et al). 2005;149:309-15

Papini B (see Petronio et al). 2005;149:520-6

Parameswaran AC, Tang WHW, Francis GS, Gupta R, Young JB. Why do patients fail to receive *<gb>*-blockers for chronic heart failure over time? A "real-world" single-center, 2-year follow-up experience of *<gb>*-blocker therapy in patients with chronic heart failure. 2005;149:921-6

Parfrey PS (see Mix et al). 2005;149:408-13 (Trial design)

Paris M (see Zhang et al). 2005;149:856-61

Park SJ (see Kim et al). 2005;149:336-41

Park S-W (see Kim et al). 2005;149:336-41

Parving HH (see Mix et al). 2005;149:408-13 (Trial design)

Pascual LG (see Glasser et al). 2005;149:290.e1-290.e9

Passman R, Kadish A. Rate control versus rhythm control: choose your poison. 2005;149:957-9 (Editorial)

Pasternak RC (see Matthews et al). 2005;149:1066-73

Patel K (see Mukherjee et al). 2005;149:1003-8 (Trial design)

Patel M (see Shah et al). 2005;149:240-53 (Meetings)

Patel MR, Baeza RG, Goyal A, Halabi AR, Melloni C, Oliveira GBG, Tricoci P, Valente AM. Highlights from the American College of Cardiology Annual Scientific Session 2005: March 6 to 9, 2005, Orlando, Florida. 2005;149:1009-19 (Meetings)

Patel MR (see Meine et al). 2005;149:1043-9

Patel S (see Budhwani et al). 2005;149:709-14

Patton KK, Page RL. New-onset paroxysmal atrial fibrillation: is permanence inevitable? 2005;149:388-90 (Editorial)

Pavay S (see Casscells et al). 2005;149:927-33

Peacock WF (see Meine et al). 2005;149:1043-9

Pedersen SS, van Domburg RT, Theuns DAMJ, Jordans L, Erdman RAM. Concerns about the implantable cardioverter defibrillator: a determinant of anxiety and depressive symptoms independent of experienced shocks. 2005;149:664-9

Pellegrini F (see Franciosi et al). 2005;149:104-11

Pellicer M (see Bodi et al). 2005;149:268-74

Pennell DJ (see Janardhanan et al). 2005;149:355-62

Pepine CJ (see Lewis et al). 2005;149:527-33

Pereira BJG (see Mix et al). 2005;149:408-13 (Trial design)

Pérez-Vizcayno MJ (see Alfonso et al). 2005;149:335.e1-335.e8

Perna ER (see Macin et al). 2005;149:451-7

Perry GJ (see Ahmed et al). 2005;149:737-43

Person D (see Mukherjee et al). 2005;149:1003-8 (Trial design)

Petersen JL, Harrington RA. Revascularization of coronary atherosclerosis in patients with diabetes mellitus—there is more to it than meets the image intensifier. 2005;149:190-3 (Editorial)

Petersen JL (see Calif et al). 2005;149:S91-9

Peterson E (see Whellan et al). 2005;149:722-9

Peterson ED (see Kandzari et al). 2005;149:474-81

Peterson ED (see Meine et al). 2005;149:1043-9

Peterson ED (see Roe and Peterson). 2005;149:751-2 (Editorial)

Peterson GE (see Sims et al). 2005;149:1062-5

Peterson GM (see Jackson et al). 2005;149:e3 (Letter)

Petronio AS, Amoroso G, Limbruno U, Papini B, De Carlo M, Micheli A, Ciabatti N, Mariani M. Simvastatin does not inhibit intimal hyperplasia and restenosis but promotes plaque regression in normocholesterolemic patients undergoing coronary stenting: a randomized study with intravascular ultrasound. 2005;149:520-6

Pfeffer MA (see Mitchell and Pfeffer). 2005;149:776-84 (Meetings)

Pfeffer MA (see Mix et al). 2005;149:408-13 (Trial design)

Picard MH (see Zavik et al). 2005;149:1128-34

Picton P (see Nolan et al). 2005;149:1137.e1-1137.e7

Picton PE (see Harvey et al). 2005;149:291-7

Pierdomenico SD, Lapenna D, Bucci A, Manente BM, Mancini M, Cuccurullo F, Mezzetti A. Blood pressure variability and prognosis in uncomplicated mild hypertension. 2005;149:934-8

Pilger E (see Seino et al). 2005;149:1050-4

Pilote L (see Beck et al). 2005;149:194-9 (Curriculum cardiol.)

Pilote L (see Eisenberg et al). 2005;149:813-9

Pimentel G (see Alfonso et al). 2005;149:335.e1-335.e8

Pineda-Pompa LR (see Barrera-Ramirez et al). 2005;149:e5 (Letter)

Plehn JF (see Sachdev et al). 2005;149:730-6

Pocock S, Wang D, Wilhelmsen L, Hennekens CH. The data monitoring experience in the Candesartan in Heart Failure Assessment of Reduction in Mortality and morbidity (CHARM) program. 2005;149:939-43

Pogue J (see Dagenais et al). 2005;149:54-60

Pollack CV Jr (see Kandzari et al). 2005;149:474-81

Pollack CV Jr (see Meine et al). 2005;149:1043-9

Poole-Wilson PA (see Torp-Pedersen et al). 2005;149:370-6

Popma JJ (see Silber et al). 2005;149:689-94

Popp RL. Conflict of interest for the physician-inventor using a device in human subjects. 2005;149:1-3 (Editorial)

Pothier CE (see Rajagopal et al). 2005;149:534-40

Powell LH, Catellier D, Freedland KE, Burg MM, Woods SL, Bittner V, Calvin JE, Blumenthal JA, ENRICHD Investigators. Depression and heart failure in patients with a new myocardial infarction. 2005;149:851-5

Prins JB (see Fang et al). 2005;149:349-54

PRISON II study investigators (see Rahel et al). 2005;149:414.e1-414.e3 (Trial design)

PROSPECT Investigators (see Yu et al). 2005;149:600-5 (Trial design)

Punjabi P (see Kapur et al). 2005;149:13-9 (Trial design)

Q

Quality of Care and Outcomes in Type 2 Diabetes (QuED) Study Group (see Franciosi et al). 2005;149:104-11

Quan L (see Kim et al). 2005;149:336-41

R

Racine N (see Blanchet et al). 2005;149:938.e1-938.e7

Radovancevic B (see Vrtovec et al). 2005;149:632-6

Raggi P (see Ferramosca et al). 2005;149:820-5

Rahel BM, Laarman GJ, Suttorp MJ, PRISON II study investigators. Primary stenting of occluded native coronary arteries II—rationale and design of the PRISON II study: a randomized comparison of bare metal stent implantation with sirolimus-eluting stent implantation for the treatment of chronic total coronary occlusions. 2005;149:414.e1-414.e3 (Trial design)

Rajagopal V, Bhatt DL. Acute coronary syndrome statistics: what you don't see can hurt you. 2005;149:955-6 (Editorial)

Rajagopal V, Gurm HS, Brunkun RC, Pothier CE, Bhatt DL, Lauer MS. Prediction of death or myocardial infarction by exercise single photon emission computed tomography perfusion scintigraphy in patients who have had recent coronary artery stenting. 2005;149:534-40

Rajagopalan S (see Mukherjee et al). 2005;149:1003-8 (Trial design)

Ranchor AV (see Hagens et al). 2005;149:1106-11

RAte Control versus Electrical cardioversion for persistent atrial fibrillation study group (see Hagens et al). 2005;149:1106-11

Rathore SS, Foody JM, Wang Y, Herrin J, Masoudi FA, Havranek EP, Ordin DL, Krumholz HM. Sex, quality of care, and outcomes of

elderly patients hospitalized with heart failure: findings from the National Heart Failure Project. 2005;149:121-8

Rathore SS, Frederick PD, Every NR, Barron HV, Krumholz HM. Racial differences in reperfusion therapy use in patients hospitalized with myocardial infarction: a regional phenomenon. 2005;149:1074-81

Ratti C (see Ferramosca et al). 2005;149:820-5

Raza ST (see Dawn et al). 2005;149:908-16

Reed SD, Anstrom KJ, Bakha A, Briggs AH, Calif RM, Cohen DJ, Drummond MF, Glick HA, Gnanasakthy A, Hlatky MA, O'Brien BJ, Torti FM Jr, Tsatsis AA, Willan AR, Mark DB, Schulman KA. Conducting economic evaluations alongside multinational clinical trials: toward a research consensus. 2005;149:434-43 (Meetings)

Rehders TC (see Nienaber et al). 2005;149:592-9 (Trial design)

Reid RD, Dafoe WA, Morrin L, Mayhew A, Papadakis S, Beaton L, Oldridge NB, Coyle D, Wells GA. Impact of program duration and contact frequency on efficacy and cost of cardiac rehabilitation: results of a randomized trial. 2005;149:862-8

Reisman M (see Silber et al). 2005;149:689-94

Remme WJ (see Torp-Pedersen et al). 2005;149:370-6

Remuzzi G (see Mix et al). 2005;149:408-13 (Trial design)

Riba A (see Mukherjee et al). 2005;149:1003-8 (Trial design)

Richardson K, Engel G, Yamazaki T, Chun S, Froelicher VF. Electrocardiographic damage scores and cardiovascular mortality. 2005;149:458-63

Richardt G (see Steen et al). 2005;149:564.e1-564.e7

Richartz BM (see Haberl et al). 2005;149:1112-9

Rienstra M (see Hagens et al). 2005;149:1106-11

Rifkin RD, Mernoff DB. Noninvasive evaluation of pericardial effusion composition by computed tomography. 2005;149:1120-7

Rihal CS (see Singh et al). 2005;149:753-60 (Curriculum cardiol.)

Risérus U (see Årnöv et al). 2005;149:902-7

Roberto M (see Faglia et al). 2005;149:283.e1-283.e6

Rocha-Singh K (see Holmes et al). 2005;149:883-7

Roe MT, Peterson ED. Improvements in quality improvement. 2005;149:751-2 (Editorial)

Roe MT (see Kandzari et al). 2005;149:474-81

Roe MT (see Meine et al). 2005;149:1043-9

Rogowski O (see Berliner et al). 2005;149:260-7

Rosales AG (see Gurevitz et al). 2005;149:316-21

Rosenfeld LE (see DiMarco et al). 2005;149:650-6

Rosenfield K (see Holmes et al). 2005;149:883-7

Rosenthal JE (see Gami et al). 2005;149:e11 (Letter reply)

Roser LP (see Zambroski et al). 2005;149:558-64

Rossi MCE (see Franciosi et al). 2005;149:104-11

Rozenblat M (see Berliner et al). 2005;149:260-7

Rubboli A, Colletta M, Di Pasquale G. Regarding antithrombotic treatment after coronary stenting in patients on chronic oral anticoagulation. 2005;149:e1 (Letter)

Ruddy TD (see Ling et al). 2005;149:1137.e9-1137.e16

Ruiz V (see Bodí et al). 2005;149:268-74

Rupp H (see Alter et al). 2005;149:1082-90

Rutkowski KC (see Mukherjee et al). 2005;149:1003-8 (Trial design)

S

Sabaté M (see Alfonso et al). 2005;149:335.e1-335.e8

Sabatine MS, McCabe CH, Gibson CM, Cannon CP. Design and rationale of Clopidogrel as Adjunctive Reperfusion Therapy-Thrombolysis in Myocardial Infarction (CLARITY-TIMI) 28 trial. 2005;149:227-33 (Trial design)

Sabatine MS (see Mega et al). 2005;149:846-50

Sacco M (see Franciosi et al). 2005;149:104-11

Sacco RL (see Kohsaka et al). 2005;149:181-6

Sachdev V, Shizukuda Y, Brenneman CL, Birdsall CW, Waclawiw MA, Arai AE, Mohiddin SA, Tripodi D, Fananapazir L, Plehn JF. Left atrial volumetric remodeling is predictive of functional capacity in nonobstructive hypertrophic cardiomyopathy. 2005;149:730-6

Safford R (see Flaker et al). 2005;149:657-63

Safford RE (see Curtis et al). 2005;149:304-8

Safford RE (see DiMarco et al). 2005;149:650-6

Sager PT (see Kastelein et al). 2005;149:234-9 (Trial design)

Saia F (see Arampatzis et al). 2005;149:329-35

Saito S (see Kim et al). 2005;149:336-41

Saleh N, Svane B, Jensen J, Hansson L-O, Nordin M, Tornvall P. Stent implantation, but not pathogen burden, is associated with plasma C-reactive protein and interleukin-6 levels after percutaneous coronary intervention in patients with stable angina pectoris. 2005;149:876-82

Saligrama RS (see Eisenberg et al). 2005;149:813-9

Saltzman H (see Palagummi et al). 2005;149:S32-5

Sammicheli L (see Conti et al). 2005;149:894-901

Sanborn TA (see Dzavik et al). 2005;149:1128-34

Sanchis J (see Bodí et al). 2005;149:268-74

Sanders GD (see Al-Khatib et al). 2005;149:1020-34 (Meetings)

Sanderson JE (see Zhang et al). 2005;149:497-503

Santoso T (see Kim et al). 2005;149:336-41

Sato I (see Sequist et al). 2005;149:74-81

Saucedo J (see Dzavik et al). 2005;149:1128-34

Savage PD, Banzer JA, Balady GJ, Ades PA. Prevalence of metabolic syndrome in cardiac rehabilitation/secondary prevention programs. 2005;149:627-31

Schaefer M (see Sequist et al). 2005;149:74-81

Schäfer C (see Meyer et al). 2005;149:926.e1-926.e7

Schareck W (see Nienaber et al). 2005;149:592-9 (Trial design)

Scharhag J (see Meyer et al). 2005;149:926.e1-926.e7

Scherhag A (see Torp-Pedersen et al). 2005;149:370-6

Schmideder RE (see John et al). 2005;149:473.e1-473.e10

Schneider MP (see John et al). 2005;149:473.e1-473.e10

Schröder K (see Zeymer et al). 2005;149:91-7

Schröder R (see Zeymer et al). 2005;149:91-7

Schuijff JD (see Bax and Schuijff). 2005;149:960-61 (Editorial)

Schuler G (see Sick et al). 2005;149:681-8. Correction 2005;149:1136

Schull-Meade R (see Fang et al). 2005;149:349-54

Schulman KA (see Eisenstein et al). 2005;149:482-8

Schulman KA (see Reed et al). 2005;149:434-43 (Meetings)

Schulman KA (see Whellan et al). 2005;149:722-9

Schuster L (see Steen et al). 2005;149:564.e1-564.e7

Schwaab B (see Meyer et al). 2005;149:926.e1-926.e7

Schwartz GG. Statins in acute coronary syndromes: the sooner, the better? 2005;149:377-80 (Editorial)

Schwartz G (see Werner et al). 2005;149:129-37

Sciaccia RH (see Kohsaka et al). 2005;149:181-6

Seals AA (see Curtis et al). 2005;149:304-8

Seinost G, Wimmer G, Skerget M, Thaller E, Brodmann M, Gasser R, Bratschko RO, Pilger E. Periodontal treatment improves endothelial dysfunction in patients with severe periodontitis. 2005;149:1050-4

Senges J (see Zeymer et al). 2005;149:91-7

Senior R (see Janardhanan et al). 2005;149:355-62

Sequist TD, Bates DW, Cook EF, Lampert S, Schaefer M, Wright J, Sato L, Lee TH. Prediction of missed myocardial infarction among symptomatic outpatients without coronary heart disease. 2005;149:74-81

Serio K (see Eisenberg et al). 2005;149:813-9

Serov J (see Berliner et al). 2005;149:260-7

Serruy PW (see Arampatzis et al). 2005;149:329-35

Serruy PW (see Ix et al). 2005;149:512-9

Sezgin AT (see Gulcan et al). 2005;149:917-20

Al-Shaer MH. Is atorvastatin more appropriate to use in combination with niacin than simvastatin in patients with the metabolic syndrome? 2005;149:e17 (Letter)

Shah MR, Flavell CM, Weintraub JR, Young MA, Hasselblad V, Fang JC, Nohria A, Lewis EF, Givertz MM, Mudge G Jr, Stevenson LW. Intensity and focus of heart failure disease management after hospital discharge. 2005;149:715-21

Shah S, Patel M, Goyal A, Amos A, Baeza R, Halabi A, Lam G, Mitchell RG, Oliveira G, Valente AM. Highlights from the American Heart Association Annual Scientific Sessions 2004: November 7-10, 2004. 2005;149:240-53 (Meetings)

Shapiro I (see Berliner et al). 2005;149:260-7

Sharaf BL (see Lewis et al). 2005;149:527-33

Sharma D (see Antman et al). 2005;149:217-26 (Trial design)

Sharma SK (see Silber et al). 2005;149:689-94

Sheldon R (see Kerr et al). 2005;149:489-96

Shen W-K (see Elesber et al). 2005;149:826-31

Sheppard R (see Blanchet et al). 2005;149:938.e1-938.e7

Shigematsu Y (see Ogimoto et al). 2005;149:e19 (Letter)

Shizukuda Y (see Sachdev et al). 2005;149:730-6

Shlipak MG (see Ix et al). 2005;149:512-9

SHOCK Investigators (see Dzavik et al). 2005;149:1128-34

Siadaty MS (see Casscells et al). 2005;149:927-33

Sick PB, Brosteau O, Ulrich M, Thieli H, Niebauer J, Busch I, Schuler G. Prospective randomized comparison of early and late results of a carbonized stent versus a high-grade stainless steel stent of identical design: the Prevention of Recurrent Venous Thromboembolism (PREVENT) trial. 2005;149:681-8. Correction 2005;149:1136

Siddiqui H (see Casscells et al). 2005;149:927-33

Siegbahn A (see James et al). 2005;149:619-26

Silber S, Popma JJ, Suntharalingam M, Lansky AJ, Heuser RR, Speiser B, Teirstein PS, Bass T, O'Neill W, Lasala J, Reisman M, Sharma SK, Kuntz RE, Bonan R, START Investigators. Two-year

clinical follow-up of $^{90}\text{Sr}/^{90}\text{Y}$ -radiation versus placebo control for the treatment of in-stent restenosis. 2005;149:689-94

Sims JB, de Lemos JA, Maewal P, Warner JJ, Peterson GE, McGuire DK. Urinary tract infection in patients with acute coronary syndrome: a potential systemic inflammatory connection. 2005;149:1062-5

Singh AK (see Mix et al). 2005;149:408-13 (Trial design)

Singh M, Rihal CS, Lennon RJ, Garratt KN, Holmes DR Jr. A critical appraisal of current models of risk stratification for percutaneous coronary interventions. 2005;149:753-60 (Curriculum cardiol.)

Singh S (see Al-Khatib et al). 2005;149:1020-34 (Meetings)

Singh SN (see Maggioni et al). 2005;149:548-57

Sirois P (see Blanchet et al). 2005;149:938.e1-938.e7

Skene A (see Torp-Pedersen et al). 2005;149:370-6

Skerget M (see Seinost et al). 2005;149:1050-4

Slater JN (see Dzavik et al). 2005;149:1128-34

Slater W (see Curtis et al). 2005;149:304-8

Slee A (see Curtis et al). 2005;149:304-8

Sleeper LA (see Dzavik et al). 2005;149:1128-34

Smart PA (see Elesber et al). 2005;149:826-31

Smart N, Haluska B, Leano R, Case C, Mottram PM, Marwick TH. Determinants of functional capacity in patients with chronic heart failure: role of filling pressure and systolic and diastolic function. 2005;149:152-8

Smith CS, Cannon CP, McCabe CH, Murphy SA, Bentley J, Braunwald E. Early initiation of lipid-lowering therapy for acute coronary syndromes improves compliance with guideline recommendations: observations from the Orbofiban in Patients with Unstable Coronary Syndromes (OPUS-TIMI 16) trial. 2005;149:444-50

Smooke S, Horwitz TB, Fonarow GC. Insulin-treated diabetes is associated with a marked increase in mortality in patients with advanced heart failure. 2005;149:168-74

Snappi SM (see Mega et al). 2005;149:846-50

So NMC (see Zhang et al). 2005;149:497-503

Sobkowski W (see Eisenberg et al). 2005;149:813-9

Sohal C (see Mukherjee et al). 2005;149:1003-8 (Trial design)

Solomon SD (see Mix et al). 2005;149:408-13 (Trial design)

Sowers MF (see Matthews et al). 2005;149:1066-73

Speiser B (see Silber et al). 2005;149:689-94

Spencer F (see Avezum et al). 2005;149:67-73

Spencer FA (see Tran and Spencer). 2005;149:S9-18

Spinar J (see Deedwania et al). 2005;149:159-67

Spodick DH. To the Editor. 2005;149:e9 (Letter)

Stanbrook H (see Deedwania et al). 2005;149:159-67

Stanley J (see Nolan et al). 2005;149:1137.e1-1137.e7

Starling RC (see O'Neill et al). 2005;149:363-9

START Investigators (see Silber et al). 2005;149:689-94

Steen H, Lehrke S, Wiegand UKH, Merten C, Schuster L, Richardt G, Kulke C, Gehl HB, Lima JA, Katus HA, Giannitsis E. Very early cardiac magnetic resonance imaging for quantification of myocardial tissue perfusion in patients receiving tirofiban before percutaneous coronary intervention for ST-elevation myocardial infarction. 2005;149:564.e1-564.e7

Stehman-Breen C (see Mix et al). 2005;149:408-13 (Trial design)

Stein E (see Matthews et al). 2005;149:1066-73

Steinbigler P (see Haberl et al). 2005;149:1112-9

Steneström U, Lindbäck J, Wallentin L. Hospital therapy traditions influence long-term survival in patients with acute myocardial infarction. 2005;149:82-90

Stevenson LW (see Shah et al). 2005;149:715-21

Stoddard MF (see Dawn et al). 2005;149:908-16

Strasser R (see Aspelin et al). 2005;149:298-303

Strong JT (see Giugliano et al). 2005;149:994-1002 (Trial design)

Su WS (see Harvey et al). 2005;149:291-7

Sugioka K (see Kohsaka et al). 2005;149:181-6

Sun JP (see Yu et al). 2005;149:600-5 (Trial design)

Suntharalingam M (see Silber et al). 2005;149:689-94

Surber R (see Werner et al). 2005;149:129-37

Suryapranata H (see van der Horst et al). 2005;149:1135.e1-1135.e9

Suttorp MJ (see Rahel et al). 2005;149:414.e1-414.e3 (Trial design)

Swane B (see Saleh et al). 2005;149:876-82

Svensson L (see Herlitz et al). 2005;149:61-6

Svetkey LP (see Ard and Svetkey). 2005;149:804-12 (Meetings)

Swedberg K (see Torp-Pedersen et al). 2005;149:370-6

Tahk SJ (see Kim et al). 2005;149:336-41

Tajer C (see Macin et al). 2005;149:451-7

Takasu J (see Budoff et al). 2005;149:695-700

Talajic M (see Kerr et al). 2005;149:489-96

Tang WHW (see Parameswaran et al). 2005;149:921-6

Taniguchi M (see Hayashi et al). 2005;149:284-90

Tardif JC (see Blanchet et al). 2005;149:938.e1-938.e7

Tardiff BE (see Eisenstein et al). 2005;149:482-8

Tavazzi L (see Yu et al). 2005;149:600-5 (Trial design)

Tcheng JE (see Denardo et al). 2005;149:138-44

Teirstein PS (see Silber et al). 2005;149:689-94

Teng FF (see Eisenberg et al). 2005;149:813-9

Testa L (see Biondi-Zoccali et al). 2005;149:504-11

Thalassinos N (see Koulouris et al). 2005;149:840-5

Thaller E (see Seinost et al). 2005;149:1050-4

Théroux P (see Mega et al). 2005;149:846-50

Theuns DAMJ (see Pedersen et al). 2005;149:664-9

Thiele H (see Sick et al). 2005;149:681-8. Correction 2005;149:1136

Thom T (see Bertoni et al). 2005;149:1055-61

Thomas M (see Kapur et al). 2005;149:13-9 (Trial design)

Tijssen JGP (see Hagens et al). 2005;149:1106-11

Timmer JR (see van der Horst et al). 2005;149:585-91 (Trial design)

Tittus J (see Haberl et al). 2005;149:1112-9

Todaro TG (see Armstrong et al). 2005;149:402-7 (Trial design)

Tognoni G (see Franciosi et al). 2005;149:104-11

Tognoni G (see Maggioni et al). 2005;149:548-57

Tolshinsky T (see Berliner et al). 2005;149:260-7

Tommaso C (see Holmes et al). 2005;149:883-7

Topol E (see Meine et al). 2005;149:670-4

Topol EJ. A contemporary assessment of low-molecular-weight heparin for the treatment of acute coronary syndromes: factoring in new trials and meta-analysis data. 2005;149:S100-6

Topol EJ (see Berger et al). 2005;149:869-75

Tornvall P (see Saleh et al). 2005;149:876-82

Torp-Pedersen C, Poole-Wilson PA, Swedberg K, Cleland JGF, Di Lenarda A, Hanrath P, Komajda M, Lutiger B, Metra M, Remme WJ, Scherlag A, Skene A, COMET Investigators. Effects of metoprolol and carvedilol on cause-specific mortality and morbidity in patients with chronic heart failure—COMET. 2005;149:370-6

Torti FM Jr (see Reed et al). 2005;149:434-43 (Meetings)

Toto RD (see Mix et al). 2005;149:408-13 (Trial design)

Tran M, Spencer FA. Thromboepidemiology: identifying patients with heritable risk for thrombin-mediated thromboembolic events. 2005;149:59-18

Trani C (see Biondi-Zoccali et al). 2005;149:504-11

TriActiv Pilot Study Investigators (see Carrozza et al). 2005;149:1136.e1-1136.e7

Triantafillou K (see Koulouris et al). 2005;149:840-5

Tricoci P (see Patel et al). 2005;149:1009-19 (Meetings)

Tripodi D (see Sachdev et al). 2005;149:730-6

Troughton RW (see O'Neil et al). 2005;149:363-9

Tsiatis AA (see Reed et al). 2005;149:434-43 (Meetings)

Tsuyuki R (see King et al). 2005;149:761-7 (Trial design)

Tullo NG (see Curtis et al). 2005;149:304-8

Tung R (see Krauser et al). 2005;149:744-50

Turkoz R (see Gulcan et al). 2005;149:917-20

U

Ueno M (see Hayashi et al). 2005;149:284-90

Ukkonen H (see Ling et al). 2005;149:1138.e9-1138.e16

Ulrich M (see Sick et al). 2005;149:681-8. Correction 2005;149:1136

V

Vahanian A (see Armstrong et al). 2005;149:402-7 (Trial design)

Valente AM (see Patel et al). 2005;149:1009-19 (Meetings)

Valente AM (see Shah et al). 2005;149:240-53 (Meetings)

Valentini M (see Franciosi et al). 2005;149:104-11

Vamvakou G (see Ikonomidis et al). 2005;149:832-9

Van de Werf F (see Armstrong et al). 2005;149:402-7 (Trial design)

Van de Werf F (see Giugliano et al). 2005;149:994-1002 (Trial design)

Van de Werf F (see Kaul et al). 2005;149:637-44

Van Den Berg MP (see Hagens et al). 2005;149:1106-11

van der Horst ICC, De Luca G, Ottavanger JP, de Boer MJ, Hoornje JCA, Suryaprana H, Dambrink JHE, Gosselink ATM, Zijlstra F, van 't Hof AWJ. ST-segment elevation resolution and outcome in patients treated with primary angioplasty and glucose-insulin-potassium infusion. 2005;149:1135.e1-1135.e9

van der Horst ICC, Timmer JR, Ottavanger JP, Bilo HJG, Gans ROB, de Boer MJ, Zijlstra F, GIPS Investigators. Glucose-insulin-potassium and reperfusion in acute myocardial infarction: rationale and design of the Glucose-Insulin-Potassium Study-2 (GIPS-2). 2005;149:585-91 (Trial design)

van der Wall EE (see Kaandorp et al). 2005;149:200-8 (Curriculum cardiol.)

van Domburg RT (see Pedersen et al). 2005;149:664-9

Van Gelder IC (see Hagens et al). 2005;149:1106-11

Van Laethem C, Bartunek J, Goethals M, Nellens P, Andries E, Vanderheyden M. Oxygen uptake efficiency slope, a new submaximal parameter in evaluating exercise capacity in chronic heart failure patients. 2005;149:175-80

van 't Hof AWJ (see van der Horst et al). 2005;149:1135.e1-1135.e9

Van Veldhuisen DJ (see Hagens et al). 2005;149:1106-11

Vanderheyden M (see Van Laethem et al). 2005;149:175-80

Vasseghi MF (see Casscells et al). 2005;149:927-33

Veeger NJGM (see Hagens et al). 2005;149:1106-11

Veltri E (see Kastelein et al). 2005;149:234-9 (Trial design)

Verheugt FWA. Morpheus, God of Sleep or God of Death? 2005;149:945-6 (Editorial)

Vidaillet H (see Curtis et al). 2005;149:304-8

Vidaillet H (see Flaker et al). 2005;149:657-63

Viles-Gonzalez JF, Fuster V, Badimon JJ. Thrombin/inflammation paradigms: a closer look at arterial and venous thrombosis. 2005;149:S19-31

Vincenzo C (see Faglia et al). 2005;149:283.e1-283.e6

Vitovc J (see Deedwania et al). 2005;149:159-67

Vogt S (see Alter et al). 2005;149:1082-90

Vrtovec B (see Vrtovec et al). 2005;149:632-6

Vrtovec M, Vrtovec B, Briski A, Kocjancic A, Anderson RA, Radovancevic B. Chromium supplementation shortens QTc interval duration in patients with type 2 diabetes mellitus. 2005;149:632-6

W

Waclawiw MA (see Sachdev et al). 2005;149:730-6

Waldo AL (see DiMarco et al). 2005;149:650-6

Walldorf J (see Meyer et al). 2005;149:926.e1-926.e7

Wallentin L (see James et al). 2005;149:619-26

Wallentin L (see Stenstrand et al). 2005;149:82-90

Wallet F (see Klug et al). 2005;149:322-8

Walters G (see Carrozza et al). 2005;149:1136.e1-1136.e7

Wang D (see Pocock et al). 2005;149:939-43

Wang M (see Zhang et al). 2005;149:497-503

Wang Y (see Rathore et al). 2005;149:121-8

Warner JJ (see Sims et al). 2005;149:1062-5

Washam JB (see Meine et al). 2005;149:1043-9

Watanaabe T (see Yoshida et al). 2005;149:e2

Wattananit K, Folsom AR, Chambliss LE, Nieto FJ. Risk factors for cardiovascular event recurrence in the Atherosclerosis Risk in Communities (ARIC) study. 2005;149:606-12

Weaver MT (see Ahmed et al). 2005;149:737-43

Webb JG (see Dzavik et al). 2005;149:1128-34

Wegscheider K (see Zeymer et al). 2005;149:91-7

Weintraub JR (see Shah et al). 2005;149:715-21

Weissman NJ (see Kim et al). 2005;149:336-41

Welk GJ (see Eisenmann et al). 2005;149:46-53

Wells GA (see Reid et al). 2005;149:862-8

Werner GS, Surber R, Kuether F, Emig U, Schwarz G, Bahrmann P, Figulla HR. Collaterals and the recovery of left ventricular

function after recanalization of a chronic total coronary occlusion. 2005;149:129-37

Whellan DJ, Hasselblad V, Peterson E, O'Connor CM, Schulman KA. Metaanalysis and review of heart failure disease management randomized controlled clinical trials. 2005;149:722-9

White CM. Thrombin-directed inhibitors: pharmacology and clinical use. 2005;149:S54-60

White HD (see Antman et al). 2005;149:217-26 (Trial design)

White HD (see Meine et al). 2005;149:670-4

White J (see Berger et al). 2005;149:869-75

White K (see Avezum et al). 2005;149:67-73

White M (see Blanchet et al). 2005;149:938.e1-938.e7

White RD (see Gurevitz et al). 2005;149:316-21

Wickel EE (see Eisenmann et al). 2005;149:46-53

Wiegand UKH (see Steen et al). 2005;149:564.e1-564.e7

Wijns W (see Ix et al). 2005;149:512-9

Wikstrand J (see Deedwania et al). 2005;149:159-67

Wilber DJ (see Curtis et al). 2005;149:304-8

Wilhelmsen L (see Pocock et al). 2005;149:939-43

Willan AR (see Reed et al). 2005;149:434-43 (Meetings)

Willenbrock R (see Aspelin et al). 2005;149:298-303

Williams K (see Meine et al). 2005;149:670-4

Williams KAP (see Ling et al). 2005;149:1137.e9-1137.e16

Wimmer G (see Steinost et al). 2005;149:1050-4

Woods SL (see Powell et al). 2005;149:851-5

Wright J (see Sequist et al). 2005;149:74-81

Wu M-T (see Chiou et al). 2005;149:701-8

Y

Yabushita H (see Hayashi et al). 2005;149:284-90

Yamazaki T (see Richardson et al). 2005;149:458-63

Yang C-F (see Chiou et al). 2005;149:701-8

Yang J-Y (see Kim et al). 2005;149:336-41

Yi Q (see Dagenais et al). 2005;149:54-60

Yip GWK (see Zhang et al). 2005;149:497-503

Yoshida O, Hirayama H, Nanasato M, Watanabe T, Murohara T. The angiotensin II receptor blocker candesartan cilexetil reduces neointima proliferation after coronary stent implantation: a prospective randomized study under intravascular ultrasound guidance. 2005;149:e2

Young JB (see O'Neill et al). 2005;149:363-9

Young JB (see Parameswaran et al). 2005;149:921-6

Young M (see Herlitz et al). 2005;149:61-6

Young MA (see Shah et al). 2005;149:715-21

Young QR (see Nolan et al). 2005;149:1137.e1-1137.e7

Yu C-M, Abraham WT, Bax J, Chung E, Fedewa M, Ghio S, Leclercq C, León AR, Merlino J, Nihoyannopoulos P, Notabartolo D, Sun JP, Tavazzi L, PROSPECT Investigators. Predictors of response to cardiac resynchronization therapy (PROSPECT)—study design. 2005;149:600-5 (Trial design)

Yu C-M (see Zhang et al). 2005;149:497-503

Yu D (see Budoff et al). 2005;149:695-700

Yuan Z (see Ballantyne et al). 2005;149:464-73. Correction 2005;149:882

Yusuf S (see Dagenais et al). 2005;149:54-60

Yusuf SW, McLean KA, Mishra RA. Thrombolytic therapy for eligible elderly patients with acute myocardial infarction. 2005;149:e25-6 (Letter)

Z

Zambroski CH, Moser DK, Roser LP, Heo S, Chung ML. Patients with heart failure who die in hospice. 2005;149:558-64

Zannetti S (see Nienaber et al). 2005;149:592-9 (Trial design)

Zeltzer D (see Berliner et al). 2005;149:260-7

Zeymer U, Schröder K, Wegscheider K, Senges J, Neuhaus K-L, Schröder R. ST resolution in a single electrocardiographic lead: a simple and accurate predictor of cardiac mortality in patients with fibrinolytic therapy for acute ST-elevation myocardial infarction. 2005;149:91-7

Zhang H, Alexander JA, Luttrell J, O'Connor GT, Daley J, Paris M. Data feedback and clinical process improvement in acute myocardial infarction. 2005;149:856-61

Zhang Y, Chan AKY, Yu C-M, Lam WWM, Yip GWK, Fung W-H, So NMC, Wang M, Sanderson JE. Left ventricular systolic asynchrony after acute myocardial infarction in patients with narrow QRS complexes. 2005;149:497-503

Zhao X-Q (see Mega et al). 2005;149:846-50

Zijlstra F (see van der Horst et al). 2005;149:585-91 (Trial design), 1135.e1-1135.e9

Zuckerman BD (see Muni et al). 2005;149:415-33 (Meetings)

Subject Index

A

Abciximab

Economic analysis of the Assessment of the Safety and Efficacy of a New Thrombolytic Regimen (ASSENT-3) study: Costs of reperfusion strategies in acute myocardial infarction (Kaul et al). 2005;149:637-44

Effects of abciximab and preprocedural glycemic control in diabetic patients undergoing elective coronary stenting (De Luca et al). 2005;149:1135.e11-1135.e18

The relation of renal function to ischemic and bleeding outcomes with 2 different glycoprotein IIb/IIIa inhibitors: The Do Tirofiban and ReoPro Give Similar Efficacy Outcome (TARGET) trial (Berger et al). 2005;149:869-75

ACE inhibitors; see Angiotensin-converting enzyme inhibitors

Activities of daily living

Impact of cardioversion strategy on functional capacity in patients with atrial fibrillation: The Assessment of Cardioversion Using Transesophageal Echocardiography (ACUTE) Study (Jasper et al). 2005;149:309-15

Acute coronary syndromes; see Angina, unstable; Myocardial infarction; Myocardial ischemia

Adolescence

Relationship between adolescent fitness and fatness and cardiovascular disease risk factors in adulthood: The Aerobics Center Longitudinal Study (ACLS) (Eisenmann et al). 2005;149:46-53

Adrenergic beta-agonists

Effects of metoprolol and carvedilol on cause-specific mortality and morbidity in patients with chronic heart failure-COMET (Torp-Pedersen et al). 2005;149:370-6

Efficacy, safety and tolerability of metoprolol CR/XL in patients with diabetes and chronic heart failure: Experiences from MERIT-HF (Deedwania et al). 2005;149:159-67

Practical considerations of β-blockade in the management of the post-myocardial infarction patient (Fonarow). 2005;149:984-93 (Curriculum cardiol.)

Why do patients fail to receive β-blockers for chronic heart failure over time? A "real-world" single-center, 2-year follow-up experience of β-blocker therapy in patients with chronic heart failure (Parameswaran et al). 2005;149:921-6

Adulthood

Relationship between adolescent fitness and fatness and cardiovascular disease risk factors in adulthood: The Aerobics Center Longitudinal Study (ACLS) (Eisenmann et al). 2005;149:46-53

Age factors

Factors associated with an increased chance of survival among patients suffering from an out-of-hospital cardiac arrest in a national perspective in Sweden (Herlitz et al). 2005;149:61-6

Impact of age on management and outcome of acute coronary syndrome: Observations from the Global Registry of Acute Coronary Events (GRACE) (Avezum et al). 2005;149:67-73

Should we aggressively treat elderly patients with cardiogenic shock? (Hasdai). 2005;149:962-3 (Editorial)

Thrombolytic therapy for eligible elderly patients with acute myocardial infarction (Yusuf et al) (Letter); (Avezum and Makdisse) (Reply). 2005;149:e25-e26, e27

Aged

A Doppler-derived index of combined left ventricular systolic and diastolic function is an independent predictor of cardiovascular mortality in elderly men (Årnöv et al). 2005;149:902-7

Impact of age on management and outcome of acute coronary syndrome: Observations from the Global Registry of Acute Coronary Events (GRACE) (Avezum et al). 2005;149:67-73

Outcome of patients aged ≥ 75 years in the SHould we emergently revascularize Occluded Coronaries in cardiogenic shock (SHOCK) trial: Do elderly patients with acute myocardial infarction complicated by cardiogenic shock respond differently to emergent revascularization? (Dzavik et al). 2005;149:1128-34

A propensity score analysis of the impact of angiotensin-converting enzyme inhibitors on long-term survival of older adults with heart failure and perceived contraindications (Ahmed et al). 2005;149:737-43

Sex, quality of care, and outcomes of elderly patients hospitalized with heart failure: Findings from the National Heart Failure Project (Rathore et al). 2005;149:121-8

Should we aggressively treat elderly patients with cardiogenic shock? (Hasdai). 2005;149:962-3 (Editorial)

Thrombolytic therapy for eligible elderly patients with acute myocardial infarction (Yusuf et al) (Letter); (Avezum and Makdisse) (Reply). 2005;149:e25-e26, e27

Albuminuria

Microalbuminuria: A strong predictor of 3-year adverse prognosis in nondiabetic patients with acute myocardial infarction (Koulouris et al). 2005;149:840-5

Alcohol drinking

Diet and blood pressure: Applying the evidence to clinical practice (Ard and Svetkey). 2005;149:804-12 (Meetings)

Algorithms

Prediction of missed myocardial infarction among symptomatic outpatients without coronary heart disease (Sequist et al). 2005;149:74-81

Alteplase

ST resolution in a single electrocardiographic lead: A simple and accurate predictor of cardiac mortality in patients with fibrinolytic therapy for acute ST-elevation myocardial infarction (Zeymer et al). 2005;149:91-7

Ambulatory care

Intensity and focus of heart failure disease management after hospital discharge (Shah et al). 2005;149:715-21

Prediction of missed myocardial infarction among symptomatic outpatients without coronary heart disease (Sequist et al). 2005;149:74-81

American College of Cardiology

Highlights from the American College of Cardiology Annual Scientific Session 2005: March 6 to 9, 2005, Orlando, Florida (Patel et al). 2005;149:1009-19 (Meetings)

American Heart Association

Highlights from the American Heart Association Annual Scientific Sessions 2004: November 7-10, 2004 (Shah et al.). 2005;149:240-53 (Meetings)

Anaerobic threshold

Oxygen uptake efficiency slope, a new submaximal parameter in evaluating exercise capacity in chronic heart failure patients (Van Laethem et al.). 2005;149:175-80

Anemia

Prevalence of anemia and effects on mortality in patients with heart failure (Lindenfield). 2005;149:391-401 (Curriculum cardiol.)

Rationale — Trial to Reduce Cardiovascular Events with Aranesp Therapy (TREAT): Evolving the management of cardiovascular risk in patients with chronic kidney disease (Mix et al.). 2005;149:408-13 (Trial design)

Aneurysm, dissecting

INvestigation of STENT grafts in patients with type B Aortic Dissection: Design of the INSTEAD trial — a prospective, multicenter, European randomized trial (Nienaber et al.). 2005;149:592-9 (Trial design)

Aneurysmectomy

Effect of coronary artery bypass grafting and aneurysmectomy on QT dispersion in moderate or severe left ventricular dysfunction (Gulcan et al.). 2005;149:917-20

Angina, unstable; see also Myocardial ischemia

Acute coronary syndrome national statistics: Challenges in definitions (Bertoni et al.). 2005;149:1055-61

Acute coronary syndrome statistics: What you don't see can hurt you (Rajagopal and Bhatt). 2005;149:955-6 (Editorial)

Are we appropriately triaging patients with unstable angina? (Gomberg-Maitland et al.). 2005;149:613-18

Association of intravenous morphine use and outcomes in acute coronary syndromes: Results from the CRUSADE Quality Improvement Initiative (Meine et al.). 2005;149:1043-9

Atorvastatin has an important acute anti-inflammatory effect in patients with acute coronary syndrome: Results of a randomized, double-blind, placebo-controlled study (Macin et al.). 2005;149:451-7

Correlation between the TIMI risk score and high-risk angiographic findings in non-ST-elevation acute coronary syndromes: Observations from the Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) trial (Mega et al.). 2005;149:846-50

Does current treatment of cardiogenic shock complicating the acute coronary syndromes comply with guidelines? (Iakobishvili et al.). 2005;149:98-103

Early cardiac catheterization is associated with lower mortality only among high-risk patients with ST- and non-ST-elevation acute coronary syndromes: Observations from the OPUS-TIMI 16 trial (Cantor et al.). 2005;149:275-83

The Early Glycoprotein IIb/IIIa Inhibition in Non-ST-Segment Elevation Acute Coronary Syndrome (EARLY ACS) trial:

A randomized placebo-controlled trial evaluating the clinical benefits of early front-loaded eptifibatide in the treatment of patients with non-ST-segment elevation acute coronary syndrome—Study design and rationale (Giugliano et al.). 2005;149:994-1002 (Trial design)

Early initiation of lipid-lowering therapy for acute coronary syndromes improves compliance with guideline recommendations: Observations from the Orbofiban in Patients with Unstable Coronary Syndromes (OPUS-TIMI 16) trial (Smith et al.). 2005;149:444-50

Impact of age on management and outcome of acute coronary syndrome: Observations from the Global Registry of Acute Coronary Events (GRACE) (Avezum et al.). 2005;149:67-73

Influence of clinical trial enrollment on the quality of care and outcomes for patients with non-ST-segment elevation acute coronary syndromes (Kandzari et al.). 2005;149:474-81

Long-term benefits of an early invasive management in acute coronary syndromes depend on intracoronary stenting and aggressive antiplatelet treatment: A metaregression (Biondi-Zoccali et al.). 2005;149:504-11

Statins in acute coronary syndromes: The sooner, the better? (Schwartz). 2005;149:377-80 (Editorial)

Urinary tract infection in patients with acute coronary syndrome: A potential systemic inflammatory connection (Sims et al.). 2005;149:1063-6

Angina pectoris

Efficacy and safety of a once-daily graded-release diltiazem formulation dosed at bedtime compared to placebo and to morning dosing in chronic stable angina pectoris (Glasser et al.). 2005;149:290.e1-290.e9

Stent implantation, but not pathogen burden, is associated with plasma C-reactive protein and interleukin-6 levels after percutaneous coronary intervention in patients with stable angina pectoris (Saleh et al.). 2005;149:876-82

Angiography

Correlation between the TIMI risk score and high-risk angiographic findings in non-ST-elevation acute coronary syndromes: Observations from the Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) trial (Mega et al.). 2005;149:846-50

Does current treatment of cardiogenic shock complicating the acute coronary syndromes comply with guidelines? (Iakobishvili et al.). 2005;149:98-103

Indications for angiography subsequent to coronary artery bypass grafting (Alter et al.). 2005;149:1082-90

Magnetic resonance imaging of coronary arteries, the ischemic cascade, and myocardial infarction (Kaandorp et al.). 2005;149:200-8 (Curriculum cardiol.)

Multislice spiral computed tomographic angiography of coronary arteries in patients with suspected coronary artery disease: An effective filter before catheter angiography? (Haberl et al.). 2005;149:1112-19

Repeat stenting for the prevention of the early lumen loss phenomenon in patients with in-stent restenosis: Angiographic and intravascular ultrasound findings of a randomized study (Alfonso et al.). 2005;149:335.e1-335.e8

Which role for multislice computed tomography in clinical cardiology? (Bax and Schuijff). 2005;149:960-1 (Editorial)

Angioplasty

Assessment of Pexelizumab in Acute Myocardial Infarction (APEX AMI): A multicenter, randomized, double-blind, parallel-group, placebo-controlled study of pexelizumab in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention (Armstrong et al.). 2005;149:402-7 (Trial design)

A critical appraisal of current models of risk stratification for percutaneous coronary interventions (Singh et al.). 2005;149:753-60 (Curriculum cardiol.)

Fluvastatin reduces the impact of diabetes on long-term outcome after coronary intervention—A Lescol Intervention Prevention Study (LIPS) substudy (Arampatzis et al.). 2005;149:329-35

Repeat stenting for the prevention of the early lumen loss phenomenon in patients with in-stent restenosis: Angio-

graphic and intravascular ultrasound findings of a randomized study (Alfonso et al). 2005;149:335.e1-335.e8

ST-segment elevation resolution and outcome in patients treated with primary angioplasty and glucose-insulin-potassium infusion (van der Horst et al). 2005;149:1135.e1-1135.e9

Stent implantation, but not pathogen burden, is associated with plasma C-reactive protein and interleukin-6 levels after percutaneous coronary intervention in patients with stable angina pectoris (Saleh et al). 2005;149:876-82

Angioplasty, balloon

Elective percutaneous coronary intervention using broad-spectrum antiplatelet therapy (epitifibatide, clopidogrel, and aspirin) alone, without scheduled unfractionated heparin or other antithrombin therapy (Denardo et al). 2005;149:138-44

Angiotensin-converting enzyme inhibitors

Aortic stenosis and angiotensin-converting enzyme inhibitors-Rupture of an ancient paradigm? (Barrera-Ramirez et al) (Letter); (Chockalingam) (Reply). 2005;149:e5, e7

Effects of angiotensin-converting enzyme inhibitor plus ibesartan on maximal and submaximal exercise capacity and neurohumoral activation in patients with congestive heart failure (Blanchet et al). 2005;149:938.e1-938.e7

A propensity score analysis of the impact of angiotensin-converting enzyme inhibitors on long-term survival of older adults with heart failure and perceived contraindications (Ahmed et al). 2005;149:737-43

Angiotensin II

Carvedilol therapy is associated with a sustained decline in brain natriuretic peptide levels in patients with congestive heart failure (Frantz et al). 2005;149:541-7

Angiotensin II type 1 receptor blockers

The angiotensin II receptor blocker candesartan cilexetil reduces neointima proliferation after coronary stent implantation: A prospective randomized study under intravascular ultrasound guidance (Yoshida et al). 2005;149:144.e1-144.e6

Anticoagulants

Factors affecting bleeding risk during anticoagulant therapy in patients with atrial fibrillation: Observations from the Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) Study (DiMarco et al). 2005;149:650-6

Regarding antithrombotic treatment after coronary stenting in patients on chronic oral anticoagulation (Rubboli et al). 2005;149(2)e1 (Letter)

Antilipemic agents

Early initiation of lipid-lowering therapy for acute coronary syndromes improves compliance with guideline recommendations: Observations from the Orbofiban in Patients with Unstable Coronary Syndromes (OPUS-TIMI 16) trial (Smith et al). 2005;149:444-50

Impact of physicians' beliefs and practices on cholesterol levels in patients with type 2 diabetes: A longitudinal assessment (Franciosi et al). 2005;149:104-11

Antithrombins

Elective percutaneous coronary intervention using broad-spectrum antiplatelet therapy (epitifibatide, clopidogrel, and aspirin) alone, without scheduled unfractionated heparin or other antithrombin therapy; (Denardo et al). 2005;149:138-44

Enoxaparin versus unfractionated heparin as antithrombin therapy in patients receiving fibrinolysis for ST-elevation myocardial infarction: Design and rationale for the Enoxaparin and Thrombolysis Reperfusion for Acute Myocardial Infarction Treatment-Thrombolysis In Myocardial Infarction study 25 (ExTRACT-TIMI 25) (Antman et al). 2005;149:217-26 (Trial design)

Regarding antithrombotic treatment after coronary stenting in patients on chronic oral anticoagulation (Rubboli et al). 2005;149(2)e1 (Letter)

Anxiety

Concerns about the implantable cardioverter defibrillator: A determinant of anxiety and depressive symptoms independent of experienced shocks (Pedersen et al). 2005;149:664-9

Aortic valve stenosis

Aortic stenosis and angiotensin-converting enzyme inhibitors-Rupture of an ancient paradigm? (Barrera-Ramirez et al) (Letter); (Chockalingam) (Reply). 2005;149:e5, e7

Transseptal left heart catheterization as an alternative to retrograde left ventricular catheterization for patients with aortic stenosis (Cheng). 2005;149:e15 (Letter)

Apolipoprotein B

Comparison of the efficacy and safety of atorvastatin initiated at different starting doses in patients with dyslipidemia (Jones et al). 2005;149:111.e1-111.e8

Aranesp

Rationale-Trial to Reduce Cardiovascular Events with Aranesp Therapy (TREAT): Evolving the management of cardiovascular risk in patients with chronic kidney disease (Mix et al). 2005;149:408-13 (Trial design)

Arrhythmia; see also Atrial fibrillation

Factors associated with an increased chance of survival among patients suffering from an out-of-hospital cardiac arrest in a national perspective in Sweden (Herlitz et al). 2005;149:61-6

Arteriosclerosis

The biology, utilization, and attenuation of C-reactive protein in cardiovascular disease: Part II (Armani and Becker). 2005;149:977-83 (Progress cardiol.)

Comparison of ezetimibe plus simvastatin versus simvastatin monotherapy on atherosclerosis progression in familial hypercholesterolemia: Design and rationale of the Ezetimibe and Simvastatin in Hypercholesterolemia Enhances Atherosclerosis Regression (ENHANCE) trial (Kastelein et al). 2005;149:234-9 (Trial design)

Diabetes and progression of coronary calcium under the influence of statin therapy (Budoff et al). 2005;149:695-700

Erythrocyte adhesiveness/aggregation: A novel biomarker for the detection of low-grade internal inflammation in individuals with atherothrombotic risk factors and proven vascular disease (Berliner et al). 2005;149:260-7

Metabolic syndrome: Evaluation of pathological and therapeutic outcomes (Miranda et al). 2005;149:20-32 (Meetings)

Plaque regression-A new target for antiatherosclerotic therapy (Karha and Bhatt). 2005;149:384-7 (Editorial)

Potential antiatherogenic and anti-inflammatory properties of sevelamer in maintenance hemodialysis patients (Ferramosca et al). 2005;149:820-5

Risk factors for cardiovascular event recurrence in the Atherosclerosis Risk in Communities (ARIC) study (Wattanakit et al). 2005;149:606-12

Simvastatin does not inhibit intimal hyperplasia and restenosis but promotes plaque regression in normocholesterolemic patients undergoing coronary stenting: A randomized study with intravascular ultrasound (Petronio et al). 2005;149:520-6

Aspirin

Cigarette smoking is associated with increased circulating proinflammatory and procoagulant markers in patients with

chronic coronary artery disease: Effects of aspirin treatment (Ikonomidis et al). 2005;149:832-9

Clopidogrel-aspirin combination for atrial fibrillation: CLAAF is not CLEAR (Jackson et al) (Letter); (De Caterina and Lorenzoni) (Reply). 2005;149(1):e3, e4

Effect of clopidogrel plus aspirin on tissue perfusion and coronary flow in patients with ST-segment elevation myocardial infarction: A new reperfusion strategy (Dogan et al). 2005;149:1037-42

Elective percutaneous coronary intervention using broad-spectrum antiplatelet therapy (eptifibatide, clopidogrel, and aspirin) alone, without scheduled unfractionated heparin or other antithrombin therapy (Denardo et al). 2005;149:138-44

Regarding antithrombotic treatment after coronary stenting in patients on chronic oral anticoagulation (Rubboli et al). 2005;149(2):e1 (Letter)

The role of platelet glycoprotein IIIa polymorphism in the high prevalence of in vitro aspirin resistance in patients with intracoronary stent restenosis (Pamukcu et al). 2005;149:675-80

Atherectomy, coronary

Elective percutaneous coronary intervention using broad-spectrum antiplatelet therapy (eptifibatide, clopidogrel, and aspirin) alone, without scheduled unfractionated heparin or other antithrombin therapy (Denardo et al). 2005;149:138-44

Atherosclerosis; see Arteriosclerosis

Atorvastatin

Atorvastatin has an important acute anti-inflammatory effect in patients with acute coronary syndrome: Results of a randomized, double-blind, placebo-controlled study (Macin et al). 2005;149:451-7

Comparison of the efficacy and safety of atorvastatin initiated at different starting doses in patients with dyslipidemia (Jones et al). 2005;149:111.e1-111.e8

Dose-comparison study of the combination of ezetimibe and simvastatin (Vytorin) versus atorvastatin in patients with hypercholesterolemia: The Vytorin Versus Atorvastatin (VVVA) Study (Ballantyne et al). 2005;149:464-73

Is atorvastatin more appropriate to use in combination with niacin than simvastatin in patients with the metabolic syndrome? (Al-Shaer). 2005;149:e17 (Letter)

Atrial fibrillation

Angiotensin-converting enzyme inhibitors as a new therapy for atrial fibrillation? Controversy (Ogimoto et al). 2005;149:e19 (Letter)

Asymptomatic atrial fibrillation: Demographic features and prognostic information from the Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) study (Flaker et al). 2005;149:657-63

Atrial fibrillation and quality of life: Clarity or evidence-based confusion? (Newman). 2005;149:4-6 (Editorial)

Clinical factors associated with abandonment of a rate-control or a rhythm-control strategy for the management of atrial fibrillation in the AFFIRM study (Curtis et al). 2005;149:304-8

Clinical factors that influence response to treatment strategies in atrial fibrillation: The Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) Study (AFFIRM Investigators). 2005;149:645-9

Clopidogrel-aspirin combination for atrial fibrillation: CLAAF is not CLEAR (Jackson et al) (Letter); (De Caterina and Lorenzoni) (Reply). 2005;149(1):e3, e4

Comparative efficacy of monophasic and biphasic waveforms for transthoracic cardioversion of atrial fibrillation and atrial flutter (Gurevitz et al). 2005;149:316-21

Factors affecting bleeding risk during anticoagulant therapy in patients with atrial fibrillation: Observations from the Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) Study (DiMarco et al). 2005;149:650-6

Impact of cardioversion strategy on functional capacity in patients with atrial fibrillation: The Assessment of Cardioversion Using Transesophageal Echocardiography (ACUTE) Study (Jasper et al). 2005;149:309-15

New-onset paroxysmal atrial fibrillation: Is permanence inevitable? (Patton and Page). 2005;149:388-90 (Editorial)

Progression to chronic atrial fibrillation after the initial diagnosis of paroxysmal atrial fibrillation: Results from the Canadian Registry of Atrial Fibrillation (Kerr et al). 2005;149:489-96

Quality of life in atrial fibrillation: The Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) study (AFFIRM Investigators). 2005;149:112-20

Rate control versus rhythm control: Choose your poison (Passman and Kadish). 2005;149:957-9 (Editorial)

Rate control versus rhythm control for patients with persistent atrial fibrillation with mild to moderate heart failure: Results from the Rate Control versus Electrical cardioversion (RACE) study (Hagens et al). 2005;149:1106-11

Valsartan reduces the incidence of atrial fibrillation in patients with heart failure: Results from the Valsartan Heart Failure Trial (Val-HeFT) (Maggioni et al). 2005;149:548-57

Atrial flutter

Comparative efficacy of monophasic and biphasic waveforms for transthoracic cardioversion of atrial fibrillation and atrial flutter (Gurevitz et al). 2005;149:316-21

Atrial natriuretic peptide, N-terminal

Carvedilol therapy is associated with a sustained decline in brain natriuretic peptide levels in patients with congestive heart failure (Frantz et al). 2005;149:541-7

Atrioventricular block; see Heart block

Autonomic nervous system

A polymorphism of the endothelial nitric oxide synthase promoter is associated with an increase in autonomic imbalance in patients with congestive heart failure (Binkley et al). 2005;149:342-8

B

B-type natriuretic peptide (BNP); see Natriuretic peptide, brain

Bacterial infection

Detailed bacteriologic tests to identify the origin of transvenous pacing system infections indicate a high prevalence of multiple organisms (Klug et al). 2005;149:322-8

Bacteriological techniques

Detailed bacteriologic tests to identify the origin of transvenous pacing system infections indicate a high prevalence of multiple organisms (Klug et al). 2005;149:322-8

Balloon occlusion

Embolectic protection during saphenous vein graft intervention using a second-generation balloon protection device-Results from the combined US and European pilot study of the TriActiv Balloon Protected Flush Extraction System (Carrozza, Jr et al). 2005;149:1136.e1-1136.e7

beta-Blockers; see Adrenergic beta-antagonists

Beta rays

Two-year clinical follow up of $^{90}\text{Sr}/^{90}\text{Y}$ β -radiation versus placebo control for the treatment of in-stent restenosis (Silber et al). 2005;149:689-94

Big endothelin (big-ET); see Endothelins**Biofeedback**

Heart rate variability biofeedback as a behavioral neurocardiac intervention to enhance vagal heart rate control (Nolan et al). 2005;149:1137.e1-1137.e7

Biological markers

B-type natriuretic peptide levels are not a surrogate marker for invasive hemodynamics during management of patients with severe heart failure (O'Neill et al). 2005;149:363-9

Cigarette smoking is associated with increased circulating proinflammatory and procoagulant markers in patients with chronic coronary artery disease: Effects of aspirin treatment (Ikonomidis et al). 2005;149:832-9

Erythrocyte adhesiveness/aggregation: A novel biomarker for the detection of low-grade internal inflammation in individuals with atherosclerotic risk factors and proven vascular disease (Berliner et al). 2005;149:260-7

Multimarker risk strategy for predicting 1-month and 1-year major events in non-ST elevation acute coronary syndromes (Bodi et al). 2005;149:268-74

Risk factors for cardiovascular event recurrence in the Atherosclerosis Risk in Communities (ARIC) study (Wattanakit et al). 2005;149:606-12

Biopsy

Diagnostic approach to the patient with cardiomyopathy: Whom to biopsy (Ardehali et al). 2005;149:7-12 (Curriculum cardiol.)

Bleeding; see Hemorrhage**Blood flow velocity**

Behavior of both epicardial and intramural coronary artery flow velocities in various models of myocardial hypertrophy: Role for left ventricular outflow tract obstruction (De Gregorio et al). 2005;149:1091-8

Blood platelets

Cigarette smoking is associated with increased circulating proinflammatory and procoagulant markers in patients with chronic coronary artery disease: Effects of aspirin treatment (Ikonomidis et al). 2005;149:832-9

Blood pressure

Barriers to hypertension control (Borzecki et al). 2005;149:785-94 (Meetings)

Blood pressure variability and prognosis in uncomplicated mild hypertension (Pierdomenico et al). 2005;149:934-8

Diet and blood pressure: Applying the evidence to clinical practice (Ard and Svetkey). 2005;149:804-12 (Meetings)

Improving blood pressure control by tailored feedback to patients and clinicians (Bosworth et al). 2005;149:795-803 (Meetings)

Relationship between adolescent fitness and fatness and cardiovascular disease risk factors in adulthood: The Aerobics Center Longitudinal Study (ACLS) (Eisenmann et al). 2005;149:46-53

Blood vessel prosthesis implantation

INvestigation of STEnt grafts in patients with type B Aortic Dissection: Design of the INSTEAD trial-a prospective, multicenter, European randomized trial (Nienaber et al). 2005;149:592-9 (Trial design)

Body mass index

Effect of body mass index on natriuretic peptide levels in patients with acute congestive heart failure: A ProBNP

Investigation of Dyspnea in the Emergency Department (PRIDE) substudy (Krauser et al). 2005;149:744-50

Prognostic impact of body weight and abdominal obesity in women and men with cardiovascular disease (Dagenais et al). 2005;149:54-60

Relationship between adolescent fitness and fatness and cardiovascular disease risk factors in adulthood: The Aerobics Center Longitudinal Study (ACLS) (Eisenmann et al). 2005;149:46-53

Body weight

Prognostic impact of body weight and abdominal obesity in women and men with cardiovascular disease (Dagenais et al). 2005;149:54-60

Relationship between adolescent fitness and fatness and cardiovascular disease risk factors in adulthood: The Aerobics Center Longitudinal Study (ACLS) (Eisenmann et al). 2005;149:46-53

Brachytherapy

Two-year clinical follow up of $^{90}\text{Sr}/^{90}\text{Y}$ β -radiation versus placebo control for the treatment of in-stent restenosis (Silber et al). 2005;149:689-94

Brain ischemia

Additional impact of electrocardiographic over echocardiographic diagnosis of left ventricular hypertrophy for predicting the risk of ischemic stroke (Kohsaka et al). 2005;149:181-6

Brain natriuretic peptide; see Natriuretic peptide, brain**Brazil**

Benign outcome in a long-term follow-up of patients with hypertrophic cardiomyopathy in Brazil (Arteaga et al). 2005;149:1099-05

C**C-reactive protein**

An acute inflammatory reaction induced by myocardial damage is superimposed on a chronic inflammation in unstable coronary artery disease (James et al). 2005;149:619-26

Atorvastatin has an important acute anti-inflammatory effect in patients with acute coronary syndrome: Results of a randomized, double-blind, placebo-controlled study (Macin et al). 2005;149:451-7

The biology, utilization, and attenuation of C-reactive protein in cardiovascular disease: Part I (Armani and Becker). 2005;149:971-6 (Progress cardiol.)

The biology, utilization, and attenuation of C-reactive protein in cardiovascular disease: Part II (Armani and Becker). 2005;149:977-83 (Progress cardiol.)

Cigarette smoking is associated with increased circulating proinflammatory and procoagulant markers in patients with chronic coronary artery disease: Effects of aspirin treatment (Ikonomidis et al). 2005;149:832-9

Multimarker risk strategy for predicting 1-month and 1-year major events in non-ST elevation acute coronary syndromes (Bodi et al). 2005;149:268-74

A perspective on the potential cardioprotective benefits of periodontal therapy (Offenbacher and Beck). 2005;149:950-4 (Editorial)

Statins in acute coronary syndromes: The sooner, the better? (Schwartz). 2005;149:377-80 (Editorial)

Stent implantation, but not pathogen burden, is associated with plasma C-reactive protein and interleukin-6 levels after percutaneous coronary intervention in patients with stable angina pectoris (Saleh et al). 2005;149:876-82

CABG; see Coronary artery bypass

Calcium

Diabetes and progression of coronary calcium under the influence of statin therapy (Budoff et al). 2005;149:695-700

Calcium antagonists; see Calcium channel blockers

Canada

Progression to chronic atrial fibrillation after the initial diagnosis of paroxysmal atrial fibrillation: Results from the Canadian Registry of Atrial Fibrillation (Kerr et al). 2005;149:489-96

Candesartan

The angiotensin II receptor blocker candesartan cilexetil reduces neointima proliferation after coronary stent implantation: A prospective randomized study under intravascular ultrasound guidance (Yoshida et al). 2005;149:144.e1-144.e6

The data monitoring experience in the Candesartan in Heart Failure Assessment of Reduction in Mortality and morbidity (CHARM) program (Pocock et al). 2005;149:939-43

Carbon

Prospective randomized comparison of early and late results of a carbonized stent versus a high-grade stainless steel stent of identical design: The Prevention of Recurrent Venous Thromboembolism (PREVENT) trial (Sick et al).

2005;149:681-8

Randomized comparison of carbon ion-implanted stent versus bare metal stent in coronary artery disease: The Asian Pacific Multicenter Arthos Stent Study (PASS) trial (Kim et al). 2005;149:336-41

Cardiac arrest; see Heart arrest

Cardiac catheterization; see Heart catheterization

Cardiac death; see Mortality

Cardiac pacing, artificial

Implantable cardioverter defibrillators and cardiac resynchronization therapy in patients with left ventricular dysfunction: Randomized trial evidence through 2004 (Al-Khatib et al). 2005;149:1020-34 (Meetings)

Predictors of response to cardiac resynchronization therapy (PROSPECT)-study design (Yu et al). 2005;149:600-5 (Trial design)

Cardiac rehabilitation

Impact of program duration and contact frequency on efficacy and cost of cardiac rehabilitation: Results of a randomized trial (Reid et al). 2005;149:862-8

Prevalence of metabolic syndrome in cardiac rehabilitation/secondary prevention programs (Savage et al). 2005;149:627-31

Cardiac resynchronization therapy

Implantable cardioverter defibrillators and cardiac resynchronization therapy in patients with left ventricular dysfunction: Randomized trial evidence through 2004 (Al-Khatib et al). 2005;149:1020-34 (Meetings)

Predictors of response to cardiac resynchronization therapy (PROSPECT)-study design (Yu et al). 2005;149:600-5 (Trial design)

Cardiac volume

Left atrial volumetric remodeling is predictive of functional capacity in nonobstructive hypertrophic cardiomyopathy (Sachdev et al). 2005;149:730-6

Cardiogenic shock; see Shock, cardiogenic

Cardiology

Genetic association studies in cardiology (Donahue and Allen). 2005;149:964-70 (Progress cardiol.)

Which role for multislice computed tomography in clinical cardiology? (Bax and Schuijff). 2005;149:960-1 (Editorial)

Cardiomyopathy

An acute inflammatory reaction induced by myocardial damage is superimposed on a chronic inflammation in unstable coronary artery disease (James et al). 2005;149:619-26

Diagnostic approach to the patient with cardiomyopathy: Whom to biopsy (Ardehali et al). 2005;149:7-12 (Curriculum cardiol.)

Cardiomyopathy, hypertrophic

Benign outcome in a long-term follow-up of patients with hypertrophic cardiomyopathy in Brazil (Arteaga et al). 2005;149:1099-05

Left atrial volumetric remodeling is predictive of functional capacity in nonobstructive hypertrophic cardiomyopathy (Sachdev et al). 2005;149:730-6

Cardioprotection

Cardioprotection before revascularization in ischemic myocardial injury and the potential role of hemoglobin-based oxygen carriers (Burkhoff and Lefer). 2005;149:573-9 (Progress cardiol.)

A perspective on the potential cardioprotective benefits of periodontal therapy (Offenbacher and Beck). 2005;149:950-4 (Editorial)

Cardiopulmonary resuscitation

Factors associated with an increased chance of survival among patients suffering from an out-of-hospital cardiac arrest in a national perspective in Sweden (Herlitz et al). 2005;149:61-6

Cardiorespiratory fitness; see Physical fitness

Cardiovascular diseases

The biology, utilization, and attenuation of C-reactive protein in cardiovascular disease: Part I (Armani and Becker). 2005;149:971-6 (Progress cardiol.)

The biology, utilization, and attenuation of C-reactive protein in cardiovascular disease: Part II (Armani and Becker). 2005;149:977-83 (Progress cardiol.)

Cardiovascular disease in Latin America (Medina-Lezama et al). 2005;149:e13 (Letter)

Ethnic differences in cardiovascular risk factor burden among middle-aged women: Study of Women's Health Across the Nation (SWAN) (Matthews et al). 2005;149:1066-73

Examining the coverage of influenza vaccination among people with cardiovascular disease in the United States (Ajani et al). 2005;149:254-9

Prognostic impact of body weight and abdominal obesity in women and men with cardiovascular disease (Dagenais et al). 2005;149:54-60

Rationale-Trial to Reduce Cardiovascular Events with Aranesp Therapy (TREAT): Evolving the management of cardiovascular risk in patients with chronic kidney disease (Mix et al). 2005;149:408-13 (Trial design)

Relationship between adolescent fitness and fatness and cardiovascular disease risk factors in adulthood: The Aerobics Center Longitudinal Study (ACLS) (Eisenmann et al). 2005;149:46-53

Risk factors for cardiovascular event recurrence in the Atherosclerosis Risk in Communities (ARIC) study (Wattanakitt et al). 2005;149:606-12

Cardioversion; see Electric countershock

Carvedilol

Carvedilol therapy is associated with a sustained decline in brain natriuretic peptide levels in patients with congestive heart failure (Frantz et al). 2005;149:541-7

Effects of metoprolol and carvedilol on cause-specific mortality and morbidity in patients with chronic heart failure-COMET (Torp-Pedersen et al). 2005;149:370-6

Cerebrovascular accident

Additional impact of electrocardiographic over echocardiographic diagnosis of left ventricular hypertrophy for predicting the risk of ischemic stroke (Kohsaka et al). 2005;149:181-6

Risk factors for cardiovascular event recurrence in the Atherosclerosis Risk in Communities (ARIC) study (Wattanakit et al). 2005;149:606-12

Chest pain

Assessment of patients with low-risk chest pain in the emergency department: Head-to-head comparison of exercise stress echocardiography and exercise myocardial SPECT (Conti et al). 2005;149:894-901

Left ventricular outflow tract obstruction provoked during dobutamine stress echocardiography predicts future chest pain, syncope, and near syncope (Dawn et al). 2005;149:908-16

Cholesterol; see Hyperlipidemia; Lipids and lipoproteins**Chromium picolinate**

Chromium supplementation shortens QTc interval duration in patients with type 2 diabetes mellitus (Vrtovec et al). 2005;149:632-6

Cigarette smoking; see Smoking**Clinical trials**

Atrial fibrillation and quality of life: Clarity or evidence-based confusion? (Newman). 2005;149:4-6 (Editorial)

Clopidogrel-aspirin combination for atrial fibrillation: CLAAF is not CLEAR (Jackson et al) (Letter); (De Caterina and Lorenzoni) (Reply). 2005;149(1):e3, e4

Conducting economic evaluations alongside multinational clinical trials: Toward a research consensus (Reed et al). 2005;149:434-43 (Meetings)

Conflict of interest for the physician-inventor using a device in human subjects (Popp). 2005;149:1-3 (Editorial)

Coronary drug-eluting stent development: Issues in trial design (Muni et al). 2005;149:415-33 (Meetings)

Highlights from the American College of Cardiology Annual Scientific Session 2005: March 6 to 9, 2005, Orlando, Florida (Patel et al). 2005;149:1009-19 (Meetings)

Influence of clinical trial enrollment on the quality of care and outcomes for patients with non-ST-segment elevation acute coronary syndromes (Kandzari et al). 2005;149:474-81

Invasive versus noninvasive management of ST-elevation acute myocardial infarction: A review of clinical trials and observational studies (Beck et al). 2005;149:194-9 (Curriculum cardiol.)

Metabolic syndrome: Evaluation of pathological and therapeutic outcomes (Miranda et al). 2005;149:20-32 (Meetings)

Rationale-Trial to Reduce Cardiovascular Events with Aranesp Therapy (TREAT): Evolving the management of cardiovascular risk in patients with chronic kidney disease (Mix et al). 2005;149:408-13 (Trial design)

Reducing the costs of phase III cardiovascular clinical trials (Eisenstein et al). 2005;149:482-8

Clinical trials data monitoring committees

The data monitoring experience in the Candesartan in Heart Failure Assessment of Reduction in Mortality and morbidity (CHARM) program (Pocock et al). 2005;149:939-43

Clopidogrel

Clopidogrel-aspirin combination for atrial fibrillation: CLAAF is not CLEAR (Jackson et al) (Letter); (De Caterina and Lorenzoni) (Reply). 2005;149(1):e3, e4

Design and rationale of Clopidogrel as Adjunctive Reperfusion Therapy-Thrombolysis in Myocardial Infarction (CLARITY-

TIMI) 28 trial (Sabatine et al). 2005;149:227-33 (Trial design)

Effect of clopidogrel plus aspirin on tissue perfusion and coronary flow in patients with ST-segment elevation myocardial infarction: A new reperfusion strategy (Dogan et al). 2005;149:1037-42

Elective percutaneous coronary intervention using broad-spectrum antiplatelet therapy (eptifibatide, clopidogrel, and aspirin) alone, without scheduled unfractionated heparin or other antithrombin therapy (Denardo et al). 2005;149:138-44

Regarding antithrombotic treatment after coronary stenting in patients on chronic oral anticoagulation (Rubboli et al). 2005;149(2):e1 (Letter)

Collateral circulation

Collaterals and the recovery of left ventricular function after recanalization of a chronic total coronary occlusion (Werner et al). 2005;149:129-37

Computed tomography; see Tomography, x-ray computed**Conflict of interest**

Conflict of interest for the physician-inventor using a device in human subjects (Popp). 2005;149:1-3 (Editorial)

Congestive heart failure; see Heart failure, congestive**Consensus**

Conducting economic evaluations alongside multinational clinical trials: Toward a research consensus (Reed et al). 2005;149:434-43 (Meetings)

Contraindications, drug

A propensity score analysis of the impact of angiotensin-converting enzyme inhibitors on long-term survival of older adults with heart failure and perceived contraindications (Ahmed et al). 2005;149:737-43

Contrast media

Cost-effectiveness of iodixanol in patients at high risk of contrast-induced nephropathy (Aspelin et al). 2005;149:298-303

Coronary angiography; see Angiography**Coronary arteriosclerosis**

Plaque erosion in the culprit lesion is prone to develop a smaller myocardial infarction size compared with plaque rupture (Hayashi et al). 2005;149:284-90

Revascularization of coronary atherosclerosis in patients with diabetes mellitus-There is more to it than meets the image intensifier (Petersen and Harrington). 2005;149:190-3 (Editorial)

Coronary artery bypass

Association of chronic kidney disease with clinical outcomes after coronary revascularization: The arterial revascularization therapies study (ARTS) (Ili et al). 2005;149:512-9

The Coronary Artery Revascularisation in Diabetes (CARDia) trial: Background, aims, and design (Kapur et al). 2005;149:13-19 (Trial design)

Does current treatment of cardiogenic shock complicating the acute coronary syndromes comply with guidelines? (Iakobishvili et al). 2005;149:98-103

Effect of coronary artery bypass grafting and aneurysmectomy on QT dispersion in moderate or severe left ventricular dysfunction (Gulcan et al). 2005;149:917-20

Indications for angiography subsequent to coronary artery bypass grafting (Alter et al). 2005;149:1082-90

Magnetic resonance imaging of coronary arteries, the ischemic cascade, and myocardial infarction (Kaandorp et al). 2005;149:200-8 (Curriculum cardiol.)

Coronary atherosclerosis; see Coronary arteriosclerosis
Coronary circulation

Behavior of both epicardial and intramural coronary artery flow velocities in various models of myocardial hypertrophy: Role for left ventricular outflow tract obstruction (De Gregorio et al). 2005;149:1091-8

Effect of clopidogrel plus aspirin on tissue perfusion and coronary flow in patients with ST-segment elevation myocardial infarction: A new reperfusion strategy (Dogan et al). 2005;149:1037-42

Very early cardiac magnetic resonance imaging for quantification of myocardial tissue perfusion in patients receiving tirofiban before percutaneous coronary intervention for ST-elevation myocardial elevation (Steen et al). 2005;149:564.e1-564.e7

Coronary disease

An acute inflammatory reaction induced by myocardial damage is superimposed on a chronic inflammation in unstable coronary artery disease (James et al). 2005;149:619-26

Cigarette smoking is associated with increased circulating proinflammatory and procoagulant markers in patients with chronic coronary artery disease: Effects of aspirin treatment (Klonomidis et al). 2005;149:832-9

Impact of program duration and contact frequency on efficacy and cost of cardiac rehabilitation: Results of a randomized trial (Reid et al). 2005;149:862-8

Multislice spiral computed tomographic angiography of coronary arteries in patients with suspected coronary artery disease: An effective filter before catheter angiography? (Haberl et al). 2005;149:1112-19

Randomized comparison of carbon ion-implanted stent versus bare metal stent in coronary artery disease: The Asian Pacific Multicenter Arthos Stent Study (PASS) trial (Kim et al). 2005;149:336-41

Risk factors for cardiovascular event recurrence in the Atherosclerosis Risk in Communities (ARIC) study (Wattanakiet et al). 2005;149:606-12

Smoking cessation in patients with coronary artery disease (Ludvig et al). 2005;149:565-72 (Curriculum cardiol.)

Which role for multislice computed tomography in clinical cardiology? (Bax and Schuijff). 2005;149:960-1 (Editorial)

Coronary disease, diagnosis

Assessment of patients with low-risk chest pain in the emergency department: Head-to-head comparison of exercise stress echocardiography and exercise myocardial SPECT (Conti et al). 2005;149:894-901

Prediction of missed myocardial infarction among symptomatic outpatients without coronary heart disease (Sequist et al). 2005;149:74-81

Risk reduction of cardiac events by screening of unknown asymptomatic coronary artery disease in subjects with type 2 diabetes mellitus at high cardiovascular risk: An open-label randomized pilot study (Faglia et al). 2005;149:283.e1-283.e6

Screening for heart disease in diabetic subjects (Fang et al). 2005;149:349-54

Coronary disease, drug therapy

Early effects of statin therapy on endothelial function and microvascular reactivity in patients with coronary artery disease (Ling et al). 2005;149:1137.e9-1137.e16

Coronary disease, therapy

Collaterals and the recovery of left ventricular function after recanalization of a chronic total coronary occlusion (Werner et al). 2005;149:129-37

The Coronary Artery Revascularisation in Diabetes (CARDia) trial: Background, aims, and design (Kapur et al). 2005;149:13-19 (Trial design)

Heart rate variability biofeedback as a behavioral neurocardiac intervention to enhance vagal heart rate control (Nolan et al). 2005;149:1137.e1-1137.e7

Prevalence of metabolic syndrome in cardiac rehabilitation/secondary prevention programs (Savage et al). 2005;149:627-31

Primary stenting of occluded native coronary arteries II Rationale and design of the PRISON II study: A randomized comparison of bare metal stent implantation with sirolimus-eluting stent implantation for the treatment of chronic total coronary occlusions (Rahel et al). 2005;149:414.e1-414.e3 (Trial design)

Coronary occlusion; see Coronary disease

Coronary restenosis

Repeat stenting for the prevention of the early lumen loss phenomenon in patients with in-stent restenosis: Angiographic and intravascular ultrasound findings of a randomized study (Alfonso et al). 2005;149:335.e1-335.e8

The role of platelet glycoprotein IIIa polymorphism in the high prevalence of in vitro aspirin resistance in patients with intracoronary stent restenosis (Pamukcu et al). 2005;149:675-80

Safety and accuracy of multidetector row computed tomography for early assessment of residual stenosis of the infarct-related artery and the number of diseased vessels after acute myocardial infarction (Chiou et al). 2005;149:701-8

Should we routinely supplement coronary patients with folate therapy to prevent in-stent restenosis? (Halabi and Harrington). 2005;149:1035-6

Simvastatin does not inhibit intimal hyperplasia and restenosis but promotes plaque regression in normocholesterolemic patients undergoing coronary stenting: A randomized study with intravascular ultrasound (Petronio et al). 2005;149:520-6

Two-year clinical follow up of ⁹⁰Sr/⁹⁰Y β-radiation versus placebo control for the treatment of in-stent restenosis (Silber et al). 2005;149:689-94

Coronary stenosis

Magnetic resonance imaging of coronary arteries, the ischemic cascade, and myocardial infarction (Kaandorp et al). 2005;149:200-8 (Curriculum cardiol.)

Corrections

Acute effects of β-endorphin on cardiovascular function in patients with mild to moderate chronic heart failure (Cozzolino et al) (2004;148:e13). 2005;149:267

Dose-comparison study of the combination of ezetimibe and simvastatin (Vytorin) versus atorvastatin in patients with hypercholesterolemia: The Vytorin Versus Atorvastatin (VVVA) Study (Ballantyne et al) (2005;149:464-73). 2005;149:882

Prospective randomized comparison of early and late results of a carbonized stent versus a high-grade stainless steel stent of identical design: The Prevention of Recurrent Venous Thromboembolism (PREVENT) trial (Sick et al). (2005;149:681-8). 2005;149:1136

Real-time 3-dimensional echocardiography in assessing atrial and ventricular septal defects: An echocardiographic-surgical correlative study (Cheng et al) (2004;148:1091-5). 2005;149:208

Correspondence; see Letters to the Editor

Cost-effectiveness; see Costs and cost analysis

Costs and cost analysis

Conducting economic evaluations alongside multinational clinical trials: Toward a research consensus (Reed et al). 2005;149:434-43 (Meetings)

Cost-effectiveness of iodixanol in patients at high risk of contrast-induced nephropathy (Aspelin et al). 2005;149:298-303

Economic analysis of the Assessment of the Safety and Efficacy of a New Thrombolytic Regimen (ASSENT-3) study: Costs of reperfusion strategies in acute myocardial infarction (Kaul et al). 2005;149:637-44

Impact of program duration and contact frequency on efficacy and cost of cardiac rehabilitation: Results of a randomized trial (Reid et al). 2005;149:862-8

Metabolic syndrome: Evaluation of pathological and therapeutic outcomes (Miranda et al). 2005;149:20-32 (Meetings)

Practical considerations of β-blockade in the management of the post-myocardial infarction patient (Fonarow). 2005;149:984-93 (Curriculum cardiol).

Reducing the costs of phase III cardiovascular clinical trials (Eisenstein et al). 2005;149:482-8

CRP; see C-reactive protein**Culture**

Hospital therapy traditions influence long-term survival in patients with acute myocardial infarction (Stenstrand et al). 2005;149:82-90

Cytokines

Cigarette smoking is associated with increased circulating proinflammatory and procoagulant markers in patients with chronic coronary artery disease: Effects of aspirin treatment (Ikonomidis et al). 2005;149:832-9

D**Database**

Development of a multicenter peripheral arterial interventional database: the PVD-QI² (Mukherjee et al). 2005;149:1003-8 (Trial design)

Death; see Mortality**Defibrillators, implantable**

Concerns about the implantable cardioverter defibrillator: A determinant of anxiety and depressive symptoms independent of experienced shocks (Pedersen et al). 2005;149:664-9

Implantable cardioverter defibrillators and cardiac resynchronization therapy in patients with left ventricular dysfunction: Randomized trial evidence through 2004 (Al-Khatib et al). 2005;149:1020-34 (Meetings)

Delayed-action preparations

Efficacy, safety and tolerability of metoprolol CR/XL in patients with diabetes and chronic heart failure: Experiences from MERIT-HF (Deedwania et al). 2005;149:159-67

Demography

Asymptomatic atrial fibrillation: Demographic features and prognostic information from the Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) study (Flaker et al). 2005;149:657-63

Systolic hypertension: An overview (Griffith et al). 2005;149:769-75 (Meetings)

Dental care

Periodontal treatment improves endothelial dysfunction in patients with severe periodontitis (Seinost et al). 2005;149:1050-4

A perspective on the potential cardioprotective benefits of periodontal therapy (Offenbacher and Beck). 2005;149:950-4 (Editorial)

Depression

Concerns about the implantable cardioverter defibrillator: A determinant of anxiety and depressive symptoms independent of experienced shocks (Pedersen et al). 2005;149:664-9

Depression and heart failure in patients with a new myocardial infarction (Powell et al). 2005;149:851-5

Heart rate variability biofeedback as a behavioral neurocardiac intervention to enhance vagal heart rate control (Nolan et al). 2005;149:1137.e1-1137.e7

Diabetes mellitus

Chromium supplementation shortens QTc interval duration in patients with type 2 diabetes mellitus (Vrtovec et al). 2005;149:632-6

The Coronary Artery Revascularisation in Diabetes (CARDia) trial: Background, aims, and design (Kapur et al). 2005;149:13-19 (Trial design)

Diabetes and progression of coronary calcium under the influence of statin therapy (Budoff et al). 2005;149:695-700

Effects of abciximab and preprocedural glycemic control in diabetic patients undergoing elective coronary stenting (De Luca et al). 2005;149:1135.e11-1135.e18

Efficacy, safety and tolerability of metoprolol CR/XL in patients with diabetes and chronic heart failure: Experiences from MERIT-HF (Deedwania et al). 2005;149:159-67

Fluvastatin reduces the impact of diabetes on long-term outcome after coronary intervention-A Lescol Intervention Prevention Study (LIPS) substudy (Arampatzis et al). 2005;149:329-35

Impact of physicians' beliefs and practices on cholesterol levels in patients with type 2 diabetes: A longitudinal assessment (Franciosi et al). 2005;149:104-11

Insulin-treated diabetes is associated with a marked increase in mortality in patients with advanced heart failure (Smooke et al). 2005;149:168-74

Microalbuminuria: A strong predictor of 3-year adverse prognosis in nondiabetic patients with acute myocardial infarction (Koulouris et al). 2005;149:840-5

Rationale-Trial to Reduce Cardiovascular Events with Aranesp Therapy (TREAT): Evolving the management of cardiovascular risk in patients with chronic kidney disease (Mix et al). 2005;149:408-13 (Trial design)

Revascularization of coronary atherosclerosis in patients with diabetes mellitus-There is more to it than meets the image intensifier (Petersen and Harrington). 2005;149:190-3 (Editorial)

Risk reduction of cardiac events by screening of unknown asymptomatic coronary artery disease in subjects with type 2 diabetes mellitus at high cardiovascular risk: An open-label randomized pilot study (Faglia et al). 2005;149:283.e1-283.e6

Screening for heart disease in diabetic subjects (Fang et al). 2005;149:349-54

Diastole

Determinants of functional capacity in patients with chronic heart failure: Role of filling pressure and systolic and diastolic function (Smart et al). 2005;149:152-8

A Doppler-derived index of combined left ventricular systolic and diastolic function is an independent predictor of cardiovascular mortality in elderly men (Årnöv et al). 2005;149:902-7

Diet, sodium-restricted

Diet and blood pressure: Applying the evidence to clinical practice (Ard and Svetkey). 2005;149:804-12 (Meetings)

Diet therapy

Diet and blood pressure: Applying the evidence to clinical practice (Ard and Svetkey). 2005;149:804-12 (Meetings)

Dietary supplements

Should we routinely supplement coronary patients with folate therapy to prevent in-stent restenosis? (Halabi and Harrington). 2005;149:1035-6

Diltiazem

Efficacy and safety of a once-daily graded-release diltiazem formulation dosed at bedtime compared to placebo and to morning dosing in chronic stable angina pectoris (Glasser et al.). 2005;149:290.e1-290.e9

Disease classification

A critical appraisal of current models of risk stratification for percutaneous coronary interventions (Singh et al.). 2005;149:753-60 (Curriculum cardiol.)

Disease management

Barriers to hypertension control (Borzecki et al.). 2005; 149:785-94 (Meetings)

Evaluation and management of patients with uncontrolled systolic hypertension: Is another new paradigm really needed? (Mitchell and Pfeffer). 2005;149:776-84 (Meetings)

Impact of invasive management versus noninvasive management on functional status and quality of life following non-Q-wave myocardial infarction: A randomized clinical trial (Eisenberg et al.). 2005;149:813-19

Intensity and focus of heart failure disease management after hospital discharge (Shah et al.). 2005;149:715-21

Metaanalysis and review of heart failure disease management randomized controlled clinical trials (Whellan et al.). 2005;149:722-9

Disease progression

Diabetes and progression of coronary calcium under the influence of statin therapy (Budoff et al.). 2005;149:695-700

New-onset paroxysmal atrial fibrillation: Is permanence inevitable? (Patton and Page). 2005;149:388-90 (Editorial)

Progression to chronic atrial fibrillation after the initial diagnosis of paroxysmal atrial fibrillation: Results from the Canadian Registry of Atrial Fibrillation (Kerr et al.). 2005;149:489-96

Dobutamine Left ventricular outflow tract obstruction provoked during dobutamine stress echocardiography predicts future chest pain, syncope, and near syncope (Dawn et al.). 2005;149:908-16

Dose-response relationship, drug

Comparison of the efficacy and safety of atorvastatin initiated at different starting doses in patients with dyslipidemia (Jones et al.). 2005;149:111.e1-111.e8

Dose-comparison study of the combination of ezetimibe and simvastatin (Vytorin) versus atorvastatin in patients with hypercholesterolemia: The Vytorin Versus Atorvastatin (VYVA) Study (Ballantyne et al.). 2005;149:464-73

To the Editor (Nagge et al.) (Letter); (Kruse and Lee) (Reply). 2005;149:e21, e23-e24

Efficacy and safety of a once-daily graded-release diltiazem formulation dosed at bedtime compared to placebo and to morning dosing in chronic stable angina pectoris (Glasser et al.). 2005;149:290.e1-290.e9

Statins in acute coronary syndromes: The sooner, the better? (Schwartz). 2005;149:377-80 (Editorial)

Drug administration schedule

Efficacy and safety of a once-daily graded-release diltiazem formulation dosed at bedtime compared to placebo and to morning dosing in chronic stable angina pectoris (Glasser et al.). 2005;149:290.e1-290.e9

Statins in acute coronary syndromes: The sooner, the better? (Schwartz). 2005;149:377-80 (Editorial)

Drug combinations

Clopidogrel-aspirin combination for atrial fibrillation: CLAAF is not CLEAR (Jackson et al.) (Letter); (De Caterina and Lorenzoni) (Reply). 2005;149(1):e3, e4

Comparison of ezetimibe plus simvastatin versus simvastatin monotherapy on atherosclerosis progression in familial hypercholesterolemia: Design and rationale of the Ezetimibe and Simvastatin in Hypercholesterolemia Enhances Atherosclerosis Regression (ENHANCE) trial (Kastelein et al.). 2005;149:234-9 (Trial design)

Dose-comparison study of the combination of ezetimibe and simvastatin (Vytorin) versus atorvastatin in patients with hypercholesterolemia: The Vytorin Versus Atorvastatin (VYVA) Study (Ballantyne et al.). 2005;149:464-73

Effect of clopidogrel plus aspirin on tissue perfusion and coronary flow in patients with ST-segment elevation myocardial infarction: A new reperfusion strategy (Dogan et al.). 2005;149:1037-42

Is atorvastatin more appropriate to use in combination with niacin than simvastatin in patients with the metabolic syndrome? (Al-Shaer). 2005;149:e17 (Letter)

Regarding antithrombotic treatment after coronary stenting in patients on chronic oral anticoagulation (Rubboli et al.). 2005;149(2):e1 (Letter)

Drug resistance

The role of platelet glycoprotein IIIa polymorphism in the high prevalence of in vitro aspirin resistance in patients with intracoronary stent restenosis (Pamukcu et al.). 2005;149:675-80

Drug utilization

Practical considerations of β-blockade in the management of the post-myocardial infarction patient (Fonarow). 2005;149:984-93 (Curriculum cardiol.)

Why do patients fail to receive β-blockers for chronic heart failure over time? A "real-world" single-center, 2-year follow-up experience of β-blocker therapy in patients with chronic heart failure (Parameswaran et al.). 2005;149:921-6

Dyslipidemia; see Hyperlipidemia

E

ECG; see Electrocardiography

Echocardiography

Additional impact of electrocardiographic over echocardiographic diagnosis of left ventricular hypertrophy for predicting the risk of ischemic stroke (Kohsaka et al.). 2005;149:181-6

Assessment of left ventricular mass using echocardiography: Use of fundamental imaging (Mansencal and Dubourg) (Letter); (Kohsaka and Di Tullio) (Reply). 2005;149:e29, e31

Impact of cardioversion strategy on functional capacity in patients with atrial fibrillation: The Assessment of Cardioversion Using Transesophageal Echocardiography (ACUTE) Study (Jasper et al.). 2005;149:309-15

Myocardial contrast echocardiography accurately reflects transmurality of myocardial necrosis and predicts contractile reserve after acute myocardial infarction (Janardhanan et al.). 2005;149:355-62

Predictors of response to cardiac resynchronization therapy (PROSPECT)-study design (Yu et al.). 2005;149:600-5 (Trial design)

Echocardiography, Doppler

Determinants of functional capacity in patients with chronic heart failure: Role of filling pressure and systolic and diastolic function (Smart et al). 2005;149:152-8
A Doppler-derived index of combined left ventricular systolic and diastolic function is an independent predictor of cardiovascular mortality in elderly men (Åmlöv et al). 2005;149:902-7

Echocardiography, stress

Assessment of patients with low-risk chest pain in the emergency department: Head-to-head comparison of exercise stress echocardiography and exercise myocardial SPECT (Conti et al). 2005;149:894-901

Left ventricular outflow tract obstruction provoked during dobutamine stress echocardiography predicts future chest pain, syncope, and near syncope (Dawn et al). 2005;149:908-16
Marked differences between patients referred for stress echocardiography and myocardial perfusion imaging studies (Bart et al). 2005;149:888-93

Editorials

Acute coronary syndrome statistics: What you don't see can hurt you (Rajagopal and Bhatt). 2005;149:955-6

Atrial fibrillation and quality of life: Clarity or evidence-based confusion? (Newman). 2005;149:4-6

Conflict of interest for the physician-inventor using a device in human subjects (Popp). 2005;149:1-3

Enhancing reperfusion therapy for myocardial infarction with dual antiplatelet therapy: Breaking the glass ceiling (Fathi and Bhatt). 2005;149:947-9

Improvements in quality improvement (Roe and Peterson). 2005;149:751-2

Morpheus, God of sleep or God of Death? (Verheugt). 2005;149:945-6

New-onset paroxysmal atrial fibrillation: Is permanence inevitable? (Patton and Page). 2005;149:388-90

A perspective on the potential cardioprotective benefits of periodontal therapy (Offenbacher and Beck). 2005;149:950-4

Plaque regression-A new target for antiatherosclerotic therapy (Kartha and Bhatt). 2005;149:384-7

Rate control versus rhythm control: Choose your poison (Passman and Kadish). 2005;149:957-9

Revascularization of coronary atherosclerosis in patients with diabetes mellitus-There is more to it than meets the image intensifier (Petersen and Harrington). 2005;149:190-3

Should we aggressively treat elderly patients with cardiogenic shock? (Hasdai). 2005;149:962-3

Statin therapy—Time to turn the focus from efficacy to implementation? (Blazing). 2005;149:381-3

Statins in acute coronary syndromes: The sooner, the better? (Schwartz). 2005;149:377-80

Unexpected BNP levels in patients with advanced heart failure: A tale of caution and promise (Drazner and de Lemos). 2005;149:187-9

Which role for multislice computed tomography in clinical cardiology? (Bax and Schuijt). 2005;149:960-1

Education, medical

Renal and iliac artery stenting by interventional cardiologists and vascular surgeons: The Foundation to Advance Medical Education (FAME) initiative (Holmes, Jr et al). 2005;149:883-7

Ejection fraction; see Stroke volume

Elderly; see Aged

Electric countershock

Comparative efficacy of monophasic and biphasic waveforms for transthoracic cardioversion of atrial fibrillation and atrial flutter (Gurevitz et al). 2005;149:316-21

Concerns about the implantable cardioverter defibrillator: A determinant of anxiety and depressive symptoms independent of experienced shocks (Pedersen et al). 2005;149:664-9

Impact of cardioversion strategy on functional capacity in patients with atrial fibrillation: The Assessment of Cardioversion Using Transesophageal Echocardiography (ACUTE) Study (Jasper et al). 2005;149:309-15

Rate control versus rhythm control: Choose your poison (Passman and Kadish). 2005;149:957-9 (Editorial)

Rate control versus rhythm control for patients with persistent atrial fibrillation with mild to moderate heart failure: Results from the RAtc Control versus Electrical cardioversion (RACE) study (Hagens et al). 2005;149:1106-11

Electrical cardioversion; see Electric countershock

Electrocardiography

Additional impact of electrocardiographic over echocardiographic diagnosis of left ventricular hypertrophy for predicting the risk of ischemic stroke (Kohsaka et al). 2005;149:181-6

Chromium supplementation shortens QTc interval duration in patients with type 2 diabetes mellitus (Vrtovec et al). 2005;149:632-6

To the Editor (Spodick) (Letter); (Gami et al) (Reply). 2005;149:e9, e11

Effect of coronary artery bypass grafting and aneurysmectomy on QT dispersion in moderate or severe left ventricular dysfunction (Gulcan et al). 2005;149:917-20

Electrocardiographic damage scores and cardiovascular mortality (Richardson et al). 2005;149:458-63

Electrocardiographic diagnosis of left ventricular hypertrophy: The effect of left ventricular thickness, size, and mass on the specific criteria for left ventricular hypertrophy (Budhwani et al). 2005;149:709-14

Incremental prognostic value of exercise single-photon emission computed tomographic (SPECT) thallium 201 imaging in patients with ST-T abnormalities on their resting electrocardiograms (Kwok et al). 2005;149:145-51

ST resolution in a single electrocardiographic lead: A simple and accurate predictor of cardiac mortality in patients with fibrinolytic therapy for acute ST-elevation myocardial infarction (Zeymer et al). 2005;149:91-7

Electron beam tomography; see Tomography, x-ray computed

Embolism

Embolectic protection during saphenous vein graft intervention using a second-generation balloon protection device-Results from the combined US and European pilot study of the TriActiv Balloon Protected Flush Extraction System (Carrozza, Jr et al). 2005;149:1136.e1-1136.e7

Emergency medicine

Assessment of patients with low-risk chest pain in the emergency department: Head-to-head comparison of exercise stress echocardiography and exercise myocardial SPECT (Conti et al). 2005;149:894-901

Impact of the application of the American College of Emergency Physicians recommendations for the admission of patients with syncope on a retrospectively studied population presenting to the emergency department (Elesber et al). 2005;149:826-31

Outcome of patients aged ≥75 years in the SHould we emergently revascularize Occluded Coronaries in cardiogenic shock (SHOCK) trial: Do elderly patients with acute myocardial infarction complicated by cardiogenic shock respond differently to emergent revascularization? (Dzavik et al). 2005;149:1128-34

Endomyocardial biopsy; see Biopsy

Endothelins

Carvedilol therapy is associated with a sustained decline in brain natriuretic peptide levels in patients with congestive heart failure (Frantz et al). 2005;149:541-7

Endothelium, vascular

Early effects of statin therapy on endothelial function and microvascular reactivity in patients with coronary artery disease (Ling et al). 2005;149:1137.e9-1137.e16

Exercise as an alternative to oral estrogen for amelioration of endothelial dysfunction in postmenopausal women (Harvey et al). 2005;149:291-7

Lipid-independent effects of statins on endothelial function and bioavailability of nitric oxide in hypercholesterolemic patients (John et al). 2005;149:473.e1-473.e10

Periodontal treatment improves endothelial dysfunction in patients with severe periodontitis (Seinost et al). 2005;149:1050-4

A perspective on the potential cardioprotective benefits of periodontal therapy (Offenbacher and Beck). 2005;149:950-4 (Editorial)

Energy metabolism

Metabolic syndrome: Definition, pathophysiology, and mechanisms (Miranda et al). 2005;149:33-45

Enoxaparin

Economic analysis of the Assessment of the Safety and Efficacy of a New Thrombolytic Regimen (ASSENT-3) study: Costs of reperfusion strategies in acute myocardial infarction (Kaul et al). 2005;149:637-44

To the Editor (Nagge et al) (Letter); (Kruse and Lee) (Reply). 2005;149:e21, e23-e24

Enoxaparin versus unfractionated heparin as antithrombin therapy in patients receiving fibrinolysis for ST-elevation myocardial infarction: Design and rationale for the Enoxaparin and Thrombolysis Reperfusion for Acute Myocardial Infarction Treatment-Thrombolysis In Myocardial Infarction study 25 (ExTRACT-TIMI 25) (Antman et al). 2005;149:217-26 (Trial design)

Epidemiology

Systolic hypertension: An overview (Griffith et al). 2005;149:769-75 (Meetings)

Eptifibatide

The Early Glycoprotein IIb/IIIa Inhibition in Non-ST-Segment Elevation Acute Coronary Syndrome (EARLY ACS) trial: A randomized placebo-controlled trial evaluating the clinical benefits of early front-loaded eptifibatide in the treatment of patients with non-ST-segment elevation acute coronary syndrome—Study design and rationale (Giugliano et al). 2005;149:994-1002 (Trial design)

Elective percutaneous coronary intervention using broad-spectrum antiplatelet therapy (eptifibatide, clopidogrel, and aspirin) alone, without scheduled unfractionated heparin or other antithrombin therapy (Denardo et al). 2005;149:138-44

Equipment and supplies

Conflict of interest for the physician-inventor using a device in human subjects (Popp). 2005;149:1-3 (Editorial)

Erythrocyte aggregation

Erythrocyte adhesiveness/aggregation: A novel biomarker for the detection of low-grade internal inflammation in individuals with atherosclerotic risk factors and proven vascular disease (Berliner et al). 2005;149:260-7

Estrogen

Exercise as an alternative to oral estrogen for amelioration of endothelial dysfunction in postmenopausal women (Harvey et al). 2005;149:291-7

Ethics, medical

Conflict of interest for the physician-inventor using a device in human subjects (Popp). 2005;149:1-3 (Editorial)

Ethnic groups

Ethnic differences in cardiovascular risk factor burden among middle-aged women: Study of Women's Health Across the Nation (SWAN) (Matthews et al). 2005;149:1066-73

Racial differences in reperfusion therapy use in patients hospitalized with myocardial infarction: A regional phenomenon (Rathore et al). 2005;149:1074-81

Evidence-based medicine

Atrial fibrillation and quality of life: Clarity or evidence-based confusion? (Newman). 2005;149:4-6 (Editorial)

Diet and blood pressure: Applying the evidence to clinical practice (Ard and Svetkey). 2005;149:804-12 (Meetings)

Statin therapy—Time to turn the focus from efficacy to implementation? (Blazing). 2005;149:381-3 (Editorial)

Exercise test

Assessment of patients with low-risk chest pain in the emergency department: Head-to-head comparison of exercise stress echocardiography and exercise myocardial SPECT (Conti et al). 2005;149:894-901

Exercise treadmill testing using a modified exercise protocol in women with suspected myocardial ischemia: Findings from the National Heart, Lung and Blood Institute-sponsored Women's Ischemia Syndrome Evaluation (WISE) (Lewis et al). 2005;149:527-33

Incremental prognostic value of exercise single-photon emission computed tomographic (SPECT) thallium 201 imaging in patients with ST-T abnormalities on their resting electrocardiograms (Kwok et al). 2005;149:145-51

Oxygen uptake efficiency slope, a new submaximal parameter in evaluating exercise capacity in chronic heart failure patients (Van Laethem et al). 2005;149:175-80

Prediction of death or myocardial infarction by exercise single photon emission computed tomography perfusion scintigraphy in patients who have had recent coronary artery stenting (Rajagopal et al). 2005;149:534-40

Exercise therapy

An alternative approach for exercise prescription and efficacy testing in patients with chronic heart failure: A randomized controlled training study (Meyer et al). 2005;149:926.e1-926.e7

Exercise as an alternative to oral estrogen for amelioration of endothelial dysfunction in postmenopausal women (Harvey et al). 2005;149:291-7

Exercise tolerance

Effects of angiotensin-converting enzyme inhibitor plus irbesartan on maximal and submaximal exercise capacity and neurohumoral activation in patients with congestive heart failure (Blanchet et al). 2005;149:938.e1-938.e7

Left atrial volumetric remodeling is predictive of functional capacity in nonobstructive hypertrophic cardiomyopathy (Sachdev et al). 2005;149:730-6

Ezetimibe

Comparison of ezetimibe plus simvastatin versus simvastatin monotherapy on atherosclerosis progression in familial hypercholesterolemia: Design and rationale of the Ezetimibe and Simvastatin in Hypercholesterolemia Enhances Atherosclerosis Regression (ENHANCE) trial (Kastelein et al). 2005;149:234-9 (Trial design)

Dose-comparison study of the combination of ezetimibe and simvastatin (Vytorin) versus atorvastatin in patients with hypercholesterolemia: The Vytorin Versus Atorvastatin (VVVA) Study (Ballantyne et al). 2005;149:464-73

F

Familial hypercholesterolemia; see Hypercholesterolemia, familial

Feedback

Data feedback and clinical process improvement in acute myocardial infarction (Zhang et al). 2005;149:856-61
Improving blood pressure control by tailored feedback to patients and clinicians (Bosworth et al). 2005;149:795-803 (Meetings)

Fibrinogen

An acute inflammatory reaction induced by myocardial damage is superimposed on a chronic inflammation in unstable coronary artery disease (James et al). 2005;149:619-26
Multimarker risk strategy for predicting 1-month and 1-year major events in non-ST elevation acute coronary syndromes (Bodi et al). 2005;149:268-74

Fibrinolysis

Enoxaparin versus unfractionated heparin as antithrombin therapy in patients receiving fibrinolysis for ST-elevation myocardial infarction: Design and rationale for the Enoxaparin and Thrombolysis Reperfusion for Acute Myocardial Infarction Treatment-Thrombolysis In Myocardial Infarction study 25 (ExTRACT-TIMI 25) (Antman et al). 2005;149:217-26 (Trial design)

Fibrinolytic therapy; see Thrombolytic therapy

Fluvastatin

Fluvastatin reduces the impact of diabetes on long-term outcome after coronary intervention—A Lescol Intervention Prevention Study (LIPS) substudy (Arampatzis et al). 2005;149:329-35

Folic acid

Should we routinely supplement coronary patients with folate therapy to prevent in-stent restenosis? (Halabi and Harrington). 2005;149:1035-6

Free fatty acids; see Fatty acids, nonesterified

G

Genetics

Genetic association studies in cardiology (Donahue and Allen). 2005;149:964-70 (Progress cardiol.)

A polymorphism of the endothelial nitric oxide synthase promoter is associated with an increase in autonomic imbalance in patients with congestive heart failure (Binkley et al). 2005;149:342-8

The role of platelet glycoprotein IIIa polymorphism in the high prevalence of in vitro aspirin resistance in patients with intracoronary stent restenosis (Pamukcu et al). 2005;149:675-80

Geography

Racial differences in reperfusion therapy use in patients hospitalized with myocardial infarction: A regional phenomenon (Rathore et al). 2005;149:1074-81

Glucose

Relationship between adolescent fitness and fatness and cardiovascular disease risk factors in adulthood: The Aerobics Center Longitudinal Study (ACLS) (Eisenmann et al). 2005;149:46-53

Glucose-insulin-potassium substrate

Glucose-insulin-potassium and reperfusion in acute myocardial infarction: Rationale and design of the Glucose-Insulin-Potassium Study-2 (GIPS-2) (van der Horst et al). 2005;149:585-91 (Trial design)

ST-segment elevation resolution and outcome in patients treated with primary angioplasty and glucose-insulin-potassium infusion (van der Horst et al). 2005;149:1135.e1-1135.e9

Glycoprotein IIb/IIIa inhibitors; see Platelet aggregation inhibitors

H

HCM; see Cardiomyopathy, hypertrophic

Health care quality, access, and evaluation

Are we appropriately triaging patients with unstable angina? (Gomberg-Maitland et al). 2005;149:613-18

Barriers to hypertension control (Borzecki et al). 2005;149:785-94 (Meetings)

Data feedback and clinical process improvement in acute myocardial infarction (Zhang et al). 2005;149:856-61

Development of a multicenter peripheral arterial interventional database: the PVD-QI² (Mukherjee et al). 2005;149:1003-8 (Trial design)

Improvements in quality improvement (Roe and Peterson). 2005;149:751-2

Influence of clinical trial enrollment on the quality of care and outcomes for patients with non-ST-segment elevation acute coronary syndromes (Kandzari et al). 2005;149:474-81

Sex, quality of care, and outcomes of elderly patients hospitalized with heart failure: Findings from the National Heart Failure Project (Rathore et al). 2005;149:121-8

Health personnel

Improving blood pressure control by tailored feedback to patients and clinicians (Bosworth et al). 2005;149:795-803 (Meetings)

Health plan implementation

Statin therapy—Time to turn the focus from efficacy to implementation? (Blazing). 2005;149:381-3 (Editorial)

Health status

Impact of invasive management versus noninvasive management on functional status and quality of life following non-Q-wave myocardial infarction: A randomized clinical trial (Eisenberg et al). 2005;149:813-19

Heart arrest

Factors associated with an increased chance of survival among patients suffering from an out-of-hospital cardiac arrest in a national perspective in Sweden (Herlitz et al). 2005;149:61-6

Heart atria

Left atrial volumetric remodeling is predictive of functional capacity in nonobstructive hypertrophic cardiomyopathy (Sachdev et al). 2005;149:730-6

Heart block

Incidence, predictors, and outcomes of high-degree atrioventricular block complicating acute myocardial infarction treated with thrombolytic therapy (Meine et al). 2005;149:670-4

Heart catheterization

Early cardiac catheterization is associated with lower mortality only among high-risk patients with ST- and non-ST-elevation acute coronary syndromes: Observations from the OPUS-TIMI 16 trial (Cantor et al). 2005;149:275-83

Invasive versus noninvasive management of ST-elevation acute myocardial infarction: A review of clinical trials and observational studies (Beck et al). 2005;149:194-9 (Curriculum cardiol.)

Transseptal left heart catheterization as an alternative to retrograde left ventricular catheterization for patients with aortic stenosis (Cheng). 2005;149:e15 (Letter)

Heart diseases

Screening for heart disease in diabetic subjects (Fang et al). 2005;149:349-54

Heart failure, congestive

B-type natriuretic peptide levels are not a surrogate marker for invasive hemodynamics during management of patients with severe heart failure (O'Neill et al). 2005;149:363-9

Characteristics and outcomes of patients hospitalized for heart failure in the United States: Rationale, design, and preliminary observations from the first 100,000 cases in the Acute Decompensated Heart Failure National Registry (ADHERE) (Adams Jr. et al). 2005;149:209-16 (Trial design)

Depression and heart failure in patients with a new myocardial infarction (Powell et al). 2005;149:851-5

Determinants of functional capacity in patients with chronic heart failure: Role of filling pressure and systolic and diastolic function (Smart et al). 2005;149:152-8

Effect of body mass index on natriuretic peptide levels in patients with acute congestive heart failure: A ProBNP Investigation of Dyspnea in the Emergency Department (PRIDE) substudy (Krauser et al). 2005;149:744-50

Hypothermia is a bedside predictor of imminent death in patients with congestive heart failure (Casscells et al). 2005;149:927-33

Insulin-treated diabetes is associated with a marked increase in mortality in patients with advanced heart failure (Smoore et al). 2005;149:168-74

Intensity and focus of heart failure disease management after hospital discharge (Shah et al). 2005;149:715-21

Metaanalysis and review of heart failure disease management randomized controlled clinical trials (Whellan et al). 2005;149:722-9

Oxygen uptake efficiency slope, a new submaximal parameter in evaluating exercise capacity in chronic heart failure patients (Van Laethem et al). 2005;149:175-80

Patients with heart failure who die in hospice (Zambroski et al). 2005;149:558-64

A polymorphism of the endothelial nitric oxide synthase promoter is associated with an increase in autonomic imbalance in patients with congestive heart failure (Binkley et al). 2005;149:342-8

Prevalence of anemia and effects on mortality in patients with heart failure (Lindenfeld). 2005;149:391-401 (Curriculum cardiol.)

Sex, quality of care, and outcomes of elderly patients hospitalized with heart failure: Findings from the National Heart Failure Project (Rathore et al). 2005;149:121-8

Unexpected BNP levels in patients with advanced heart failure: A tale of caution and promise (Drazner and de Lemos). 2005;149:187-9 (Editorial)

Heart failure, congestive, drug therapy

Carvedilol therapy is associated with a sustained decline in brain natriuretic peptide levels in patients with congestive heart failure (Frantz et al). 2005;149:541-7

The data monitoring experience in the Candesartan in Heart Failure Assessment of Reduction in Mortality and morbidity ~ (CHARM) program (Pocock et al). 2005;149:939-43

Effects of angiotensin-converting enzyme inhibitor plus irbesartan on maximal and submaximal exercise capacity and neurohumoral activation in patients with congestive heart failure (Blanchet et al). 2005;149:938.e1-938.e7

Effects of metoprolol and carvedilol on cause-specific mortality and morbidity in patients with chronic heart failure—COMET (Torp-Pedersen et al). 2005;149:370-6

Efficacy, safety and tolerability of metoprolol CR/XL in patients with diabetes and chronic heart failure: Experiences from MERIT-HF (Deedwania et al). 2005;149:159-67

A propensity score analysis of the impact of angiotensin-converting enzyme inhibitors on long-term survival of older adults with heart failure and perceived contraindications (Ahmed et al). 2005;149:737-43

Rate control versus rhythm control: Choose your poison (Passman and Kadish). 2005;149:957-9 (Editorial)

Rate control versus rhythm control for patients with persistent atrial fibrillation with mild to moderate heart failure: Results from the RAtc Control versus Electrical cardioversion (RACE) study (Hagens et al). 2005;149:1106-11

Valsartan reduces the incidence of atrial fibrillation in patients with heart failure: Results from the Valsartan Heart Failure Trial (Val-HeFT) (Maggioni et al). 2005;149:548-57

Why do patients fail to receive β-blockers for chronic heart failure over time? A "real-world" single-center, 2-year follow-up experience of β-blocker therapy in patients with chronic heart failure (Parameswaran et al). 2005;149:921-6

Heart failure, congestive, therapy

An alternative approach for exercise prescription and efficacy testing in patients with chronic heart failure: A randomized controlled training study (Meyer et al). 2005;149:926.e1-926.e7

Predictors of response to cardiac resynchronization therapy (PROSPECT)—study design (Yu et al). 2005;149:600-5 (Trial design)

Rate control versus rhythm control for patients with persistent atrial fibrillation with mild to moderate heart failure: Results from the RAtc Control versus Electrical cardioversion (RACE) study (Hagens et al). 2005;149:1106-11

Heart rate

Atrial fibrillation and quality of life: Clarity or evidence-based confusion? (Newman). 2005;149:4-6 (Editorial)

Clinical factors associated with abandonment of a rate-control or a rhythm-control strategy for the management of atrial fibrillation in the AFFIRM study (Curtis et al). 2005;149:304-8

Clinical factors that influence response to treatment strategies in atrial fibrillation: The Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) Study (AFFIRM Investigators). 2005;149:645-9

Heart rate variability biofeedback as a behavioral neurocardiac intervention to enhance vagal heart rate control (Nolan et al). 2005;149:1137.e1-1137.e7

Quality of life in atrial fibrillation: The Atrial Fibrillation Follow up Investigation of Rhythm Management (AFFIRM) study (AFFIRM Investigators). 2005;149:112-20

Rate control versus rhythm control: Choose your poison (Passman and Kadish). 2005;149:957-9 (Editorial)

Rate control versus rhythm control for patients with persistent atrial fibrillation with mild to moderate heart failure: Results from the RAtc Control versus Electrical cardioversion (RACE) study (Hagens et al). 2005;149:1106-11

Heart septum

Transseptal left heart catheterization as an alternative to retrograde left ventricular catheterization for patients with aortic stenosis (Cheng). 2005;149:e15 (Letter)

Heart ventricles

Transseptal left heart catheterization as an alternative to retrograde left ventricular catheterization for patients with aortic stenosis (Cheng). 2005;149:e15 (Letter)

Hematocrit

Nominvasive evaluation of pericardial effusion composition by computed tomography (Rifkin et al). 2005;149:1120-7

Hemodialysis

Potential antiatherogenic and anti-inflammatory properties of sevelamer in maintenance hemodialysis patients (Ferramosca et al). 2005;149:820-5

Hemodynamics

B-type natriuretic peptide levels are not a surrogate marker for invasive hemodynamics during management of patients with severe heart failure (O'Neill et al). 2005;149:363-9

Unexpected BNP levels in patients with advanced heart failure: A tale of caution and promise (Drazner and de Lemos). 2005;149:187-9 (Editorial)

Hemoglobin-based oxygen carriers (HBOCs);

see Hemoglobins

Hemoglobins

Cardioprotection before revascularization in ischemic myocardial injury and the potential role of hemoglobin-based oxygen carriers (Burkhoff and Lefer). 2005;145:573-9 (Progress cardiol.)

Hemorrhage

To the Editor (Nagge et al) (Letter); (Kruse and Lee) (Reply). 2005;149:e21, e23-e24

Factors affecting bleeding risk during anticoagulant therapy in patients with atrial fibrillation: Observations from the Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) Study (DiMarco et al). 2005;149:650-6

The relation of renal function to ischemic and bleeding outcomes with 2 different glycoprotein IIb/IIIa inhibitors: The Do Tirofiban and ReoPro Give Similar Efficacy Outcome (TARGET) trial (Berger et al). 2005;149:869-75

Heparin

Economic analysis of the Assessment of the Safety and Efficacy of a New Thrombolytic Regimen (ASSENT-3) study: Costs of reperfusion strategies in acute myocardial infarction (Kaul et al). 2005;149:637-44

To the Editor (Nagge et al) (Letter); (Kruse and Lee) (Reply). 2005;149:e21, e23-e24

Elective percutaneous coronary intervention using broad-spectrum antiplatelet therapy (epitifibatide, clopidogrel, and aspirin) alone, without scheduled unfractionated heparin or other antithrombin therapy (Denardo et al). 2005;149:138-44

Enoxaparin versus unfractionated heparin as antithrombin therapy in patients receiving fibrinolysis for ST-elevation myocardial infarction: Design and rationale for the Enoxaparin and Thrombolysis Reperfusion for Acute Myocardial Infarction Treatment-Thrombolytic In Myocardial Infarction study 25 (ExTRACT-TIMI 25) (Antman et al). 2005;149:217-26 (Trial design)

Homocysteine

Multimarker risk strategy for predicting 1-month and 1-year major events in non-ST elevation acute coronary syndromes (Bodi et al). 2005;149:268-74

Hospice care

Patients with heart failure who die in hospice (Zambroski et al). 2005;149:558-64

Hospital mortality; *see Mortality***Hospitalization**

Characteristics and outcomes of patients hospitalized for heart failure in the United States: Rationale, design, and preliminary observations from the first 100,000 cases in the Acute Decompensated Heart Failure National Registry (ADHERE) (Adams Jr. et al). 2005;149:209-16 (Trial design)

Efficacy, safety and tolerability of metoprolol CR/XL in patients with diabetes and chronic heart failure: Experiences from MERIT-HF (Deedwania et al). 2005;149:159-67

Metaanalysis and review of heart failure disease management randomized controlled clinical trials (Whellan et al). 2005;149:722-9

Sex, quality of care, and outcomes of elderly patients hospitalized with heart failure: Findings from the National Heart Failure Project (Rathore et al). 2005;149:121-8

Hospitals

Hospital therapy traditions influence long-term survival in patients with acute myocardial infarction (Stenestrand et al). 2005;149:82-90

Hydroxymethylglutaryl-CoA reductase inhibitors

The biology, utilization, and attenuation of C-reactive protein in cardiovascular disease: Part II (Armani and Becker). 2005;149:977-83 (Progress cardiol.)

Diabetes and progression of coronary calcium under the influence of statin therapy (Budoff et al). 2005;149:695-700

Early effects of statin therapy on endothelial function and microvascular reactivity in patients with coronary artery disease (Ling et al). 2005;149:1137.e9-1137.e16

Lipid-independent effects of statins on endothelial function and bioavailability of nitric oxide in hypercholesterolemic patients (John et al). 2005;149:473.e1-473.e10

Plaque regression—A new target for antiatherosclerotic therapy (Kartha and Bhatt). 2005;149:384-7 (Editorial)

Statin therapy—Time to turn the focus from efficacy to implementation? (Blazing). 2005;149:381-3 (Editorial)

Statins in acute coronary syndromes: The sooner, the better? (Schwartz). 2005;149:377-80 (Editorial)

Hypercholesterolemia

Dose-comparison study of the combination of ezetimibe and simvastatin (Vytorin) versus atorvastatin in patients with hypercholesterolemia: The Vytorin Versus Atorvastatin (VVVA) Study (Ballantyne et al). 2005;149:464-73

Lipid-independent effects of statins on endothelial function and bioavailability of nitric oxide in hypercholesterolemic patients (John et al). 2005;149:473.e1-473.e10

Hypercholesterolemia, familial

Comparison of ezetimibe plus simvastatin versus simvastatin monotherapy on atherosclerosis progression in familial hypercholesterolemia: Design and rationale of the Ezetimibe and Simvastatin in Hypercholesterolemia Enhances Atherosclerosis Regression (ENHANCE) trial (Kastelein et al). 2005;149:234-9 (Trial design)

Hyperglycemia

Effects of abciximab and preprocedural glycemic control in diabetic patients undergoing elective coronary stenting (De Luca et al). 2005;149:1135.e11-1135.e18

Hyperlipidemia

Comparison of the efficacy and safety of atorvastatin initiated at different starting doses in patients with dyslipidemia (Jones et al). 2005;149:111.e1-111.e8

Metabolic syndrome: Definition, pathophysiology, and mechanisms (Miranda et al). 2005;149:33-45

Hyperoxemia

Attenuation of reperfusion microvascular ischemia by aqueous oxygen: Experimental and clinical observations (Glazier). 2005;149:580-4 (Progress cardiol.)

Hyperplasia

Simvastatin does not inhibit intimal hyperplasia and restenosis but promotes plaque regression in normocholesterolemic patients undergoing coronary stenting: A randomized study with intravascular ultrasound (Petrovino et al). 2005;149:520-6

Hypertension

Barriers to hypertension control (Borzecki et al). 2005;149:785-94 (Meetings)
Blood pressure variability and prognosis in uncomplicated mild hypertension (Pierdomenico et al). 2005;149:934-8
Diet and blood pressure: Applying the evidence to clinical practice (Ard and Svetkey). 2005;149:804-12 (Meetings)
Evaluation and management of patients with uncontrolled systolic hypertension: Is another new paradigm really needed? (Mitchell and Pfeffer). 2005;149:776-84 (Meetings)
Metabolic syndrome: Definition, pathophysiology, and mechanisms (Miranda et al). 2005;149:33-45
Systolic hypertension: An overview (Griffith et al). 2005;149:769-75 (Meetings)

Hypertrophic cardiomyopathy; see Cardiomyopathy, hypertrophic

Hypertrophy, left ventricular

Additional impact of electrocardiographic over echocardiographic diagnosis of left ventricular hypertrophy for predicting the risk of ischemic stroke (Kohsaka et al). 2005;149:181-6
Assessment of left ventricular mass using echocardiography: Use of fundamental imaging (Mansencal and Dubourg) (Letter); (Kohsaka and Di Tullio) (Reply). 2005;149:e29, e31
Behavior of both epicardial and intramural coronary artery flow velocities in various models of myocardial hypertrophy: Role for left ventricular outflow tract obstruction (De Gregorio et al). 2005;149:1091-8
Electrocardiographic diagnosis of left ventricular hypertrophy: The effect of left ventricular thickness, size, and mass on the specific criteria for left ventricular hypertrophy (Budhwani et al). 2005;149:709-14

Hypothermia

Hypothermia is a bedside predictor of imminent death in patients with congestive heart failure (Casscells et al). 2005;149:927-33

Iliac artery

Renal and iliac artery stenting by interventional cardiologists and vascular surgeons: The Foundation to Advance Medical Education (FAME) initiative (Holmes, Jr et al). 2005;149:883-7

Image enhancement

Assessment of left ventricular mass using echocardiography: Use of fundamental imaging (Mansencal and Dubourg) (Letter); (Kohsaka and Di Tullio) (Reply). 2005;149:e29, e31

Implantable cardioverter defibrillator; see Defibrillators, implantable

Incidence

Acute coronary syndrome statistics: What you don't see can hurt you (Rajagopal and Bhatt). 2005;149:955-6 (Editorial)
Incidence, predictors, and outcomes of high-degree atrioventricular block complicating acute myocardial infarction treated with thrombolytic therapy (Meine et al). 2005;149:670-4

Valsartan reduces the incidence of atrial fibrillation in patients with heart failure: Results from the Valsartan Heart Failure Trial (Val-HeFT) (Maggioni et al). 2005;149:548-57

Infection

Stent implantation, but not pathogen burden, is associated with plasma C-reactive protein and interleukin-6 levels after percutaneous coronary intervention in patients with stable angina pectoris (Saleh et al). 2005;149:876-82

Inflammation

An acute inflammatory reaction induced by myocardial damage is superimposed on a chronic inflammation in unstable coronary artery disease (James et al). 2005;149:619-26
Atorvastatin has an important acute anti-inflammatory effect in patients with acute coronary syndrome: Results of a randomized, double-blind, placebo-controlled study (Macin et al). 2005;149:451-7
Cigarette smoking is associated with increased circulating proinflammatory and procoagulant markers in patients with chronic coronary artery disease: Effects of aspirin treatment (Ikonomidis et al). 2005;149:832-9

Erythrocyte adhesiveness/aggregation: A novel biomarker for the detection of low-grade internal inflammation in individuals with atherosclerotic risk factors and proven vascular disease (Berliner et al). 2005;149:260-7

Metabolic syndrome: Definition, pathophysiology, and mechanisms (Miranda et al). 2005;149:33-45

A perspective on the potential cardioprotective benefits of periodontal therapy (Offenbacher and Beck). 2005;149:950-4 (Editorial)

Potential antiatherogenic and anti-inflammatory properties of sevelamer in maintenance hemodialysis patients (Ferramosca et al). 2005;149:820-5

Urinary tract infection in patients with acute coronary syndrome: A potential systemic inflammatory connection (Sims et al). 2005;149:1062-5

Influenza

Examining the coverage of influenza vaccination among people with cardiovascular disease in the United States (Ajani et al). 2005;149:254-9

Insulin

Insulin-treated diabetes is associated with a marked increase in mortality in patients with advanced heart failure (Smooke et al). 2005;149:168-74

Metabolic syndrome: Definition, pathophysiology, and mechanisms (Miranda et al). 2005;149:33-45

Insulin resistance

Metabolic syndrome: Definition, pathophysiology, and mechanisms (Miranda et al). 2005;149:33-45

Intraleukin-6

An acute inflammatory reaction induced by myocardial damage is superimposed on a chronic inflammation in unstable coronary artery disease (James et al). 2005;149:619-26

A perspective on the potential cardioprotective benefits of periodontal therapy (Offenbacher and Beck). 2005;149:950-4 (Editorial)

Stent implantation, but not pathogen burden, is associated with plasma C-reactive protein and interleukin-6 levels after percutaneous coronary intervention in patients with stable angina pectoris (Saleh et al). 2005;149:876-82

Intra-aortic balloon pumping

Does current treatment of cardiogenic shock complicating the acute coronary syndromes comply with guidelines? (Iakobishvili et al). 2005;149:98-103

Intravascular ultrasonography; see Ultrasonography, interventional

Iodixanol

Cost-effectiveness of iodixanol in patients at high risk of contrast-induced nephropathy (Aspelin et al). 2005;149:298-303

Iohexol

Cost-effectiveness of iodixanol in patients at high risk of contrast-induced nephropathy (Aspelin et al). 2005;149:298-303

Irbesartan

Effects of angiotensin-converting enzyme inhibitor plus irbesartan on maximal and submaximal exercise capacity and neurohumoral activation in patients with congestive heart failure (Blanchet et al). 2005;149:938.e1-938.e7

Ischemic heart disease; see Myocardial ischemia

K**Kidney artery**

Renal and iliac artery stenting by interventional cardiologists and vascular surgeons: The Foundation to Advance Medical Education (FAME) initiative (Holmes, Jr et al). 2005;149:883-7

Kidney diseases

Association of chronic kidney disease with clinical outcomes after coronary revascularization: The arterial revascularization therapies study (ARTS) (Ix et al). 2005;149:512-9

Cost-effectiveness of iodixanol in patients at high risk of contrast-induced nephropathy (Aspelin et al). 2005;149:298-303

To the Editor (Nagge et al) (Letter); (Kruse and Lee) (Reply). 2005;149:e21, e23-e24

Rationale—Trial to Reduce Cardiovascular Events with Aranesp Therapy (TREAT): Evolving the management of cardiovascular risk in patients with chronic kidney disease (Mix et al). 2005;149:408-13 (Trial design)

Kidney function

The relation of renal function to ischemic and bleeding outcomes with 2 different glycoprotein IIb/IIIa inhibitors: The Do Tirofiban and ReoPro Give Similar Efficacy Outcome (TARGET) trial (Berger et al). 2005;149:869-75

L**Lanoteplase**

ST resolution in a single electrocardiographic lead: A simple and accurate predictor of cardiac mortality in patients with fibrinolytic therapy for acute ST-elevation myocardial infarction (Zeymer et al). 2005;149:91-7

Latin America

Cardiovascular disease in Latin America (Medina-Lezama et al). 2005;149:e13 (Letter)

Left ventricular dysfunction; see Ventricular dysfunction, left

Left ventricular hypertrophy; see Hypertrophy, left ventricular; Ventricular hypertrophy, left

Left ventricular outflow obstruction; see Ventricular outflow obstruction

Letters to the Editor

Angiotensin-converting enzyme inhibitors as a new therapy for atrial fibrillation? Controversy (Ogimoto et al). 2005;149:e19

Aortic stenosis and angiotensin-converting enzyme inhibitors—Rupture of an ancient paradigm? (Barrera-Ramirez et al) (Letter); (Chockalingam) (Reply). 2005;149:e5, e7

Assessment of left ventricular mass using echocardiography: Use of fundamental imaging (Mansencal and Dubourg) (Letter); (Kohsaka and Di Tullio) (Reply). 2005;149:e29, e31

Cardiovascular disease in Latin America (Medina-Lezama et al). 2005;149:e13

Clopidogrel-aspirin combination for atrial fibrillation: CLAAF is not CLEAR (Jackson et al) (Letter); (De Caterina and Lorenzoni) (Reply). 2005;149(1):e3, e4

To the Editor (Nagge et al) (Letter); (Kruse and Lee) (Reply). 2005;149:e21, e23-e24

To the Editor (Spodick) (Letter); (Gami et al) (Reply). 2005;149:e9, e11

Is atorvastatin more appropriate to use in combination with niacin than simvastatin in patients with the metabolic syndrome? (Al-Shaer). 2005;149:e17

Regarding antithrombotic treatment after coronary stenting in patients on chronic oral anticoagulation (Rubboli et al). 2005;149(2):e1

Regarding the mechanisms of statin-induced myopathy (Noël). 2005;149(2):e3

Thrombolytic therapy for eligible elderly patients with acute myocardial infarction (Yusuf et al) (Letter); (Avezum and Makdisse) (Reply). 2005;149:e25-e26, e27

Transseptal left heart catheterization as an alternative to retrograde left ventricular catheterization for patients with aortic stenosis (Cheng). 2005;149:e15

Lipids and lipoproteins; see also Hyperlipidemia

Early effects of statin therapy on endothelial function and microvascular reactivity in patients with coronary artery disease (Ling et al). 2005;149:1137.e9-1137.e16

Impact of physicians' beliefs and practices on cholesterol levels in patients with type 2 diabetes: A longitudinal assessment (Franciosi et al). 2005;149:104-11

Lipid-independent effects of statins on endothelial function and bioavailability of nitric oxide in hypercholesterolemic patients (John et al). 2005;149:473.e1-473.e10

Relationship between adolescent fitness and fatness and cardiovascular disease risk factors in adulthood: The Aerobics Center Longitudinal Study (ACLS) (Eisenmann et al). 2005;149:46-53

M**M-CSF; see Macrophage colony-stimulating factor****Macrophage colony-stimulating factor**

Cigarette smoking is associated with increased circulating proinflammatory and procoagulant markers in patients with chronic coronary artery disease: Effects of aspirin treatment (Ikonomidis et al). 2005;149:832-9

Magnetic resonance imaging

Magnetic resonance imaging of coronary arteries, the ischemic cascade, and myocardial infarction (Kaandorp et al). 2005;149:200-8 (Curriculum cardiol.)

Myocardial contrast echocardiography accurately reflects transmurality of myocardial necrosis and predicts contractile reserve after acute myocardial infarction (Janardhanan et al). 2005;149:355-62

Very early cardiac magnetic resonance imaging for quantification of myocardial tissue perfusion in patients receiving tirofiban before percutaneous coronary intervention for ST-elevation myocardial elevation (Steen et al). 2005;149:564.e1-564.e7

Mass screening

Risk reduction of cardiac events by screening of unknown asymptomatic coronary artery disease in subjects with type 2 diabetes mellitus at high cardiovascular risk: An open-label randomized pilot study (Faglia et al). 2005;149:283.e1-283.e6

Medical devices; see Equipment and supplies**Medical ethics; see Ethics, medical**

Men

A Doppler-derived index of combined left ventricular systolic and diastolic function is an independent predictor of cardiovascular mortality in elderly men (Årnlöv et al). 2005;149:902-7

Meta-analysis

Implantable cardioverter defibrillators and cardiac resynchronization therapy in patients with left ventricular dysfunction: Randomized trial evidence through 2004 (Al-Khatib et al). 2005;149:1020-34 (Meetings)

Metaanalysis and review of heart failure disease management randomized controlled clinical trials (Whellan et al). 2005;149:722-9

Metabolic syndrome

Is atorvastatin more appropriate to use in combination with niacin than simvastatin in patients with the metabolic syndrome? (Al-Shaer). 2005;149:17 (Letter)

Metabolic syndrome: Definition, pathophysiology, and mechanisms (Miranda et al). 2005;149:33-45

Metabolic syndrome: Evaluation of pathological and therapeutic outcomes (Miranda et al). 2005;149:20-32 (Meetings)

Prevalence of metabolic syndrome in cardiac rehabilitation secondary prevention programs (Savage et al). 2005;149:627-31

Metoprolol

Effects of metoprolol and carvedilol on cause-specific mortality and morbidity in patients with chronic heart failure—COMET (Torp-Pedersen et al). 2005;149:370-6

Efficacy, safety and tolerability of metoprolol CR/XL in patients with diabetes and chronic heart failure: Experiences from MERIT-HF (Deedwania et al). 2005;149:159-67

Microcirculation

Early effects of statin therapy on endothelial function and microvascular reactivity in patients with coronary artery disease (Ling et al). 2005;149:1137.e9-1137.e16

Models, statistical

A critical appraisal of current models of risk stratification for percutaneous coronary interventions (Singh et al). 2005;149:753-60 (Curriculum cardiol.)

Morbidity

The data monitoring experience in the Candesartan in Heart Failure Assessment of Reduction in Mortality and morbidity (CHARM) program (Pocock et al). 2005;149:939-43

Effects of metoprolol and carvedilol on cause-specific mortality and morbidity in patients with chronic heart failure—COMET (Torp-Pedersen et al). 2005;149:370-6

Morphine

Association of intravenous morphine use and outcomes in acute coronary syndromes: Results from the CRUSADE Quality Improvement Initiative (Meine et al). 2005;149:1043-9

Morpheus, God of sleep or God of Death? (Verheught). 2005;149:945-6 (Editorial)

Mortality

Association of intravenous morphine use and outcomes in acute coronary syndromes: Results from the CRUSADE Quality Improvement Initiative (Meine et al). 2005;149:1043-9

Benign outcome in a long-term follow-up of patients with hypertrophic cardiomyopathy in Brazil (Arteaga et al). 2005;149:1099-05

The data monitoring experience in the Candesartan in Heart Failure Assessment of Reduction in Mortality and morbidity (CHARM) program (Pocock et al). 2005;149:939-43

Does current treatment of cardiogenic shock complicating the acute coronary syndromes comply with guidelines? (Jakovishvili et al). 2005;149:98-103

A Doppler-derived index of combined left ventricular systolic and diastolic function is an independent predictor of cardiovascular mortality in elderly men (Årnlöv et al).

2005;149:902-7

Early cardiac catheterization is associated with lower mortality only among high-risk patients with ST- and non-ST-elevation acute coronary syndromes: Observations from the OPUS-TIMI 16 trial (Cantor et al). 2005;149:275-83

Effects of metoprolol and carvedilol on cause-specific mortality and morbidity in patients with chronic heart failure—COMET (Torp-Pedersen et al). 2005;149:370-6

Electrocardiographic damage scores and cardiovascular mortality (Richardson et al). 2005;149:458-63

Hospital therapy traditions influence long-term survival in patients with acute myocardial infarction (Stenstrand et al). 2005;149:82-90

Hypothermia is a bedside predictor of imminent death in patients with congestive heart failure (Casscells et al). 2005;149:927-33

Incidence, predictors, and outcomes of high-degree atrioventricular block complicating acute myocardial infarction treated with thrombolytic therapy (Meine et al). 2005;149:670-4

Insulin-treated diabetes is associated with a marked increase in mortality in patients with advanced heart failure (Smoake et al). 2005;149:168-74

Metaanalysis and review of heart failure disease management randomized controlled clinical trials (Whellan et al). 2005;149:722-9

Multimarker risk strategy for predicting 1-month and 1-year major events in non-ST elevation acute coronary syndromes (Bodi et al). 2005;149:268-74

Outcome of patients aged ≥ 75 years in the SHould we emergently revascularize Occluded Coronaries in cardiogenic shock (SHOCK) trial: Do elderly patients with acute myocardial infarction complicated by cardiogenic shock respond differently to emergent revascularization? (Dzavik et al). 2005;149:1128-34

Prediction of death or myocardial infarction by exercise single photon emission computed tomography perfusion scintigraphy in patients who have had recent coronary artery stenting (Rajagopal et al). 2005;149:534-40

Prevalence of anemia and effects on mortality in patients with heart failure (Lindenfield). 2005;149:391-401 (Curriculum cardiol.)

Prognostic impact of body weight and abdominal obesity in women and men with cardiovascular disease (Dagenais et al). 2005;149:54-60

ST resolution in a single electrocardiographic lead: A simple and accurate predictor of cardiac mortality in patients with fibrinolytic therapy for acute ST-elevation myocardial infarction (Zeymer et al). 2005;149:91-7

MRI; see Magnetic resonance imaging

Muscular diseases

Regarding the mechanisms of statin-induced myopathy (Noël). 2005;149(2):e3 (Letter)

Myocardial contraction

Myocardial contrast echocardiography accurately reflects transmurality of myocardial necrosis and predicts contractile reserve after acute myocardial infarction (Janardhanan et al). 2005;149:355-62

Myocardial infarction

Acute coronary syndrome national statistics: Challenges in definitions (Bertoni et al). 2005;149:1055-61

Acute coronary syndrome statistics: What you don't see can hurt you (Rajagopal and Bhatt). 2005;149:955-6 (Editorial)

Data feedback and clinical process improvement in acute myocardial infarction (Zhang et al). 2005;149:856-61

Depression and heart failure in patients with a new myocardial infarction (Powell et al). 2005;149:851-5

Does current treatment of cardiogenic shock complicating the acute coronary syndromes comply with guidelines? (Jakovishvili et al). 2005;149:98-103

Impact of age on management and outcome of acute coronary syndrome: Observations from the Global Registry of Acute Coronary Events (GRACE) (Avezum et al). 2005;149:67-73

Impact of invasive management versus noninvasive management on functional status and quality of life following non-Q-wave myocardial infarction: A randomized clinical trial (Eisenberg et al). 2005;149:813-19

Influence of clinical trial enrollment on the quality of care and outcomes for patients with non-ST-segment elevation acute coronary syndromes (Kandzari et al). 2005;149:474-81

Left ventricular systolic asynchrony after acute myocardial infarction in patients with narrow QRS complexes (Zhang et al). 2005;149:497-503

Multimarker risk strategy for predicting 1-month and 1-year major events in non-ST elevation acute coronary syndromes (Bodi et al). 2005;149:268-74

Myocardial contrast echocardiography accurately reflects transmurality of myocardial necrosis and predicts contractile reserve after acute myocardial infarction (Janardhanan et al). 2005;149:355-62

Plaque erosion in the culprit lesion is prone to develop a smaller myocardial infarction size compared with plaque rupture (Hayashi et al). 2005;149:284-90

Safety and accuracy of multidetector row computed tomography for early assessment of residual stenosis of the infarct-related artery and the number of diseased vessels after acute myocardial infarction (Chiou et al). 2005;149:701-8

Urinary tract infection in patients with acute coronary syndrome: A potential systemic inflammatory connection (Sims et al). 2005;149:1062-5

Myocardial infarction, diagnosis

Indications for angiography subsequent to coronary artery bypass grafting (Alter et al). 2005;149:1082-90

Magnetic resonance imaging of coronary arteries, the ischemic cascade, and myocardial infarction (Kaandorp et al). 2005;149:200-8 (Curriculum cardiol.)

Prediction of death or myocardial infarction by exercise single photon emission computed tomography perfusion scintigraphy in patients who have had recent coronary artery stenting (Rajagopal et al). 2005;149:534-40

Prediction of missed myocardial infarction among symptomatic outpatients without coronary heart disease (Sequist et al). 2005;149:74-81

Myocardial infarction, drug therapy

Assessment of Pexelizumab in Acute Myocardial Infarction (APEX AMI): A multicenter, randomized, double-blind, parallel-group, placebo-controlled study of pexelizumab in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention (Armstrong et al). 2005;149:402-7 (Trial design)

Association of intravenous morphine use and outcomes in acute coronary syndromes: Results from the CRUSADE Quality Improvement Initiative (Meine et al). 2005;149:1043-9

Atorvastatin has an important acute anti-inflammatory effect in patients with acute coronary syndrome: Results of a randomized, double-blind, placebo-controlled study (Macin et al). 2005;149:451-7

Design and rationale of Clopidogrel as Adjunctive Reperfusion Therapy-Thrombolysis in Myocardial Infarction (CLARITY-TIMI) 28 trial (Sabatine et al). 2005;149:227-33 (Trial design)

The Early Glycoprotein IIb/IIIa Inhibition in Non-ST-Segment Elevation Acute Coronary Syndrome (EARLY ACS) trial: A randomized placebo-controlled trial evaluating the clinical benefits of early front-loaded eptifibatide in the treatment of patients with non-ST-segment elevation acute coronary syndrome—Study design and rationale (Giugliano et al). 2005;149:994-1002 (Trial design)

Early initiation of lipid-lowering therapy for acute coronary syndromes improves compliance with guideline recommendations: Observations from the Orbofiban in Patients with Unstable Coronary Syndromes (OPUS-TIMI 16) trial (Smith et al). 2005;149:444-50

Economic analysis of the Assessment of the Safety and Efficacy of a New Thrombolytic Regimen (ASSENT-3) study: Costs of reperfusion strategies in acute myocardial infarction (Kaul et al). 2005;149:637-44

Effect of clopidogrel plus aspirin on tissue perfusion and coronary flow in patients with ST-segment elevation myocardial infarction: A new reperfusion strategy (Dogan et al). 2005;149:1037-42

Enhancing reperfusion therapy for myocardial infarction with dual antiplatelet therapy: Breaking the glass ceiling (Fathi and Bhatt). 2005;149:947-9 (Editorial)

Enoxaparin versus unfractionated heparin as antithrombin therapy in patients receiving fibrinolysis for ST-elevation myocardial infarction: Design and rationale for the Enoxaparin and Thrombolysis Reperfusion for Acute Myocardial Infarction Treatment-Thrombolysis in Myocardial Infarction study 25 (ExTRACT-TIMI 25) (Antman et al). 2005;149:217-26 (Trial design)

Glucose-insulin-potassium and reperfusion in acute myocardial infarction: Rationale and design of the Glucose-Insulin-Potassium Study-2 (GIPS-2) (van der Horst et al). 2005;149:585-91 (Trial design)

Incidence, predictors, and outcomes of high-degree atrioventricular block complicating acute myocardial infarction treated with thrombolytic therapy (Meine et al). 2005;149:670-4

Long-term benefits of an early invasive management in acute coronary syndromes depend on intracoronary stenting and aggressive antiplatelet treatment: A metaregression (Biondi-Zocca et al). 2005;149:504-11

Practical considerations of β -blockade in the management of the post-myocardial infarction patient (Fonarow). 2005;149:984-93 (Curriculum cardiol.)

ST-segment elevation resolution and outcome in patients treated with primary angioplasty and glucose-insulin-potassium infusion (van der Horst et al). 2005;149:1135.e1-1135.e9

Statins in acute coronary syndromes: The sooner, the better? (Schwartz). 2005;149:377-80 (Editorial)

Thrombolytic therapy for eligible elderly patients with acute myocardial infarction (Yusuf et al) (Letter); (Avezum and Makdisse) (Reply). 2005;149:e25-e27

Very early cardiac magnetic resonance imaging for quantification of myocardial tissue perfusion in patients receiving tirofiban before percutaneous coronary intervention for ST-elevation myocardial elevation (Steen et al). 2005;149:564.e1-564.e7

Myocardial infarction, prognosis

Correlation between the TIMI risk score and high-risk angiographic findings in non-ST-elevation acute coronary syndromes: Observations from the Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) trial (Mega et al). 2005;149:846-50

Microalbuminuria: A strong predictor of 3-year adverse prognosis in nondiabetic patients with acute myocardial infarction (Koulouris et al). 2005;149:840-5

ST resolution in a single electrocardiographic lead: A simple and accurate predictor of cardiac mortality in patients with fibrinolytic therapy for acute ST-elevation myocardial infarction (Zeymer et al). 2005;149:91-7

Myocardial infarction, therapy

Assessment of Pexelizumab in Acute Myocardial Infarction (APEX AMI): A multicenter, randomized, double-blind, parallel-group, placebo-controlled study of pexelizumab in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention (Armstrong et al). 2005;149:402-7 (Trial design)

Early cardiac catheterization is associated with lower mortality only among high-risk patients with ST- and non-ST-elevation acute coronary syndromes: Observations from the OPUS-TIMI 16 trial (Cantor et al). 2005;149:275-83

Enhancing reperfusion therapy for myocardial infarction with dual antiplatelet therapy: Breaking the glass ceiling (Fathi and Bhatt). 2005;149:947-9 (Editorial)

Enoxaparin versus unfractionated heparin as antithrombin therapy in patients receiving fibrinolysis for ST-elevation myocardial infarction: Design and rationale for the Enoxaparin and Thrombolysis Reperfusion for Acute Myocardial Infarction Treatment-Thrombolysis In Myocardial Infarction study 25 (EXTRACT-TIMI 25) (Antman et al). 2005;149:217-26 (Trial design)

Glucose-insulin-potassium and reperfusion in acute myocardial infarction: Rationale and design of the Glucose-Insulin-Potassium Study-2 (GIPS-2) (van der Host et al). 2005;149:585-91 (Trial design)

Hospital therapy traditions influence long-term survival in patients with acute myocardial infarction (Stenestrand et al). 2005;149:82-90

Impact of age on management and outcome of acute coronary syndrome: Observations from the Global Registry of Acute Coronary Events (GRACE) (Avezum et al). 2005;149:67-73

Invasive versus noninvasive management of ST-elevation acute myocardial infarction: A review of clinical trials and observational studies (Beck et al). 2005;149:194-9 (Curriculum cardiol.)

Long-term benefits of an early invasive management in acute coronary syndromes depend on intracoronary stenting and aggressive antiplatelet treatment: A metaregression (Biondi-Zocca et al). 2005;149:504-11

Outcome of patients aged ≥75 years in the SHould we emergently revascularize Occluded Coronaries in cardiogenic shock (SHOCK) trial: Do elderly patients with acute myocardial infarction complicated by cardiogenic shock respond differently to emergent revascularization? (Dzavik et al). 2005;149:1128-34

Racial differences in reperfusion therapy use in patients hospitalized with myocardial infarction: A regional phenomenon (Rathore et al). 2005;149:1074-81

Myocardial ischemia, diagnosis

Exercise treadmill testing using a modified exercise protocol in women with suspected myocardial ischemia: Findings

from the National Heart, Lung and Blood Institute-sponsored Women's Ischemia Syndrome Evaluation (WISE) (Lewis et al). 2005;149:527-33

Magnetic resonance imaging of coronary arteries, the ischemic cascade, and myocardial infarction (Kaandorp et al). 2005;149:200-8 (Curriculum cardiol.)

Prediction of missed myocardial infarction among symptomatic outpatients without coronary heart disease (Sequist et al). 2005;149:74-81

Myocardial ischemia, drug therapy

Attenuation of reperfusion microvascular ischemia by aqueous oxygen: Experimental and clinical observations (Glazier). 2005;149:580-4 (Progress cardiol.)

Cardioprotection before revascularization in ischemic myocardial injury and the potential role of hemoglobin-based oxygen carriers (Burkhoff and Lefer). 2005;149:573-9 (Progress cardiol.)

The relation of renal function to ischemic and bleeding outcomes with 2 different glycoprotein IIb/IIIa inhibitors: The Do Tirofiban and ReoPro Give Similar Efficacy Outcome (TARGET) trial (Berger et al). 2005;149:869-75

Statins in acute coronary syndromes: The sooner, the better? (Schwartz). 2005;149:377-80 (Editorial)

Myocardial ischemia, prognosis

Prediction of death or myocardial infarction by exercise single photon emission computed tomography perfusion scintigraphy in patients who have had recent coronary artery stenting (Rajagopal et al). 2005;149:534-40

Myocardial reperfusion

Cardioprotection before revascularization in ischemic myocardial injury and the potential role of hemoglobin-based oxygen carriers (Burkhoff and Lefer). 2005;149:573-9 (Progress cardiol.)

Design and rationale of Clopidogrel as Adjunctive Reperfusion Therapy-Thrombolysis in Myocardial Infarction (CLARITY-TIMI) 28 trial (Sabatine et al). 2005;149:227-33 (Trial design)

Effect of clopidogrel plus aspirin on tissue perfusion and coronary flow in patients with ST-segment elevation myocardial infarction: A new reperfusion strategy (Dogan et al). 2005;149:1037-42

Enhancing reperfusion therapy for myocardial infarction with dual antiplatelet therapy: Breaking the glass ceiling (Fathi and Bhatt). 2005;149:947-9 (Editorial)

Enoxaparin versus unfractionated heparin as antithrombin therapy in patients receiving fibrinolysis for ST-elevation myocardial infarction: Design and rationale for the Enoxaparin and Thrombolysis Reperfusion for Acute Myocardial Infarction Treatment-Thrombolysis In Myocardial Infarction study 25 (EXTRACT-TIMI 25) (Antman et al). 2005;149:217-26 (Trial design)

Glucose-insulin-potassium and reperfusion in acute myocardial infarction: Rationale and design of the Glucose-Insulin-Potassium Study-2 (GIPS-2) (van der Host et al). 2005;149:585-91 (Trial design)

Racial differences in reperfusion therapy use in patients hospitalized with myocardial infarction: A regional phenomenon (Rathore et al). 2005;149:1074-81

Myocardial reperfusion injury

Attenuation of reperfusion microvascular ischemia by aqueous oxygen: Experimental and clinical observations (Glazier). 2005;149:580-4 (Progress cardiol.)

Cardioprotection before revascularization in ischemic myocardial injury and the potential role of hemoglobin-based

oxygen carriers (Burkhoff and Lefer). 2005;149:573-9 (Progress cardiol.)

Myocardial revascularization

Association of chronic kidney disease with clinical outcomes after coronary revascularization: The arterial revascularization therapies study (ARTS) (Ix et al). 2005;149:512-9

Cardioprotection before revascularization in ischemic myocardial injury and the potential role of hemoglobin-based oxygen carriers (Burkhoff and Lefer). 2005;149:573-9 (Progress cardiol.)

Collaterals and the recovery of left ventricular function after recanalization of a chronic total coronary occlusion (Werner et al). 2005;149:129-37

The Coronary Artery Revascularisation in Diabetes (CARDia) trial: Background, aims, and design (Kapur et al). 2005;149:13-19 (Trial design)

Does current treatment of cardiogenic shock complicating the acute coronary syndromes comply with guidelines? (Iakovishvili et al). 2005;149:98-103

Elective percutaneous coronary intervention using broad spectrum antiplatelet therapy (epitifibatide, clopidogrel, and aspirin) alone, without scheduled unfractionated heparin or other antithrombin therapy (Denardo et al). 2005;149:138-44

Outcome of patients aged ≥75 years in the SHould we emergently revascularize Occluded Coronaries in cardiogenic shock (SHOCK) trial: Do elderly patients with acute myocardial infarction complicated by cardiogenic shock respond differently to emergent revascularization? (Dzavik et al). 2005;149:1128-34

Revascularization of coronary atherosclerosis in patients with diabetes mellitus—There is more to it than meets the image intensifier (Petersen and Harrington). 2005;149:190-3 (Editorial)

Should we aggressively treat elderly patients with cardiogenic shock? (Hasdai). 2005;149:962-3 (Editorial)

Myocarditis

Diagnostic approach to the patient with cardiomyopathy: Whom to biopsy (Ardehali et al). 2005;149:7-12 (Curriculum cardiol.)

Myoglobin

Multimarker risk strategy for predicting 1-month and 1-year major events in non-ST elevation acute coronary syndromes (Bodi et al). 2005;149:268-74

Myopathy; see Muscular diseases

N

NANP; see Atrial natriuretic peptide, N-terminal
Natriuretic peptide, brain

B-type natriuretic peptide levels are not a surrogate marker for invasive hemodynamics during management of patients with severe heart failure (O'Neill et al). 2005;149:363-9

Carvedilol therapy is associated with a sustained decline in brain natriuretic peptide levels in patients with congestive heart failure (Frantz et al). 2005;149:541-7

Effect of body mass index on natriuretic peptide levels in patients with acute congestive heart failure: A ProBNP Investigation of Dyspnea in the Emergency Department (PRIDE) substudy (Krauser et al). 2005;149:744-50

Screening for heart disease in diabetic subjects (Fang et al). 2005;149:349-54

Unexpected BNP levels in patients with advanced heart failure: A tale of caution and promise (Drazner and de Lemos). 2005;149:187-9 (Editorial)

Necrosis

Myocardial contrast echocardiography accurately reflects transmurality of myocardial necrosis and predicts contractile reserve after acute myocardial infarction (Janardhanan et al). 2005;149:355-62

Nephropathy; see Kidney diseases

Neurohormones; see Neurotransmitters

Neurotransmitters

Effects of angiotensin-converting enzyme inhibitor plus irbesartan on maximal and submaximal exercise capacity and neurohumoral activation in patients with congestive heart failure (Blanchet et al). 2005;149:938.e1-938.e7

Niacin

Is atorvastatin more appropriate to use in combination with niacin than simvastatin in patients with the metabolic syndrome? (Al-Shaer). 2005;149:e17 (Letter)

Nitric oxide

Lipid-independent effects of statins on endothelial function and bioavailability of nitric oxide in hypercholesterolemic patients (John et al). 2005;149:473.e1-473.e10

Nitric-oxide synthase

A polymorphism of the endothelial nitric oxide synthase promoter is associated with an increase in autonomic imbalance in patients with congestive heart failure (Binkley et al). 2005;149:342-8

Nitroglycerin

Association of intravenous morphine use and outcomes in acute coronary syndromes: Results from the CRUSADE Quality Improvement Initiative (Meine et al). 2005;149:1043-9

Norepinephrine

Carvedilol therapy is associated with a sustained decline in brain natriuretic peptide levels in patients with congestive heart failure (Frantz et al). 2005;149:541-7

O

Obesity

Effect of body mass index on natriuretic peptide levels in patients with acute congestive heart failure: A ProBNP Investigation of Dyspnea in the Emergency Department (PRIDE) substudy (Krauser et al). 2005;149:744-50

Metabolic syndrome: Definition, pathophysiology, and mechanisms (Miranda et al). 2005;149:33-45

Prognostic impact of body weight and abdominal obesity in women and men with cardiovascular disease (Dagenais et al). 2005;149:54-60

Orbofiban

Early initiation of lipid-lowering therapy for acute coronary syndromes improves compliance with guideline recommendations: Observations from the Orbofiban in Patients with Unstable Coronary Syndromes (OPUS-TIMI 16) trial (Smith et al). 2005;149:444-50

Outpatient care; see Ambulatory care

Oxygen

Attenuation of reperfusion microvascular ischemia by aqueous oxygen: Experimental and clinical observations (Glazier). 2005;149:580-4 (Progress cardiol.)

Cardioprotection before revascularization in ischemic myocardial injury and the potential role of hemoglobin-based oxygen carriers (Burkhoff and Lefer). 2005;149:573-9 (Progress cardiol.)

Oxygen consumption

Determinants of functional capacity in patients with chronic heart failure: Role of filling pressure and systolic and diastolic function (Smart et al). 2005;149:152-8

Oxygen uptake efficiency slope, a new submaximal parameter in evaluating exercise capacity in chronic heart failure patients (Van Laethem et al). 2005;149:175-80

P

Pacemaker, artificial

Detailed bacteriologic tests to identify the origin of transvenous pacing system infections indicate a high prevalence of multiple organisms (Klug et al). 2005;149:322-8

Patient admission

Impact of the application of the American College of Emergency Physicians recommendations for the admission of patients with syncope on a retrospectively studied population presenting to the emergency department (Elesber et al). 2005;149:826-31

Patient compliance

Clinical factors associated with abandonment of a rate-control or rhythm-control strategy for the management of atrial fibrillation in the AFFIRM study (Curtis et al). 2005;149:304-8

Early initiation of lipid-lowering therapy for acute coronary syndromes improves compliance with guideline recommendations: Observations from the Orbofiban in Patients with Unstable Coronary Syndromes (OPUS-TIMI 16) trial (Smith et al). 2005;149:444-50

Why do patients fail to receive β -blockers for chronic heart failure over time? A "real-world" single-center, 2-year follow-up experience of β -blocker therapy in patients with chronic heart failure (Parameswaran et al). 2005;149:921-6

Patient discharge

Acute coronary syndrome national statistics: Challenges in definitions (Bertoni et al). 2005;149:1055-61

Patients

Improving blood pressure control by tailored feedback to patients and clinicians (Bosworth et al). 2005;149:795-803 (Meetings)

Percutaneous coronary intervention (PCI); see Angioplasty; Myocardial revascularization; Stents

Pericardial effusion

Noninvasive evaluation of pericardial effusion composition by computed tomography (Rifkin et al). 2005;149:1120-7

Periodontitis

Periodontal treatment improves endothelial dysfunction in patients with severe periodontitis (Seinost et al). 2005;149:1050-4

A perspective on the potential cardioprotective benefits of periodontal therapy (Offenbacher and Beck). 2005;149:950-4 (Editorial)

Peripheral vascular disease

Development of a multicenter peripheral arterial interventional database: the PVD-QI² (Mukherjee et al). 2005;149:1003-8 (Trial design)

Pexelizumab

Assessment of Pexelizumab in Acute Myocardial Infarction (APEX AMI): A multicenter, randomized, double-blind, parallel-group, placebo-controlled study of pexelizumab in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention (Armstrong et al). 2005;149:402-7 (Trial design)

Physical fitness

Relationship between adolescent fitness and fatness and cardiovascular disease risk factors in adulthood: The Aerobics Center Longitudinal Study (ACLS) (Eisenmann et al). 2005;149:46-53

Physicians

Conflict of interest for the physician-inventor using a device in human subjects (Popp). 2005;149:1-3 (Editorial)

Impact of physicians' beliefs and practices on cholesterol levels in patients with type 2 diabetes: A longitudinal assessment (Franciosi et al). 2005;149:104-11

Renal and iliac artery stenting by interventional cardiologists and vascular surgeons: The Foundation to Advance Medical Education (FAME) initiative (Holmes, Jr et al). 2005;149:883-7

Platelet activation

Cigarette smoking is associated with increased circulating proinflammatory and procoagulant markers in patients with chronic coronary artery disease: Effects of aspirin treatment (Ikonomidis et al). 2005;149:832-9

Platelet aggregation inhibitors

The Early Glycoprotein IIb/IIIa Inhibition in Non-ST-Segment Elevation Acute Coronary Syndrome (EARLY ACS) trial: A randomized placebo-controlled trial evaluating the clinical benefits of early front-loaded eptifibatide in the treatment of patients with non-ST-segment elevation acute coronary syndrome—Study design and rationale (Giugliano et al). 2005;149:994-1002 (Trial design)

Elective percutaneous coronary intervention using broad-spectrum antiplatelet therapy (eptifibatide, clopidogrel, and aspirin) alone, without scheduled unfractionated heparin or other antithrombin therapy (Denardo et al). 2005;149:138-44

Enhancing reperfusion therapy for myocardial infarction with dual antiplatelet therapy: Breaking the glass ceiling (Fathi and Bhatt). 2005;149:947-9 (Editorial)

Long-term benefits of an early invasive management in acute coronary syndromes depend on intracoronary stenting and aggressive antiplatelet treatment: A metaregression (Biondi-Zocca et al). 2005;149:504-11

Regarding antithrombotic treatment after coronary stenting in patients on chronic oral anticoagulation (Rubboli et al). 2005;149(2):e1 (Letter)

The relation of renal function to ischemia and bleeding outcomes with 2 different glycoprotein IIb/IIIa inhibitors: The Do Tirofiban and ReoPro Give Similar Efficacy Outcome (TARGET) trial (Berger et al). 2005;149:869-75

The role of platelet glycoprotein IIIa polymorphism in the high prevalence of in vitro aspirin resistance in patients with intracoronary stent restenosis (Pamukcu et al). 2005;149:675-80

Postmenopause

Exercise as an alternative to oral estrogen for amelioration of endothelial dysfunction in postmenopausal women (Harvey et al). 2005;149:291-7

Practice guidelines

Does current treatment of cardiogenic shock complicating the acute coronary syndromes comply with guidelines? (Iakobishvili et al). 2005;149:98-103

Early initiation of lipid-lowering therapy for acute coronary syndromes improves compliance with guideline recommendations: Observations from the Orbofiban in Patients with Unstable Coronary Syndromes (OPUS-TIMI 16) trial (Smith et al). 2005;149:444-50

Impact of the application of the American College of Emergency Physicians recommendations for the admission of patients with syncope on a retrospectively studied population presenting to the emergency department (Elesber et al). 2005;149:826-31

Practical considerations of β -blockade in the management of the post-myocardial infarction patient (Fonarow). 2005;149:984-93 (Curriculum cardiol.)

Practice patterns

Hospital therapy traditions influence long-term survival in patients with acute myocardial infarction (Stenstrand et al). 2005;149:82-90

Prevalence

Depression and heart failure in patients with a new myocardial infarction (Powell et al). 2005;149:851-5

Prevalence of anemia and effects on mortality in patients with heart failure (Lindenfield). 2005;149:391-401
(Curriculum cardiol.)

Prevalence of metabolic syndrome in cardiac rehabilitation secondary prevention programs (Savage et al). 2005;149:627-31

Screening for heart disease in diabetic subjects (Fang et al). 2005;149:349-54

Professional practice

Impact of physicians' beliefs and practices on cholesterol levels in patients with type 2 diabetes: A longitudinal assessment (Franciosi et al). 2005;149:104-11

Prognosis

Asymptomatic atrial fibrillation: Demographic features and prognostic information from the Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) study (Flaker et al). 2005;149:657-63

Benign outcome in a long-term follow-up of patients with hypertrophic cardiomyopathy in Brazil (Arteaga et al). 2005;149:1099-05

Blood pressure variability and prognosis in uncomplicated mild hypertension (Pierdomenico et al). 2005;149:934-8

Electrocardiographic damage scores and cardiovascular mortality (Richardson et al). 2005;149:458-63

Incremental prognostic value of exercise single-photon emission computed tomographic (SPECT) thallium 201 imaging in patients with ST-T abnormalities on their resting electrocardiograms (Kwok et al). 2005;149:145-51

Insulin-treated diabetes is associated with a marked increase in mortality in patients with advanced heart failure (Smooke et al). 2005;149:168-74

Left ventricular outflow tract obstruction provoked during dobutamine stress echocardiography predicts future chest pain, syncope, and near syncope (Dawn et al). 2005;149:908-16

Prognostic impact of body weight and abdominal obesity in women and men with cardiovascular disease (Dagenais et al). 2005;149:54-60

Safety and accuracy of multidetector row computed tomography for early assessment of residual stenosis of the infarct-related artery and the number of diseased vessels after acute myocardial infarction (Chiou et al). 2005;149:701-8

Protective clothing

The Women's Recovery from Sternotomy (WREST) Study: Design of a randomized trial of a novel undergarment for early use after sternotomy (King et al). 2005;149:761-7
(Trial design)

Proteins

Noninvasive evaluation of pericardial effusion composition by computed tomography (Rifkin et al). 2005;149:1120-7

Psychological stress; see Stress, psychological**Pulmonary capillary wedge pressure (PCWP);
see Pulmonary wedge pressure****Pulmonary wedge pressure**

Unexpected BNP levels in patients with advanced heart failure: A tale of caution and promise (Drazner and de Lemos). 2005;149:187-9 (Editorial)

Q

Quality of health care; see Health care quality, access, and evaluation

Quality of life

Atrial fibrillation and quality of life: Clarity or evidence-based confusion? (Newman). 2005;149:4-6 (Editorial)

Impact of invasive management versus noninvasive management on functional status and quality of life following non-Q-wave myocardial infarction: A randomized clinical trial (Eisenberg et al). 2005;149:813-9

Quality of life in atrial fibrillation: The Atrial Fibrillation

Follow-up Investigation of Rhythm Management (AFFIRM) study (AFFIRM Investigators). 2005;149:112-20

Rate control versus rhythm control for patients with persistent atrial fibrillation with mild to moderate heart failure: Results from the RAtc Control versus Electrical cardioversion (RACE) study (Hagens et al). 2005;149:1106-11

R

Race; see Ethnic groups

Radionuclide imaging

Marked differences between patients referred for stress echocardiography and myocardial perfusion imaging studies (Bart et al). 2005;149:888-93

Recovery of function

Collaterals and the recovery of left ventricular function after recanalization of a chronic total coronary occlusion (Werner et al). 2005;149:129-37

The Women's Recovery from Sternotomy (WREST) Study:

Design of a randomized trial of a novel undergarment for early use after sternotomy (King et al). 2005;149:761-7
(Trial design)

Recurrence

Risk factors for cardiovascular event recurrence in the Atherosclerosis Risk in Communities (ARIC) study (Wattanakit et al). 2005;149:606-12

Referral and consultation

Marked differences between patients referred for stress echocardiography and myocardial perfusion imaging studies (Bart et al). 2005;149:888-93

Renal artery; see Kidney artery**Renal function; see Kidney function****Renin-angiotensin system**

Angiotensin-converting enzyme inhibitors as a new therapy for atrial fibrillation? Controversy (Ogimoto et al). 2005;149:e19 (Letter)

ReoPro; see Abciximab**Reperfusion, myocardial; see Myocardial reperfusion****Research**

Conducting economic evaluations alongside multinational clinical trials: Toward a research consensus (Reed et al). 2005;149:434-43 (Meetings)

Revascularization, myocardial; see Myocardial revascularization**Risk assessment**

Additional impact of electrocardiographic over echocardiographic diagnosis of left ventricular hypertrophy for predicting the risk of ischemic stroke (Kohsaka et al). 2005;149:181-6

Are we appropriately triaging patients with unstable angina? (Gomberg-Maitland et al). 2005;149:613-18

Concerns about the implantable cardioverter defibrillator: A determinant of anxiety and depressive symptoms

independent of experienced shocks (Pedersen et al). 2005;149:664-9

Correlation between the TIMI risk score and high-risk angiographic findings in non-ST-elevation acute coronary syndromes: Observations from the Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) trial (Mega et al). 2005;149:846-50

A critical appraisal of current models of risk stratification for percutaneous coronary interventions (Singh et al). 2005;149:753-60 (Curriculum cardiol.)

Depression and heart failure in patients with a new myocardial infarction (Powell et al). 2005;149:851-5

Early cardiac catheterization is associated with lower mortality only among high-risk patients with ST- and non-ST-elevation acute coronary syndromes: Observations from the OPUS-TIMI 16 trial (Cantor et al). 2005;149:275-83

Erythrocyte adhesiveness/aggregation: A novel biomarker for the detection of low-grade internal inflammation in individuals with atherosclerotic risk factors and proven vascular disease (Berliner et al). 2005;149:260-7

Ethnic differences in cardiovascular risk factor burden among middle-aged women: Study of Women's Health Across the Nation (SWAN) (Matthews et al). 2005;149:1066-73

Factors affecting bleeding risk during anticoagulant therapy in patients with atrial fibrillation: Observations from the Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) Study (DiMarco et al). 2005;149:650-6

Multimarker risk strategy for predicting 1-month and 1-year major events in non-ST elevation acute coronary syndromes (Bodi et al). 2005;149:268-74

Prediction of missed myocardial infarction among symptomatic outpatients without coronary heart disease (Sequist et al). 2005;149:74-81

Relationship between adolescent fitness and fatness and cardiovascular disease risk factors in adulthood: The Aerobics Center Longitudinal Study (ACLS) (Eisenmann et al). 2005;149:46-53

Risk factors for cardiovascular event recurrence in the Atherosclerosis Risk in Communities (ARIC) study (Wattanakit et al). 2005;149:606-12

Systolic hypertension: An overview (Griffith et al). 2005;149:769-75 (Meetings)

Risk management

Risk reduction of cardiac events by screening of unknown asymptomatic coronary artery disease in subjects with type 2 diabetes mellitus at high cardiovascular risk: An open-label randomized pilot study (Faglia et al). 2005;149:283.e1-283.e6

Rupture

Plaque erosion in the culprit lesion is prone to develop a smaller myocardial infarction size compared with plaque rupture (Hayashi et al). 2005;149:284-90

S

Safety

Comparison of the efficacy and safety of atorvastatin initiated at different starting doses in patients with dyslipidemia (Jones et al). 2005;149:111.e1-111.e8

Economic analysis of the Assessment of the Safety and Efficacy of a New Thrombolytic Regimen (ASSENT-3) study: Costs of reperfusion strategies in acute myocardial infarction (Kaul et al). 2005;149:637-44

Efficacy, safety and tolerability of metoprolol CR/XL in patients with diabetes and chronic heart failure: Experiences from MERIT-HF (Deedwania et al). 2005;149:159-67

Efficacy and safety of a once-daily graded-release diltiazem formulation dosed at bedtime compared to placebo and to morning dosing in chronic stable angina pectoris (Glasser et al). 2005;149:290.e1-290.e9

Saphenous vein

Embolic protection during saphenous vein graft intervention using a second-generation balloon protection device—Results from the combined US and European pilot study of the TriActiv Balloon Protected Flush Extraction System (Carrozza, Jr et al). 2005;149:1136.e1-1136.e7

Screening: *see Mass screening*

Sevelamer

Potential antiatherogenic and anti-inflammatory properties of sevelamer in maintenance hemodialysis patients (Ferramosca et al). 2005;149:820-5

Sex

Sex, quality of care, and outcomes of elderly patients hospitalized with heart failure: Findings from the National Heart Failure Project (Rathore et al). 2005;149:121-8

Shock, cardiogenic

Does current treatment of cardiogenic shock complicating the acute coronary syndromes comply with guidelines? (Iakobishvili et al). 2005;149:98-103

Outcome of patients aged ≥ 75 years in the SHould we emergently revascularize Occluded Coronaries in cardiogenic shock (SHOCK) trial: Do elderly patients with acute myocardial infarction complicated by cardiogenic shock respond differently to emergent revascularization? (Dzavik et al). 2005;149:1128-34

Should we aggressively treat elderly patients with cardiogenic shock? (Hasdai). 2005;149:962-3 (Editorial)

Simvastatin

Comparison of ezetimibe plus simvastatin versus simvastatin monotherapy on atherosclerosis progression in familial hypercholesterolemia: Design and rationale of the Ezetimibe and Simvastatin in Hypercholesterolemia Enhances Atherosclerosis Regression (ENHANCE) trial (Kastelein et al). 2005;149:234-9 (Trial design)

Dose-comparison study of the combination of ezetimibe and simvastatin (Vytorin) versus atorvastatin in patients with hypercholesterolemia: The Vytorin Versus Atorvastatin (VVVA) Study (Ballantyne et al). 2005;149:464-73

Is atorvastatin more appropriate to use in combination with niacin than simvastatin in patients with the metabolic syndrome? (Al-Shaer). 2005;149:e17 (Letter)

Simvastatin does not inhibit intimal hyperplasia and restenosis but promotes plaque regression in normocholesterolemic patients undergoing coronary stenting: A randomized study with intravascular ultrasound (Petrovic et al). 2005;149:520-6

Single-photon emission-computed tomography:
see Tomography, emission-computed, single-photon

Sirolimus

Primary stenting of occluded native coronary arteries II—Rationale and design of the PRISON II study: A randomized comparison of bare metal stent implantation with sirolimus-eluting stent implantation for the treatment of chronic total coronary occlusions (Rahel et al). 2005;149:414.e1-414.e3 (Trial design)

Smoking

Cigarette smoking is associated with increased circulating proinflammatory and procoagulant markers in patients with

chronic coronary artery disease: Effects of aspirin treatment (Ikonomidis et al). 2005;149:832-9

Smoking cessation in patients with coronary artery disease (Ludwig et al). 2005;149:565-72 (Curriculum cardiol.)

Smoking cessation

Smoking cessation in patients with coronary artery disease (Ludwig et al). 2005;149:565-72 (Curriculum cardiol.)

Specialties, medical

Renal and iliac artery stenting by interventional cardiologists and vascular surgeons: The Foundation to Advance Medical Education (FAME) initiative (Holmes, Jr et al). 2005;149:883-7

SPECT; see Tomography, emission-computed, single-photon

Spiral computed tomography; see Tomography, spiral computed

Statins; see Hydroxymethylglutaryl-CoA reductase inhibitors

Statistical models; see Models, statistical

Statistics

Acute coronary syndrome national statistics: Challenges in definitions (Bertoni et al). 2005;149:1055-61

Stents

The angiotensin II receptor blocker candesartan cilexetil reduces neointima proliferation after coronary stent implantation: A prospective randomized study under intravascular ultrasound guidance (Yoshida et al). 2005;149:144.e1-144.e6

Association of chronic kidney disease with clinical outcomes after coronary revascularization: The arterial revascularization therapies study (ARTS) (Ix et al). 2005;149:512-9

Coronary drug-eluting stent development: Issues in trial design (Muni et al). 2005;149:415-33 (Meetings)

Effects of abciximab and preprocedural glycemic control in diabetic patients undergoing elective coronary stenting (De Luca et al). 2005;149:1135.e1-1135.e18

Elective percutaneous coronary intervention using broad-spectrum antiplatelet therapy (eptifibatide, clopidogrel, and aspirin) alone, without scheduled unfractionated heparin or other antithrombin therapy (Denardo et al). 2005;149:138-44

Embolectic protection during saphenous vein graft intervention using a second-generation balloon protection device—Results from the combined US and European pilot study of the TriActiv Balloon Protected Flush Extraction System (Carrozza, Jr et al). 2005;149:1136.e1-1136.e7

INvestigation of STEn grafts in patients with type B Aortic Dissection: Design of the INSTEAD trial—a prospective, multicenter, European randomized trial (Nienaber et al). 2005;149:592-9 (Trial design)

Long-term benefits of an early invasive management in acute coronary syndromes depend on intracoronary stenting and aggressive antiplatelet treatment: A metaregression (Biondi-Zocca et al). 2005;149:504-11

Prediction of death or myocardial infarction by exercise single photon emission computed tomography perfusion scintigraphy in patients who have had recent coronary artery stenting (Rajagopal et al). 2005;149:534-40

Primary stenting of occluded native coronary arteries II—Rationale and design of the PRISON II study: A randomized comparison of bare metal stent implantation with sirolimus-eluting stent implantation for the treatment of chronic total coronary occlusions (Rahel et al). 2005;149:414.e1-414.e3 (Trial design)

Prospective randomized comparison of early and late results of a carbonized stent versus a high-grade stainless steel stent of identical design: The Prevention of Recurrent Venous Thromboembolism (PREVENT) trial (Sick et al). 2005;149:681-8

Randomized comparison of carbon ion-implanted stent versus bare metal stent in coronary artery disease: The Asian Pacific Multicenter Arthos Stent Study (PASS) trial (Kim et al). 2005;149:336-41

Regarding antithrombotic treatment after coronary stenting in patients on chronic oral anticoagulation (Rubboli et al). 2005;149(2):e1 (Letter)

Renal and iliac artery stenting by interventional cardiologists and vascular surgeons: The Foundation to Advance Medical Education (FAME) initiative (Holmes, Jr et al). 2005;149:883-7

Repeat stenting for the prevention of the early lumen loss phenomenon in patients with in-stent restenosis: Angiographic and intravascular ultrasound findings of a randomized study (Alfonso et al). 2005;149:335.e1-335.e8

The role of platelet glycoprotein IIIa polymorphism in the high prevalence of in vitro aspirin resistance in patients with intracoronary stent restenosis (Pamukcu et al). 2005;149:675-80

Should we routinely supplement coronary patients with folate therapy to prevent in-stent restenosis? (Halabi and Harrington). 2005;149:1035-6

Simvastatin does not inhibit intimal hyperplasia and restenosis but promotes plaque regression in normocholesterolemic patients undergoing coronary stenting: A randomized study with intravascular ultrasound (Petronio et al). 2005;149:520-6

Stent implantation, but not pathogen burden, is associated with plasma C-reactive protein and interleukin-6 levels after percutaneous coronary intervention in patients with stable angina pectoris (Saleh et al). 2005;149:876-82

Two-year clinical follow up of ⁹⁰Sr/⁹⁰Y β-radiation versus placebo control for the treatment of in-stent restenosis (Silber et al). 2005;149:689-94

Very early cardiac magnetic resonance imaging for quantification of myocardial tissue perfusion in patients receiving tirofiban before percutaneous coronary intervention for ST-elevation myocardial elevation (Steen et al). 2005;149:564.e1-564.e7

Sternotomy; see Thoracotomy

Stress, psychological

Heart rate variability biofeedback as a behavioral neurocardiac intervention to enhance vagal heart rate control (Nolan et al). 2005;149:1137.e1-1137.e7

Stress echocardiography; see Echocardiography, stress

Stress test; see Echocardiography, stress; Exercise test

Stroke; see Cerebrovascular accident

Stroke volume

Determinants of functional capacity in patients with chronic heart failure: Role of filling pressure and systolic and diastolic function (Smart et al). 2005;149:152-8

Oxygen uptake efficiency slope, a new submaximal parameter in evaluating exercise capacity in chronic heart failure patients (Van Laethem et al). 2005;149:175-80

Strontium radioisotopes

Two-year clinical follow up of ⁹⁰Sr/⁹⁰Y β-radiation versus placebo control for the treatment of in-stent restenosis (Silber et al). 2005;149:689-94

Survival analysis

Factors associated with an increased chance of survival among patients suffering from an out-of-hospital cardiac arrest in a national perspective in Sweden (Herlitz et al). 2005;149:61-6

A propensity score analysis of the impact of angiotensin-converting enzyme inhibitors on long-term survival of older adults with heart failure and perceived contraindications (Ahmed et al). 2005;149:737-43

Survival rate; see Mortality

Sweden

Factors associated with an increased chance of survival among patients suffering from an out-of-hospital cardiac arrest in a national perspective in Sweden (Herlitz et al). 2005;149:61-6

Syncope

Impact of the application of the American College of Emergency Physicians recommendations for the admission of patients with syncope on a retrospectively studied population presenting to the emergency department (Elesber et al). 2005;149:826-31

Left ventricular outflow tract obstruction provoked during dobutamine stress echocardiography predicts future chest pain, syncope, and near syncope (Dawn et al). 2005;149:908-16

Systole

Determinants of functional capacity in patients with chronic heart failure: Role of filling pressure and systolic and diastolic function (Smart et al). 2005;149:152-8

A Doppler-derived index of combined left ventricular systolic and diastolic function is an independent predictor of cardiovascular mortality in elderly men (Årnlöv et al). 2005;149:902-7

Evaluation and management of patients with uncontrolled systolic hypertension: Is another new paradigm really needed? (Mitchell and Pfeffer). 2005;149:776-84 (Meetings)

Left ventricular systolic asynchrony after acute myocardial infarction in patients with narrow QRS complexes (Zhang et al). 2005;149:497-503

Systolic hypertension: An overview (Griffith et al). 2005;149:769-75 (Meetings)

T

Tenecteplase

Economic analysis of the Assessment of the Safety and Efficacy of a New Thrombolytic Regimen (ASSENT-3) study: Costs of reperfusion strategies in acute myocardial infarction (Kaul et al). 2005;149:637-44

Thallium radioisotopes

Incremental prognostic value of exercise single-photon emission computed tomographic (SPECT) thallium 201 imaging in patients with ST-T abnormalities on their resting electrocardiograms (Kwok et al). 2005;149:145-51

Thoracotomy

The Women's Recovery from Sternotomy (WREST) Study: Design of a randomized trial of a novel undergarment for early use after sternotomy (King et al). 2005;149:761-7 (Trial design)

Thrombin

Cigarette smoking is associated with increased circulating proinflammatory and procoagulant markers in patients with chronic coronary artery disease: Effects of aspirin treatment (Ikonomidis et al). 2005;149:832-9

Thromboembolism

Clopidogrel-aspirin combination for atrial fibrillation: CLAAF is not CLEAR (Jackson et al) (Letter); (De Caterina and Lorenzoni) (Reply). 2005;149(1):e3, e4

Prospective randomized comparison of early and late results of a carbonized stent versus a high-grade stainless steel stent of

identical design: The Prevention of Recurrent Venous Thromboembolism (PREVENT) trial (Sick et al).

2005;149:681-8

Thrombolytic therapy

Design and rationale of Clopidogrel as Adjunctive Reperfusion Therapy-Thrombolysis in Myocardial Infarction (CLARITY-TIMI) 28 trial (Sabatine et al). 2005;149:227-33 (Trial design)

Enoxaparin versus unfractionated heparin as antithrombin therapy in patients receiving fibrinolysis for ST-elevation

myocardial infarction: Design and rationale for the Enox-

aparin and Thrombolysis Reperfusion for Acute Myocardial

Infarction Treatment-Thrombolysis In Myocardial Infarction

study 25 (ExTRACT-TIMI 25) (Antman et al).

2005;149:217-26 (Trial design)

Incidence, predictors, and outcomes of high-degree

atrioventricular block complicating acute myocardial infarc-

tion treated with thrombolytic therapy (Meine et al).

2005;149:670-4

Invasive versus noninvasive management of ST-elevation

acute myocardial infarction: A review of clinical trials and

observational studies (Beck et al). 2005;149:194-9

(Curriculum cardiol.)

ST resolution in a single electrocardiographic lead: A simple

and accurate predictor of cardiac mortality in patients with

fibrinolytic therapy for acute ST-elevation myocardial infarc-

tion (Zeymer et al). 2005;149:91-7

Thrombolytic therapy for eligible elderly patients with acute

myocardial infarction (Yusuf et al) (Letter); (Avezum and

Makdisse) (Reply). 2005;149:e25-e26, e27

Thrombosis

The biology, utilization, and attenuation of C-reactive protein in

cardiovascular disease: Part II (Armani and Becker).

2005;149:977-83 (Progress cardiol.)

Erythrocyte adhesiveness/aggregation: A novel biomarker for

the detection of low-grade internal inflammation in individ-

uals with atherosclerotic risk factors and proven vascular

disease (Berliner et al). 2005;149:260-7

Ticlopidine

Regarding antithrombotic treatment after coronary stenting in

patients on chronic oral anticoagulation (Rubboli et al).

2005;149(2):e1 (Letter)

Tirofiban

The relation of renal function to ischemic and bleeding

outcomes with 2 different glycoprotein IIb/IIIa inhibitors:

The Do Tirofiban and ReoPro Give Similar Efficacy Outcome

(TARGET) trial (Berger et al). 2005;149:869-75

Very early cardiac magnetic resonance imaging for

quantification of myocardial tissue perfusion in patients

receiving tirofiban before percutaneous coronary interven-

tion for ST-elevation myocardial elevation (Steen et al).

2005;149:564-e1-564.e7

Tissue Doppler imaging; see Echocardiography, Doppler

Tomography, computed

Safety and accuracy of multidetector row computed

tomography for early assessment of residual stenosis of the

infarct-related artery and the number of diseased vessels after

acute myocardial infarction (Chiou et al). 2005;149:701-8

Tomography, emission-computed, single-photon

Assessment of patients with low-risk chest pain in the

emergency department: Head-to-head comparison of exercise

stress echocardiography and exercise myocardial SPECT

(Conti et al). 2005;149:894-901

Incremental prognostic value of exercise single-photon

emission computed tomographic (SPECT) thallium 201

imaging in patients with ST-T abnormalities on their resting electrocardiograms (Kwok et al). 2005;149:145-51

Prediction of death or myocardial infarction by exercise single photon emission computed tomography perfusion scintigraphy in patients who have had recent coronary artery stenting (Rajagopal et al). 2005;149:534-40

Tomography, spiral computed

Multislice spiral computed tomographic angiography of coronary arteries in patients with suspected coronary artery disease: An effective filter before catheter angiography? (Haberl et al). 2005;149:1112-19

Tomography, x-ray computed

Diabetes and progression of coronary calcium under the influence of statin therapy (Budoff et al). 2005;149:695-700

Noninvasive evaluation of pericardial effusion composition by computed tomography (Rifkin et al). 2005;149:1120-7

Which role for multislice computed tomography in clinical cardiology? (Bax and Schuijff). 2005;149:960-1 (Editorial)

Transthoracic echocardiography; see Echocardiography

Treatment efficacy; see Treatment outcome

Treatment failure

Clinical factors associated with abandonment of a rate-control or a rhythm-control strategy for the management of atrial fibrillation in the AFFIRM study (Curtis et al). 2005;149:304-8

Treatment outcome

An alternative approach for exercise prescription and efficacy testing in patients with chronic heart failure: A randomized controlled training study (Meyer et al). 2005;149:926.e1-926.e7

Are we appropriately triaging patients with unstable angina? (Gomberg-Maitland et al). 2005;149:613-18

Association of chronic kidney disease with clinical outcomes after coronary revascularization: The arterial revascularization therapies study (ARTS) (Ix et al). 2005;149:512-9

Association of intravenous morphine use and outcomes in acute coronary syndromes: Results from the CRUSADE Quality Improvement Initiative (Meine et al). 2005;149:1043-9

Characteristics and outcomes of patients hospitalized for heart failure in the United States: Rationale, design, and preliminary observations from the first 100,000 cases in the Acute Decompensated Heart Failure National Registry (ADHERE) (Adams Jr. et al). 2005;149:209-16 (Trial design)

Clinical factors that influence response to treatment strategies in atrial fibrillation: The Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) Study (AFFIRM Investigators). 2005;149:645-9

Early effects of statin therapy on endothelial function and microvascular reactivity in patients with coronary artery disease (Ling et al). 2005;149:1137.e9-1137.e16

Economic analysis of the Assessment of the Safety and Efficacy of a New Thrombolytic Regimen (ASSENT-3) study: Costs of reperfusion strategies in acute myocardial infarction (Kaul et al). 2005;149:637-44

Effects of abciximab and preprocedural glycemic control in diabetic patients undergoing elective coronary stenting (De Luca et al). 2005;149:1135.e11-1135.e18

Efficacy, safety and tolerability of metoprolol CR/XL in patients with diabetes and chronic heart failure: Experiences from MERIT-HF (Deedwania et al). 2005;149:159-67

Efficacy and safety of a once-daily graded-release diltiazem formulation dosed at bedtime compared to placebo and to morning dosing in chronic stable angina pectoris (Glasser et al). 2005;149:290.e1-290.e9

Impact of age on management and outcome of acute coronary syndrome: Observations from the Global Registry of Acute Coronary Events (GRACE) (Avezum et al). 2005;149:67-73

Impact of invasive management versus noninvasive management on functional status and quality of life following non-Q-wave myocardial infarction: A randomized clinical trial (Eisenberg et al). 2005;149:813-19

Impact of program duration and contact frequency on efficacy and cost of cardiac rehabilitation: Results of a randomized trial (Reid et al). 2005;149:862-8

Incidence, predictors, and outcomes of high-degree atrioventricular block complicating acute myocardial infarction treated with thrombolytic therapy (Meine et al). 2005;149:670-4

Investigation of STEMI grafts in patients with type B Aortic Dissection: Design of the INSTEAD trial—a prospective, multicenter, European randomized trial (Nienaber et al). 2005;149:592-9 (Trial design)

Metaanalysis and review of heart failure disease management randomized controlled clinical trials (Whellan et al). 2005;149:722-9

Metabolic syndrome: Evaluation of pathological and therapeutic outcomes (Miranda et al). 2005;149:20-32 (Meetings)

Outcome of patients aged ≥75 years in the SHould we emergently revascularize Occluded Coronaries in cardiogenic shock (SHOCK) trial: Do elderly patients with acute myocardial infarction complicated by cardiogenic shock respond differently to emergent revascularization? (Dzavik et al). 2005;149:1128-34

Predictors of response to cardiac resynchronization therapy (PROSPECT)—study design (Yu et al). 2005;149:600-5 (Trial design)

The relation of renal function to ischemic and bleeding outcomes with 2 different glycoprotein IIb/IIIa inhibitors: The Do Tirofiban and ReoPro Give Similar Efficacy Outcome (TARGET) trial (Berger et al). 2005;149:869-75

Sex, quality of care, and outcomes of elderly patients hospitalized with heart failure: Findings from the National Heart Failure Project (Rathore et al). 2005;149:121-8

ST-segment elevation resolution and outcome in patients treated with primary angioplasty and glucose-insulin-potassium infusion (van der Horst et al). 2005;149:1135.e1-1135.e9

Statin therapy—Time to turn the focus from efficacy to implementation? (Blazing). 2005;149:381-3 (Editorial)

Two-year clinical follow up of ⁹⁰Sr/⁹⁰Y β-radiation versus placebo control for the treatment of in-stent restenosis (Silber et al). 2005;149:689-94

TriActiv Balloon Protected Flush Extraction System

Embolectomy protection during saphenous vein graft intervention using a second-generation balloon protection device—Results from the combined US and European pilot study of the TriActiv Balloon Protected Flush Extraction System (Carrozza, Jr et al). 2005;149:1136.e1-1136.e7

Triglycerides; see also Hyperlipidemia

Relationship between adolescent fitness and fatness and cardiovascular disease risk factors in adulthood: The Aerobics Center Longitudinal Study (ACLS) (Eisenmann et al). 2005;149:46-53

Tropponin I

Multimarker risk strategy for predicting 1-month and 1-year major events in non-ST elevation acute coronary syndromes (Bodi et al). 2005;149:268-74

Tunica intima

The angiotensin II receptor blocker candesartan cilexetil reduces neointima proliferation after coronary stent implantation: A prospective randomized study under intravascular ultrasound guidance (Yoshida et al). 2005;149:144.e1-144.e6
Type B aortic dissection; see Aneurysm, dissecting

U

Ultrasonography, interventional

The angiotensin II receptor blocker candesartan cilexetil reduces neointima proliferation after coronary stent implantation: A prospective randomized study under intravascular ultrasound guidance (Yoshida et al). 2005;149:144.e1-144.e6
Repeat stenting for the prevention of the early lumen loss phenomenon in patients with in-stent restenosis: Angiographic and intravascular ultrasound findings of a randomized study (Alfonso et al). 2005;149:335.e1-335.e8
Simvastatin does not inhibit intimal hyperplasia and restenosis but promotes plaque regression in normocholesterolemic patients undergoing coronary stenting: A randomized study with intravascular ultrasound (Petrovic et al). 2005;149:520-6

United States

Characteristics and outcomes of patients hospitalized for heart failure in the United States: Rationale, design, and preliminary observations from the first 100,000 cases in the Acute Decompensated Heart Failure National Registry (ADHERE) (Adams Jr. et al). 2005;149:209-16 (Trial design)
Examining the coverage of influenza vaccination among people with cardiovascular disease in the United States (Ajani et al). 2005;149:254-9

Urinary tract infection

Urinary tract infection in patients with acute coronary syndrome: A potential systemic inflammatory connection (Sims et al). 2005;149:1062-5

V

Vaccination

Examining the coverage of influenza vaccination among people with cardiovascular disease in the United States (Ajani et al). 2005;149:254-9

Vagus nerve

Heart rate variability biofeedback as a behavioral neurocardiac intervention to enhance vagal heart rate control (Nolan et al). 2005;149:1137.e1-1137.e7

Valsartan

Valsartan reduces the incidence of atrial fibrillation in patients with heart failure: Results from the Valsartan Heart Failure Trial (Val-HeFT) (Maggioni et al). 2005;149:548-57

Vascular diseases

Erythrocyte adhesiveness/aggregation: A novel biomarker for the detection of low-grade internal inflammation in individuals with atherosclerotic risk factors and proven vascular disease (Berliner et al). 2005;149:260-7

Vasodilation

Exercise as an alternative to oral estrogen for amelioration of endothelial dysfunction in postmenopausal women (Harvey et al). 2005;149:291-7

Venous thrombosis

Prospective randomized comparison of early and late results of a carbonized stent versus a high-grade stainless steel stent of identical design: The Prevention of Recurrent Venous Thromboembolism (PREVENT) trial (Sick et al). 2005;149:681-8

Ventricular dysfunction, left

Effect of coronary artery bypass grafting and aneurysmectomy on QT dispersion in moderate or severe left ventricular dysfunction (Gulcan et al). 2005;149:917-20

Implantable cardioverter defibrillators and cardiac resynchronization therapy in patients with left ventricular dysfunction: Randomized trial evidence through 2004 (Al-Khatib et al). 2005;149:1020-34 (Meetings)

Left ventricular systolic asynchrony after acute myocardial infarction in patients with narrow QRS complexes (Zhang et al). 2005;149:497-503

Oxygen uptake efficiency slope, a new submaximal parameter in evaluating exercise capacity in chronic heart failure patients (Van Laethem et al). 2005;149:175-80

Predictors of response to cardiac resynchronization therapy (PROSPECT)—study design (Yu et al). 2005;149:600-5 (Trial design)

Screening for heart disease in diabetic subjects (Fang et al). 2005;149:349-54

Ventricular ejection fraction; see Stroke volume

Ventricular fibrillation; see Arrhythmia

Ventricular function, left

Collaterals and the recovery of left ventricular function after recanalization of a chronic total coronary occlusion (Werner et al). 2005;149:129-37

A Doppler-derived index of combined left ventricular systolic and diastolic function is an independent predictor of cardiovascular mortality in elderly men (Årnöö et al). 2005;149:902-7

Ventricular hypertrophy, left

Screening for heart disease in diabetic subjects (Fang et al). 2005;149:349-54

Ventricular outflow obstruction

Behavior of both epicardial and intramural coronary artery flow velocities in various models of myocardial hypertrophy: Role for left ventricular outflow tract obstruction (De Gregorio et al). 2005;149:1091-8

Left ventricular outflow tract obstruction provoked during dobutamine stress echocardiography predicts future chest pain, syncope, and near syncope (Dawn et al). 2005;149:908-16

Ventricular pressure

Determinants of functional capacity in patients with chronic heart failure: Role of filling pressure and systolic and diastolic function (Smart et al). 2005;149:152-8

Vytorin

Dose-comparison study of the combination of ezetimibe and simvastatin (Vytorin) versus atorvastatin in patients with hypercholesterolemia: The Vytorin Versus Atorvastatin (VYVA) Study (Ballantyne et al). 2005;149:464-73

W

Waist-hip ratio

Prognostic impact of body weight and abdominal obesity in women and men with cardiovascular disease (Dagenais et al). 2005;149:54-60

Warfarin

Clopidogrel-aspirin combination for atrial fibrillation: CLAAF is not CLEAR (Jackson et al) (Letter); (De Caterina and Lorenzoni) (Reply). 2005;149(1):e3, e4

Weight loss

Diet and blood pressure: Applying the evidence to clinical practice (Ard and Svetkey). 2005;149:804-12 (Meetings)

Women

Ethnic differences in cardiovascular risk factor burden among middle-aged women: Study of Women's Health Across the Nation (SWAN) (Matthews et al). 2005;149:1066-73

Exercise treadmill testing using a modified exercise protocol in women with suspected myocardial ischemia: Findings from the National Heart, Lung and Blood Institute-sponsored Women's Ischemia Syndrome Evaluation (WISE) (Lewis et al). 2005;149:527-33

The Women's Recovery from Sternotomy (WREST) Study: Design of a randomized trial of a novel undergarment for

early use after sternotomy (King et al). 2005;149:761-7
(Trial design)

Y**Yttrium radioisotopes**

Two-year clinical follow up of $^{90}\text{Sr}/^{90}\text{Y}$ β -radiation versus placebo control for the treatment of in-stent restenosis (Silber et al). 2005;149:689-94

